0001479290-19-000109.txt : 20191104 0001479290-19-000109.hdr.sgml : 20191104 20191104161407 ACCESSION NUMBER: 0001479290-19-000109 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 191189954 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 10-Q 1 rvncq31910q.htm 10-Q Document
false--12-31Q32019000147929014.95341130000.0010.001950000009500000036975203441084073697520305210000.0010.0015000000500000000000 0001479290 2019-01-01 2019-09-30 0001479290 2019-10-24 0001479290 2018-12-31 0001479290 2019-09-30 0001479290 2018-07-01 2018-09-30 0001479290 2019-07-01 2019-09-30 0001479290 2018-01-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001479290 us-gaap:RetainedEarningsMember 2017-12-31 0001479290 us-gaap:RetainedEarningsMember 2018-12-31 0001479290 us-gaap:CommonStockMember 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2019-06-30 0001479290 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001479290 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-12-31 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-06-30 0001479290 us-gaap:RetainedEarningsMember 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2019-06-30 0001479290 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-01 2019-09-30 0001479290 2017-12-31 0001479290 2019-01-01 0001479290 rvnc:MylanIrelandLimitedMember 2018-02-28 0001479290 rvnc:DevelopmentServicesMember 2019-09-30 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-09-30 0001479290 rvnc:DevelopmentServicesMember 2018-01-01 2018-09-30 0001479290 rvnc:DevelopmentServicesMember 2019-07-01 2019-09-30 0001479290 rvnc:MylanIrelandLimitedMember 2018-02-28 2018-02-28 0001479290 rvnc:DevelopmentServicesMember 2018-12-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-01 2019-09-30 0001479290 rvnc:DevelopmentServicesMember 2018-07-01 2018-09-30 0001479290 rvnc:DevelopmentServicesMember 2019-01-01 2019-09-30 0001479290 rvnc:MylanIrelandLimitedMember 2019-08-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2018-12-01 2018-12-31 0001479290 rvnc:MylanIrelandLimitedMember rvnc:DevelopmentMilestonesMember 2018-02-28 2018-02-28 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-01 2019-01-31 0001479290 rvnc:MylanIrelandLimitedMember 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2019-09-30 0001479290 rvnc:MedicisPharmaceuticalCorporationMember 2012-10-01 2012-10-31 0001479290 us-gaap:CreditRiskContractMember rvnc:ValeantPharmaceuticalsInternationalInc.Member 2019-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputEntityCreditRiskMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2014-01-01 2014-12-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputExpectedTermMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2012-10-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputRiskFreeInterestRateMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputEntityCreditRiskMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2013-01-01 2013-12-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputRiskFreeInterestRateMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputExpectedTermMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 rvnc:JPMorganChaseCo.andWhollyownedSubsidiariesMember 2018-01-01 2018-12-31 0001479290 rvnc:JPMorganChaseCo.andWhollyownedSubsidiariesMember 2019-01-01 2019-09-30 0001479290 rvnc:J.P.MorganSecuritiesLLCMember 2018-12-31 0001479290 us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:CommercialPaperMember 2018-12-31 0001479290 us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:OtherCurrentAssetsMember 2018-12-31 0001479290 us-gaap:RepurchaseAgreementsMember 2018-12-31 0001479290 us-gaap:CashEquivalentsMember 2018-12-31 0001479290 us-gaap:OtherCurrentAssetsMember 2019-09-30 0001479290 us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:CashEquivalentsMember 2019-09-30 0001479290 2018-01-01 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2019-01-01 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:ListLaboratoriesMember 2019-09-30 0001479290 us-gaap:OtherCurrentLiabilitiesMember 2019-01-01 2019-09-30 0001479290 us-gaap:ServiceAgreementsMember rvnc:AjinomotoAltheaInc.Member 2019-09-30 0001479290 rvnc:BotulinumToxinResearchAssociatesInc.Member 2019-09-30 0001479290 rvnc:BioSentinelInc.Member 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-01 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-07-01 2019-09-30 0001479290 srt:WeightedAverageMember us-gaap:WarrantMember 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2019-09-30 0001479290 rvnc:AttheMarketOfferingMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockMember 2019-01-01 2019-01-01 0001479290 us-gaap:EmployeeStockMember 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-01-01 2019-01-01 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2019-01-01 2019-09-30 0001479290 us-gaap:OverAllotmentOptionMember 2019-01-01 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-09-30 0001479290 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001479290 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001479290 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001479290 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001479290 rvnc:ESPPPurchasesMember 2018-01-01 2018-09-30 0001479290 rvnc:ESPPPurchasesMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001479290 srt:WeightedAverageMember us-gaap:WarrantMember 2018-12-31 0001479290 rvnc:AttheMarketOfferingMember 2018-01-01 2018-09-30 0001479290 stpr:CA 2019-01-01 2019-09-30 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 0001479290 rvnc:FormerPresidentandChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-10-11 2019-10-11 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:PerformanceSharesMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 10-Q
 
 
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___ to ___
Commission File No. 001-36297
 
 
 
Revance Therapeutics, Inc.
 
(Exact name of registrant as specified in its charter)
 
 
 
 

Delaware
77-0551645

 
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)
 

7555 Gateway Boulevard, Newark, California, 94560
(Address, including zip code, of principal executive offices)

(510) 742-3400
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
RVNC
Nasdaq Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Emerging growth company
☐
Non-accelerated filer
☐
Smaller reporting company
☐
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial statement accounting standards provide pursuance to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No  ý
Number of shares outstanding of the registrant's common stock, par value $0.001 per share, as of October 24, 2019: 45,108,360

 



Table of Contents
 
 
 
 
 
 
Page
PART I. FINANCIAL INFORMATION
 
Item 1.
 
 
 
 
 
Item 2.
Item 3.
Item 4.
 
 
PART II. OTHER INFORMATION
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 
 
 
 
 
 
 
 
 
“Revance Therapeutics,” the Revance logos and other trademarks or service marks of Revance appearing in this quarterly report on Form 10-Q are the property of Revance Therapeutics, Inc. This Form 10-Q contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. The Company does not intend its use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by, these other companies.



PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements (Unaudited)
REVANCE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
 
September 30,
 
December 31,
 
2019
 
2018
ASSETS
CURRENT ASSETS
 
 
 
Cash and cash equivalents
$
58,922

 
$
73,256

Short-term investments
150,110

 
102,556

Accounts receivable
5,000

 
27,000

Prepaid expenses and other current assets
6,536

 
5,110

Total current assets
220,568

 
207,922

Property and equipment, net
14,917

 
14,449

Operating lease right of use assets
27,078

 
—

Restricted cash
730

 
730

Other non-current assets
2,519

 
3,247

TOTAL ASSETS
$
265,812

 
$
226,348

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
 
 
 
Accounts payable
$
6,902

 
$
8,434

Accruals and other current liabilities
18,694

 
14,948

Deferred revenue, current portion
5,241

 
8,588

Operating lease liabilities, current portion
3,317

 
—

Total current liabilities
34,154

 
31,970

Derivative liability associated with the Medicis settlement
2,892

 
2,753

Deferred revenue, net of current portion
50,707

 
42,684

Operating lease liabilities, net of current portion
26,778

 
—

Deferred rent
—

 
3,319

TOTAL LIABILITIES
114,531

 
80,726

Commitments and Contingencies (Note 7)

 

STOCKHOLDERS’ EQUITY
 
 
 
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2019 and December 31, 2018
—

 
—

Common stock, par value $0.001 per share — 95,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 44,108,407 and 36,975,203 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively
44

 
37

Additional paid-in capital
950,073

 
830,368

Accumulated other comprehensive income (loss)
42

 
(8
)
Accumulated deficit
(798,878
)
 
(684,775
)
TOTAL STOCKHOLDERS’ EQUITY
151,281

 
145,622

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$
265,812

 
$
226,348

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

3
REVANCE THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Revenue
$
46

 
$
2,362

 
$
324

 
$
3,242

Operating expenses:
 
 
 
 
 
 
 
Research and development
25,847

 
21,848

 
75,368

 
66,968

General and administrative
16,739

 
14,155

 
43,245

 
40,505

Total operating expenses
42,586

 
36,003

 
118,613

 
107,473

Loss from operations
(42,540
)
 
(33,641
)
 
(118,289
)
 
(104,231
)
Interest income
1,329

 
996

 
4,495

 
3,099

Interest expense
—

 
—

 
—

 
(44
)
Change in fair value of derivative liability associated with the Medicis settlement
(68
)
 
(45
)
 
(139
)
 
(150
)
Other expense, net
(130
)
 
(144
)
 
(170
)
 
(626
)
Net loss
(41,409
)
 
(32,834
)
 
(114,103
)
 
(101,952
)
Unrealized gain (loss) and adjustment on securities included in net loss
(74
)
 
90

 
50

 
(133
)
Comprehensive loss
$
(41,483
)
 
$
(32,744
)
 
$
(114,053
)
 
$
(102,085
)
Basic and diluted net loss
$
(41,409
)
 
$
(32,834
)
 
$
(114,103
)
 
$
(101,952
)
Basic and diluted net loss per share
$
(0.96
)
 
$
(0.91
)
 
$
(2.67
)
 
$
(2.82
)
Basic and diluted weighted-average number of shares used in computing net loss per share
43,314,831

 
36,272,445

 
42,730,983

 
36,116,745

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

4
REVANCE THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share and per share amounts)
(Unaudited) 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
 
Shares
 
Amount
 
Shares
 
Amount
 
Shares
 
Amount
 
Shares
 
Amount
Convertible Preferred Stock
—

 
$
—

 
—

 
$
—

 
—

 
$
—

 
—

 
$
—

Common Stock
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance — Beginning of period
44,105,474

 
44

 
36,917,723

 
37

 
36,975,203

 
37

 
36,516,075

 
37

Issuance of common stock in connection with the 2019 follow-on offering
—

 
—

 
—

 
—

 
6,764,705

 
7

 
—

 
—

Issuance of common stock upon exercise of stock options
—

 
—

 
51,006

 
—

 
8,240

 
—

 
284,094

 
—

Issuance of restricted stock awards, net of cancellation
9,697

 
—

 
26,598

 
—

 
400,720

 
—

 
232,284

 
—

Net settlement of restricted stock awards for employee taxes
(6,764
)
 
—

 
(3,205
)
 
—

 
(75,627
)
 
—

 
(59,126
)
 
—

Issuance of common stock relating to employee stock purchase plan
—

 
—

 
—

 
—

 
35,166

 
—

 
18,795

 
—

Balance — End of period
44,108,407

 
44

 
36,992,122

 
37

 
44,108,407

 
44

 
36,992,122

 
37

Additional Paid-In Capital
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance — Beginning of period
—

 
945,851

 
—

 
821,326

 
—

 
830,368

 
—

 
810,975

Cumulative-effect adjustment from adoption of ASU 2018-07
—

 
—

 
—

 
40

 
—

 
—

 
—

 
40

Issuance of common stock in connection with the 2019 follow-on offering, net of issuance costs of $521
—

 
—

 
—

 
—

 
—

 
107,572

 
—

 
—

Stock-based compensation expense
—

 
4,303

 
—

 
4,092

 
—

 
12,882

 
—

 
12,422

Issuance of common stock upon exercise of stock options
—

 
—

 
—

 
987

 
—

 
93

 
—

 
4,382

Net settlement of restricted stock awards for employee taxes
—

 
(81
)
 
—

 
(93
)
 
—

 
(1,229
)
 
—

 
(1,906
)
Issuance of common stock relating to employee stock purchase plan
—

 
—

 
—

 
—

 
—

 
387

 
—

 
439

Balance — End of period
—

 
950,073

 
—

 
826,352

 
—

 
950,073

 
—

 
826,352

Other Accumulated Comprehensive Gain (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance — Beginning of period
—

 
116

 
—

 
(223
)
 
—

 
(8
)
 
—

 
—

Unrealized gain (loss) and adjustment on securities included in net loss
—

 
(74
)
 
—

 
90

 
—

 
50

 
—

 
(133
)
Balance — End of period
—

 
42

 
—

 
(133
)
 
—

 
42

 
—

 
(133
)
Accumulated Deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance — Beginning of period
—

 
(757,469
)
 
—

 
(611,284
)
 
—

 
(684,775
)
 
—

 
(542,167
)
Cumulative-effect adjustment from adoption of ASU 2018-07
—

 
—

 
—

 
(40
)
 
—

 
—

 
—

 
(40
)
Net loss
—

 
(41,409
)
 
—

 
(32,834
)
 
—

 
(114,103
)
 
—

 
(101,951
)
Balance — End of period
—

 
(798,878
)
 
—

 
(644,158
)
 
—

 
(798,878
)
 
—

 
(644,158
)
Total Stockholders’ Equity
44,108,407

 
$
151,281

 
36,992,122

 
$
182,098

 
44,108,407

 
$
151,281

 
36,992,122

 
$
182,098


The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

5
REVANCE THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited) 
 
Nine Months Ended September 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES
 
 
 
Net loss
$
(114,103
)
 
$
(101,952
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation
2,152

 
1,251

Amortization of discount on investments
(2,215
)
 
(904
)
Stock-based compensation expense
12,882

 
12,422

Gain on disposal of property and equipment
(7
)
 
(1,480
)
Other non-cash operating activities
418

 
178

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
22,000

 
—

Prepaid expenses and other current assets
(1,426
)
 
(5,141
)
Operating lease right of use assets
(2,414
)
 
—

Other non-current assets
999

 
(1,919
)
Accounts payable
(1,050
)
 
793

Accruals and other liabilities
3,532

 
1,889

Deferred revenue
4,676

 
21,758

Operating lease liabilities
1,903

 
—

Net cash used in operating activities
(72,653
)
 
(73,105
)
CASH FLOWS FROM INVESTING ACTIVITIES
 
 
 
Purchases of investments
(228,568
)
 
(212,197
)
Purchases of property and equipment
(2,950
)
 
(5,367
)
Proceeds from maturities of investments
183,000

 
50,000

Proceeds from sales of property and equipment
7

 
1,537

Payment for acquisition of in-process research and development
—

 
(100
)
Net cash used in investing activities
(48,511
)
 
(166,127
)
CASH FLOWS FROM FINANCING ACTIVITIES
 
 
 
Proceeds from issuance of common stock in connection with the 2019 follow-on offering, net of commissions and discount
108,100

 
—

Proceeds from the exercise of stock options and employee stock purchase plan
480

 
4,822

Net settlement of restricted stock awards for employee taxes
(1,229
)
 
(1,906
)
Payment of offering costs
(521
)
 
(366
)
Principal payments made on financing obligations
—

 
(932
)
Net cash provided by financing activities
106,830

 
1,618

NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
(14,334
)
 
(237,614
)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period
73,986

 
283,476

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period
$
59,652

 
$
45,862

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
 
 
 
      Cash paid for income taxes
$
3,000

 
$
—

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
 
 
 
Property and equipment purchases included in accounts payable and accruals
$
313

 
$
920

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

6
REVANCE THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. The Company and Summary of Significant Accounting Policies
The Company
Revance Therapeutics, Inc. (the “Company” or “Revance”) is a biotechnology company developing new innovations in neuromodulators for aesthetic and therapeutic indications. The Company’s lead product candidate, DaxibotulinumtoxinA for Injection (“DAXI”), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. The Company has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, demonstrating efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. The Company is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as three therapeutic indications including cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine. Beyond DAXI, the Company has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.
Since inception, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DAXI, DaxibotulinumtoxinA Topical, and the biosimilar to BOTOX®. The Company has incurred losses and negative cash flows from operations. The Company has not commenced commercial operations, has not generated product revenue to date, and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended September 30, 2019, the Company had a net loss of $41.4 million and $114.1 million, respectively. As of September 30, 2019, the Company had a working capital surplus of $186.4 million and an accumulated deficit of $798.9 million. The Company has funded its operations primarily through the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2019, the Company had capital resources of $209.0 million consisting of cash, cash equivalents, and investments. The Company believes that its existing capital resources will fund the operating plan through at least the next 12 months following the issuance of this Form 10-Q, and may identify additional capital resources to fund its operations.
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented.
The Condensed Consolidated Balance Sheet for the year ended December 31, 2018 was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2019, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (“SEC”), on February 28, 2019.
The Condensed Consolidated Financial Statements include the Company’s accounts and those of its wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. The Company operates in one segment.
Principles of Consolidation
The Condensed Consolidated Financial Statements include the accounts of the company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.

7
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

Use of Estimates
The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which requires an entity to recognize right-of-use asset and lease liabilities arising from a lease for both financing and operating leases with terms greater than twelve months. In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements and ASU 2018-11, Leases (Topic 842), Targeted Improvements, to provide additional guidance for the Topic 842 adoption. ASU 2018-10 clarifies certain provisions and correct unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders’ equity. ASU 2018-11 provides an alternative transition method to allow entities initially applying Topic 842 at the adoption date, rather than at the beginning of the earliest comparative period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. ASU 2018-11 also provides a number of optional practical expedients in transition. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements. The Company evaluated ASU 2019-01 in its entirety and determined that Issue 3, Transition disclosures related to Topic 250, Accounting Changes and Error Corrections, is the only provision that currently applies to the Company. Issue 3 of ASU 2019-01 exempts certain interim disclosures in the fiscal year of adoption. ASU 2018-11, ASU 2018-10, ASU 2016-02, and Issue 3 of ASU 2019-01 (collectively, “the new lease standards”) are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has elected the transition method under ASU 2018-11 at the adoption date of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company has also elected all of the available practical expedients except the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease. For real estate leases, the Company did not elect the practical expedient to combine lease and non-lease components, therefore the Company accounts for lease and non-lease components separately. For equipment leases, lease and non-lease components are accounted for as a single lease component. The Company recognized $24.7 million and $28.2 million as total right-of-use assets and total lease liabilities, respectively, on its Condensed Consolidated Balance Sheet as of January 1, 2019 for its existing operating lease agreements for the office and manufacturing spaces in Newark, California and equipment leases. The existing deferred rent liabilities of $3.5 million associated with the same lease agreements was reversed as of January 1, 2019.
Recent Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company intends to adopt ASU 2018-15 prospectively when it becomes effective on January 1, 2020. The Company’s Condensed Consolidated Financial Statements and disclosures before adoption are not expected to be impacted as a result of the adoption.

8
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)


2. Revenue    
Mylan Collaboration and License Agreement    
The Company and Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) entered into a collaboration agreement in February 2018 (the “Mylan Collaboration”), pursuant to which the companies will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®.
Under the Mylan Collaboration, Mylan paid the Company a non-refundable upfront payment of $25.0 million with additional contingent payments of up to $100.0 million in the aggregate, upon the achievement of specified clinical and regulatory (i.e., biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to $225.0 million. The upfront payment does not represent a financing component for the transfer of goods or services. The contingent payments would be payable following Mylan’s decision (“Continuation Decision”) to continue development services for the Initial Phase and Phase 3 clinical trials and upon meeting certain milestones. In addition, Mylan would pay the Company low to mid double-digit royalties on any sales of the biosimilar in the U.S., mid double-digit royalties on any sales in Europe, and high single-digit royalties on any sales in other areas excluding Japan. However, the Company agreed to waive royalties for U.S. sales, up to a limit of $50.0 million in annual sales, during the first approximately four years after commercialization to defray launch costs.
In August 2019, the Company and Mylan entered into an amendment (the “Mylan Amendment”) to the Mylan Collaboration, pursuant to which, among other things, the Company has agreed to extend the period of time for Mylan to make the Continuation Decision under the Mylan Collaboration as to whether to continue the development and commercialization of the biosimilar beyond the initial development plan, for which both parties prepared and conducted the Biosimilar Initial Advisory Meeting (“BIAM”) with the U.S. Food and Drug Administration (“FDA”). In accordance with the Mylan Amendment, Mylan is required to notify the Company of the Continuation Decision on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that the Company provides Mylan with certain deliverables, and Mylan has agreed to make an incremental payment to the Company in the amount of $5.0 million.
Revenue Recognition
As of the Mylan Amendment date, the Company has the following unfulfilled non-distinct performance obligations within the Mylan Collaboration: (1) intellectual property (“IP”) license for technology and know–how related to the biosimilar, (2) the performance of development services after the Initial Phase for the biosimilar through the filing of an Investigational New Drug (“IND”) application by the Company, and (3) manufacturing services to provide drug substance or drug product during the development and commercialization periods. The performance obligation related to the initial development services for the biosimilar up to the BIAM was completed in February 2019.
In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The initial estimated transaction price was $81.0 million which included a $25.0 million upfront payment, $40.0 million of development milestones, and the estimated variable consideration for cost-sharing payments from Mylan. The Company re-evaluates the transaction price at each reporting period. As of September 30, 2019, the transaction price allocated to the unfulfilled performance obligations is $107.0 million, which incorporates the impact from the incremental payment of $5.0 million and estimated variable consideration for cost-sharing payments resulting from the Mylan Amendment.
The Company recognizes revenue and estimates deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. As a result of the extended period of time for Mylan to make the Continuation Decision provided in the Mylan Amendment, both short-term and long-term deferred revenue have been adjusted accordingly to reflect the impact of the extension. For revenue recognition purposes, the development period is estimated to extend through 2024. However, it is possible that this period will change and is assessed at each reporting date.

9
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

For the three and nine months ended September 30, 2019, the Company recognized revenue related to development services of less than $0.1 million and $0.3 million, respectively. For the three and nine months ended September 30, 2018, the Company recognized revenue related to development services of $2.4 million and $3.2 million, respectively. As of September 30, 2019 and December 31, 2018, the Company estimated short-term deferred revenue of $5.2 million and $8.6 million, respectively; and long-term deferred revenue of $20.7 million and $12.7 million, respectively.
Fosun License Agreement
The Company and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”) entered into a license agreement (the “Fosun License Agreement”) in December 2018, whereby the Company has granted Fosun the exclusive rights to develop and commercialize the Company’s proprietary DAXI in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.
Under the Fosun License Agreement, the Company received a non-refundable upfront payment of $30.0 million net of foreign withholding tax of $3.0 million from Fosun in January 2019. The Company is also eligible to receive (i) additional contingent payments of up to $230.5 million upon the achievement of specified milestones, and (ii) tiered royalty payments in low double-digit to high-teen percentages on annual net sales.
Revenue Recognition
In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The Company estimated the transaction price for the Fosun License Agreement using the most likely amount method. The Company evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered, and concluded only a certain milestone of $1.0 million was included in the transaction price. The Company will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of September 30, 2019, the transaction price allocated to unfulfilled performance obligation is $31.0 million. The Company will recognize revenue on the single performance obligation as control of the manufactured product is supplied to Fosun.
For the nine months ended September 30, 2019, no revenue has been recognized from the Fosun License Agreement. As of September 30, 2019 and December 31, 2018, substantially all of the $30.0 million non-refundable upfront payment was included in long-term deferred revenue.

10
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

3. Medicis Settlement
In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a proceeds sharing arrangement payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and $7.1 million in 2014, and (iii) a product approval payment of $4.0 million to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. In December 2012, Medicis was subsequently acquired by Valeant Pharmaceuticals International Inc., now known as Bausch Health Companies Inc.
The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled.
As of September 30, 2019, the fair value of the Company’s liability for the product approval payment was $2.9 million, which was measured using a term of 1.1 years, a risk-free rate of 1.7% and a credit risk adjustment of 7.5%. As of December 31, 2018, the fair value of the Company’s liability for the product approval payment was $2.7 million, which was measured using a term of 1.5 years, a risk-free rate of 2.6% and a credit risk adjustment of 8.0%. The term is based on an expected Biologics License Application (“BLA”) approval in 2020. For the nine months ended September 30, 2019 and 2018, no payment was made for the product approval payment.

11
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

4. Cash Equivalents and Investments
The Company’s cash equivalents and investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.
The following table is a summary of amortized cost, unrealized gains and losses, and fair value:
 
September 30, 2019
 
December 31, 2018
 
 
 
Unrealized
 
 
 
 
 
Unrealized
 
 
(in thousands)
Cost
 
Gains
 
Fair Value
 
Cost
 
Gains
 
Losses
 
Fair Value
Money market funds
$
40,153

 
$
—

 
$
40,153

 
$
38,354

 
$
—

 
$
—

 
$
38,354

U.S. treasury securities
75,326

 
27

 
75,353

 
80,844

 
5

 
(5
)
 
80,844

U.S. government agency obligations
32,867

 
15

 
32,882

 
52,586

 
—

 
(8
)
 
52,578

Commercial paper
43,873

 
—

 
43,873

 
—

 
—

 
—

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

 
—

 
—

 
—

Total cash equivalents and available-for-sale securities
$
206,720

 
$
42

 
$
206,762

 
$
171,784

 
$
5

 
$
(13
)
 
$
171,776

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classified as:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
$
56,652

 
 
 
 
 
 
 
$
69,220

Short-term investments
 
 
 
 
150,110

 
 
 
 
 
 
 
102,556

Total cash equivalents and available-for-sale securities
 
 
 
 
$
206,762

 
 
 
 
 
 
 
$
171,776


As of September 30, 2019 and December 31, 2018, the Company has no other-than-temporary impairments on its available-for-sale securities.
Related Party Transactions
The Company had no related party transactions for the nine months ended September 30, 2019.
As of December 31, 2018, JPMorgan Chase & Co. and its wholly owned subsidiaries JPMorgan Chase Bank, National Association (NA), J.P. Morgan Investment Management Inc., and JPMorgan Asset Management (UK) Limited held approximately 3.8 million shares or 10.3% of the Company’s outstanding common stock. J.P. Morgan Securities LLC is an affiliate of JPMorgan Chase Bank, NA, and it acts as a custodian and trustee for certain investments of the Company. As of December 31, 2018, cash, cash equivalents, and investments of $87.7 million were held in an investment account with J.P. Morgan Securities LLC. As of September 30, 2019, JPMorgan Chase & Co. and its wholly owned subsidiaries owned less than 10% of the Company’s outstanding common stock.

5. Fair Value Measurements
The Company determines the fair value of certain financial assets and liabilities using three levels of inputs as follows:
•
Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities;
•
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

12
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

•
Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.
The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:
 
September 30, 2019
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
40,153

 
$
40,153

 
$
—

 
$
—

U.S. treasury securities
75,353

 
75,353

 
—

 
—

U.S. government agency obligations
32,882

 
—

 
32,882

 
—

Commercial paper
43,873

 
—

 
43,873

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

Total assets measured at fair value
$
206,762

 
$
115,506

 
$
91,256

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,892

 
$
—

 
$
—

 
$
2,892

Total liabilities measured at fair value
$
2,892

 
$
—

 
$
—

 
$
2,892

 
December 31, 2018
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
38,354

 
$
38,354

 
$
—

 
$
—

U.S. treasury securities
80,844

 
80,844

 
—

 
—

U.S. government agency obligations
52,578

 
—

 
52,578

 
—

Total assets measured at fair value
$
171,776

 
$
119,198

 
$
52,578

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,753

 
$
—

 
$
—

 
$
2,753

Total liabilities measured at fair value
$
2,753

 
$
—

 
$
—

 
$
2,753


The Company classifies U.S. government agency obligations, commercial paper, and overnight repurchase agreements within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair values.
The following table summarizes the change in the fair value of the Company’s Level 3 financial instrument:
(in thousands)
Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2018
$
2,753

Change in fair value
139

Fair value as of September 30, 2019
$
2,892



13
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

The fair value of the derivative liability associated with the Medicis settlement was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (Note 3). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.
6. Leases
The Company has non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. One of the facility operating leases commenced in February 2019. As of September 30, 2019, the weighted average remaining lease term is 7.2 years. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of 2022. The Company has options to extend the facility operating leases for up to 14 years. The Company’s lease contracts do not contain termination options, residual value guarantees or restrictive covenants.
The operating lease costs are summarized as follows:
 
Three Months Ended
 
Nine Months Ended
(in thousands)
September 30, 2019
 
September 30, 2019
Operating lease cost
$
1,425

 
$
4,193

Variable lease cost (1)
298

 
886

Total operating lease costs
$
1,723

 
$
5,079

(1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
As of September 30, 2019, maturities of the Company’s operating lease liabilities are as follows:
Year Ending December 31,
(in thousands)
2019 remaining three months
$
1,633

2020
6,735

2021
6,942

2022
5,464

2023
5,557

2024 and thereafter
17,959

Total operating lease payments
44,290

Less imputed interest (1)
(14,195
)
Present value of operating lease payments
$
30,095

(1) The Company’s lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates.


14
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

As of December 31, 2018, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows:
Year Ending December 31,
(in thousands)
2019
$
5,826

2020
6,011

2021
6,196

2022
4,696

2023 and thereafter
20,173

Total payments
$
42,902


Supplemental cash flow information related to the operating leases was as follows:
 
Nine Months Ended
(in thousands)
September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
$
4,704

Right-of-use assets obtained in exchange for operating lease liabilities
$
3,890




15
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

7. Commitments and Contingencies
Purchase Commitments
The Company and Ajinomoto Althea, Inc. (“Althea”) are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Althea Services Agreement”), under which Althea provides the Company a contract development and manufacturing organization, which allows the Company to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DAXI. Under the Althea Services Agreement, the initial term is to 2024, unless terminated sooner by either company, and the Company has minimum purchase obligations based on its production forecasts. As of September 30, 2019, non-refundable advanced payments of $1.3 million under the Althea Services Agreement have been recorded in prepaid expense on the Company’s Condensed Consolidated Balance Sheets. The remaining services can be canceled at any time, with the Company required to pay costs incurred through the cancellation date.
Contingencies
The Company is obligated to pay $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of September 30, 2019, the milestone has not been achieved. The Company is also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.
The Company and Botulinum Toxin Research Associates, Inc. (“BTRX”) are parties to an asset purchase agreement (the “BTRX Purchase Agreement”), under which the Company is obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to the Company’s product revenue, intellectual property, and clinical and regulatory events. As of September 30, 2019, a one-time intellectual property development milestone liability of $1.0 million has been recorded in accruals on the Company’s Condensed Consolidated Balance Sheets.
The Company and BioSentinel, Inc. (“BioSentinel”) are parties to an agreement under which the Company in-licenses BioSentinel’s technology and expertise for research, development and manufacturing purposes. The Company is obligated to pay BioSentinel minimum quarterly use fees, and a one-time milestone payment of $0.3 million when regulatory approval is achieved. As of September 30, 2019, the milestone has not been achieved.
Indemnification
The Company has standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments the Company is obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against the Company in the future, but have not been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
The Company has indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
For the nine months ended September 30, 2019, no amounts associated with the indemnification agreements have been recorded.

16
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

8. Stockholders’ Equity
Common Stock Warrants
As of September 30, 2019 and December 31, 2018, 34,113 common stock warrants were outstanding at an exercise price of $14.95 per share, which expire in 2020.
Stock Option Plan
2014 Equity Incentive Plan (“2014 EIP”)
On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 1,479,008 shares. For the nine months ended September 30, 2019, 1,202,650 stock options and 513,225 restricted stock awards were granted under the 2014 EIP. As of September 30, 2019, 2,018,200 shares were available for issuance under the 2014 EIP.
2014 Inducement Plan (the “2014 IN”)
For the nine months ended September 30, 2019, no stock options or restricted stock awards were granted under the 2014 IN. As of September 30, 2019, 170,019 shares were available for issuance under the 2014 IN.
2014 Employee Stock Purchase Plan (the “2014 ESPP”)
On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 300,000 shares. As of September 30, 2019, 1,443,774 shares were available for issuance under the 2014 ESPP.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows:
(in thousands)
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Research and development
$
2,106

 
$
1,836

 
$
6,438

 
$
5,627

General and administrative
2,197

 
2,256

 
6,444

 
6,795

Total stock-based compensation expense
$
4,303

 
$
4,092

 
$
12,882

 
$
12,422


Net Loss per Share
The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive.
Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:

17
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

 
As of September 30,
 
2019
 
2018
Outstanding common stock options
4,402,244

 
3,491,751

Outstanding common stock warrants
34,113

 
34,113

Unvested restricted stock awards
788,125

 
679,541

Shares of common stock expected to be purchased on December 31 under the 2014 ESPP
45,123

 
16,712


Follow-On Public Offering
In January 2019, the Company completed the 2019 follow-on public offering, pursuant to which the Company issued 6,764,705 shares of common stock at $17.00 per share, including the exercise of the underwriters’ over-allotment option to purchase 882,352 additional shares of common stock, for aggregate net proceeds of $107.6 million, after deducting underwriting discounts, commissions and other offering expenses.
At-The-Market Offering
The Company and Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) are parties to a Controlled Equity Offering sales agreement (the “2018 ATM Agreement”), under which the Company may offer and sell common stock having aggregate proceeds of up to $125.0 million through Cantor Fitzgerald as its sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon the Company’s instructions, and the Company will pay a commission to Cantor Fitzgerald of up to 3.0% of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the nine months ended September 30, 2019 and 2018, no common stock was sold under the 2018 ATM Agreement.
9. Income Taxes
California State Apportionment
In 2018, the Company petitioned the California Franchise Tax Board for an alternative apportionment percentage due to the insignificant apportionment percentage derived from the single sales factor methodology for California. In January 2019, the California Franchise Tax Board approved the use of an alternative apportionment method. The Company’s net operating losses (“NOL”) in California is estimated to increase by approximately $219 million as a result of the change in apportionment model. The Company has increased its deferred tax assets by $15 million with a corresponding offsetting adjustment to its valuation allowance. There is no impact to the Company’s net loss in the period as a result of the adjustment.
10. Subsequent Event
Effective as of October 13, 2019, the Company’s Board of Directors (the “Board”) appointed Mark J. Foley as the Company’s President, Chief Executive Officer and Principal Executive Officer. In connection with his appointment, the Company has entered into an executive employment agreement, pursuant to which Mr. Foley will initially receive an annual base salary of $650,000 and an annual target bonus of 75% of his base salary. The Board also approved the grant of certain equity awards to Mr. Foley under the 2014 EIP. Mr. Foley received (i) a stock option to purchase 740,000 shares of the Company’s common stock at $12.18 per share, (ii) 200,000 shares of restricted common stock awards of the Company and (iii) 860,000 shares of performance-based common stock awards. The performance-based common stock awards will vest based on the Company’s certain market and performance conditions.
Effective as of October 11, 2019, the Company entered into a separation agreement with L. Daniel Browne providing for (i) a release of claims against the Company, (ii) cash severance payments to Mr. Browne in an amount equal to fifteen months of Mr. Browne’s 2019 base salary; and (iii) certain health care continuation benefits. The separation agreement

18
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)

also provides for an extension of the post-termination exercise period for all vested stock options held by Mr. Browne through the earlier of a Change in Control (as defined in the 2014 EIP) or January 31, 2021.
The Company is currently evaluating the effect on its Consolidated Financial Statements of Mr. Foley’s equity compensation and the modification to Mr. Browne’s vested stock options.

19


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

20


The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the accompanying notes appearing elsewhere in this Quarterly Report on this Form 10-Q and in our other Securities and Exchange Commission (“SEC”) filings, including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019. The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. The following discussion and analysis contains forward-looking statements within meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to, statements concerning the following:
•
our expectations regarding the results, timing and completion of our clinical trials and regulatory submissions needed for the approval of DAXI, including but not limited to, for the treatment of glabellar (frown) lines, forehead lines, lateral canthal lines, cervical dystonia, plantar fasciitis, and adult upper limb spasticity in the United States (“U.S.”), Europe and other countries;
•
our expectations regarding our future development of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates for other indications, including but not limited to, migraine;
•
our expectations regarding the development of future product candidates;
•
the potential for commercialization by us of DAXI, if approved;
•
our expectations regarding the potential market size, opportunity and growth potential for DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved for commercial use;
•
our belief that DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates can expand overall demand for botulinum toxin;
•
our ability to build our own sales and marketing capabilities, or seek collaborative partners including distributors, to commercialize our product candidates, if approved;
•
our ability to manufacture in our facility and to scale up our manufacturing capabilities and those of future third-party manufacturers if our product candidates are approved;
•
estimates of our expenses, future revenue, capital requirements and our needs for additional financing;
•
the timing or likelihood of regulatory filings and approvals;
•
our ability to advance product candidates into, and successfully complete, clinical trials;
•
the implementation of our business model, and strategic plans for our business, product candidates and technology;
•
the initiation, timing, progress and results of future preclinical studies and clinical trials and our research and development programs;
•
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
•
our ability to establish collaborations or obtain additional funding;
•
our financial performance, including future revenue targets; and
•
developments and projections relating to our competitors and our industry.

21


These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part II, Item 1A, “Risk Factors” and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is neither possible for management to predict all risks nor assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.
Overview
We are a biotechnology company developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection (“DAXI”), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, demonstrating efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. We are also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as three therapeutic indications including cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine. Beyond DAXI, we have begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. We are dedicated to making a difference by transforming patient experiences.
Since inception, we have devoted substantially all of our effort to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DAXI, DaxibotulinumtoxinA Topical and the biosimilar to BOTOX®. We have incurred losses and negative cash flows from operations. We have not commenced commercial operations, have not generated product revenue to date, and will continue to incur significant research and development and other expenses related to our ongoing operations. For the three and nine months ended September 30, 2019, we had a net loss of $41.4 million and $114.1 million, respectively. As of September 30, 2019, we had a working capital surplus of $186.4 million and an accumulated deficit of $798.9 million. We have funded our operations primarily through the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2019, we had capital resources of $209.0 million consisting of cash, cash equivalents, and investments. We believe that our existing capital resources will fund the operating plan through at least the next 12 months following the issuance of this Form 10-Q, and may identify additional capital resources to fund our operations.
Neuromodulator Pipeline
DAXI Aesthetics
Glabellar lines. In December 2018, we announced top-line results for the SAKURA 3 open-label, long-term safety study. DAXI appeared to be generally well-tolerated with no new tolerability or safety concerns reported. We held a pre-BLA meeting with the U.S. Food and Drug Administration (“FDA”) in December 2018 to agree upon the content and format of the BLA. We are in the process of compiling one of the largest clinical data packages for an aesthetic indication. We have been working in parallel to develop a 100-unit vial in addition to an initial 50-unit vial. This added additional work streams for process validation and stability. We expect to submit the BLA in November 2019, and are on track for a 2020 approval and launch for DAXI for the treatment of glabellar lines. We plan to file marketing applications in the European Union, Canada, and certain Latin American and Asian countries after filing in the U.S.
Forehead lines. In January 2019, we initiated a Phase 2 multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (also known as “frontalis”) in conjunction with treatment of the glabellar complex. The objective is to understand the potential dosing and injection patterns of DAXI in other areas of the upper face in addition to the lead indication in glabellar lines. We completed enrollment for the study in July 2019, and we expect to release top-line results in the first half of 2020.

22


Lateral canthal lines. In March 2019, we initiated a Phase 2 multicenter, open-label, dose-escalation study to evaluate the treatment of moderate or severe lateral canthal lines (also known as “crow’s feet”). Similar to the forehead lines study above, the objective is to understand the potential dosing and injection patterns of DAXI in other areas of the upper face in addition to the lead indication in glabellar lines. We completed enrollment for the study in August 2019, and we expect to release top-line results in the first half of 2020.
DAXI Therapeutics
Cervical dystonia. In June 2018, we announced the initiation of patient dosing in our ASPEN Phase 3 clinical program based on the Phase 2 safety and efficacy results and guidance from the FDA and European Medicines Agency (“EMA”). The ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DAXI for the treatment of cervical dystonia in adults including: a randomized, double-blind, placebo-controlled, parallel group trial, and an open-label, long-term safety trial. We completed the ASPEN Phase 3 pivotal trial enrollment in October 2019, and expect to release topline results in the second half of 2020.
Adult upper limb spasticity. In December 2018, we initiated a Phase 2 trial for the treatment of adult upper limb spasticity (JUNIPER). This is a randomized, double-blind, placebo-controlled, parallel group, dose-ranging trial to evaluate the efficacy and safety of DAXI for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury. We expect to complete JUNIPER Phase 2 trial enrollment in the first half of 2020.
Plantar fasciitis. In September 2018, we completed a Type C meeting with the FDA discussing the design of the Phase 2 dose-finding study. We initiated another Phase 2 trial in December 2018. The Phase 2 prospective, randomized, double-blind, multi-center, placebo-controlled study will evaluate the safety and efficacy of two doses of administration of our investigational drug candidate DAXI in reducing the signs and symptoms of plantar fasciitis. We expect to complete Phase 2 trial enrollment before the end of 2019 and release topline results in the second half of 2020.
Migraine. We are in the process of developing a migraine clinical development strategy. We may initiate a study with DAXI for the treatment of migraine in 2020.
OnabotulinumtoxinA Biosimilar
We and Mylan entered into the Mylan Collaboration in February 2018, under which the companies will collaborate exclusively, on a worldwide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. Under the Mylan Collaboration, we are responsible for conducting initial non-clinical development activities with the goal of preparing for and conducting a scientific advice meeting with the FDA to receive feedback as to whether a biosimilar biological pathway is feasible for BOTOX®.
In February 2019, we had a biosimilar initial advisory meeting (“BIAM”) with the FDA and Mylan on a proposed biosimilar to BOTOX®. In this meeting, the FDA provided guidance on their expectations for a development program to establish biosimilarity to BOTOX®. Based on the FDA’s feedback, the companies believe that a 351(k) pathway for the development of a biosimilar to onabotulinumtoxinA is viable and provides the opportunity to develop and commercialize the first biosimilar product for potentially all thirteen currently approved indications of BOTOX® and BOTOX® Cosmetic. In April 2019, we received the official FDA minutes from the BIAM.
In August 2019, we entered into the Mylan Amendment modifying the terms of the Mylan Collaboration, pursuant to which, among other things, we have agreed to extend the period of time for Mylan to make a decision under the Mylan Collaboration (“Continuation Decision”) as to whether to continue the development and commercialization of the biosimilar beyond the initial development plan for which both parties prepared and conducted the BIAM with the FDA. In accordance with the Mylan Amendment, Mylan is required to notify us of the Continuation Decision on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables, and Mylan has agreed to make a payment to us in the amount of $5.0 million incremental to the previously agreed non-refundable upfront payment of $25.0 million with contingent payments of up to $100.0 million, in the aggregate, upon the achievement of specified clinical and regulatory milestones, tiered sales milestones of up to $225.0 million, and royalties on sales of the biosimilar in the Mylan territories previously disclosed from the Mylan Collaboration.

23


Fosun License Agreement
We entered into the Fosun License Agreement in December 2018, whereby we granted Fosun the exclusive rights to develop and commercialize our proprietary DAXI in the Fosun Territory and certain sublicense rights. Additionally, our proprietary peptide excipient technology can be used for molecules other than botulinum toxin. We plan to partner or license the peptide excipient technology opportunistically to monetize our technology platform.
In January 2019, we received a non-refundable upfront payment of $30.0 million, net of foreign withholding tax of $3.0 million, from Fosun under the Fosun License Agreement.
Follow-On Public Offering
In January 2019, we completed the 2019 follow-on public offering, pursuant to which we issued 6,764,705 shares of common stock at $17.00 per share, including the exercise of the underwriters’ over-allotment option to purchase 882,352 additional shares of common stock, for aggregate net proceeds of $107.6 million, after deducting underwriting discounts, commissions and other offering expenses.
Results of Operations
Revenue
For the three and nine months ended September 30, 2019, our total revenue decreased $2.3 million or 98%, and $2.9 million or 90%, respectively, compared to the same periods in 2018, due to the timing of the initial development activities from the Mylan Collaboration which was completed in February 2019.
Operating Expenses
Our operating expenses consist of research and development expenses and general and administrative expenses. The largest component of our operating expenses is our personnel costs including stock-based compensation. We expect our operating expenses to increase in the near term as we prepare to commercialize DAXI for glabellar lines, initiate and complete additional clinical trials and associated programs related to DAXI for the treatment of facial wrinkles, cervical dystonia, plantar fasciitis, adult upper limb spasticity, and any future new indications, and our biosimilar product candidate.

24


Research and Development Expenses
We recognize research and development expenses as they are incurred. Since our inception, we have focused on our clinical development programs and the related research and development. Since 2002, we have been developing one or more of DAXI, DaxibotulinumtoxinA Topical, and our biosimilar product candidate and have typically shared our employees, consultants and infrastructure resources across all programs. We believe that the strict allocation of costs by product candidate would not be meaningful, therefore, we generally do not track these costs by product candidates.
Research and development expenses consist primarily of:
•
salaries and related expenses for personnel in research and development functions, including stock-based compensation;
•
expenses related to the initiation and completion of clinical trials and studies for DAXI, DaxibotulinumtoxinA Topical and our biosimilar candidate, including expenses related to production of clinical supplies;
•
fees paid to clinical consultants, contract research organizations (“CROs”) and other vendors, including all related fees for investigator grants, patient screening fees, laboratory work and statistical compilation and analysis;
•
other consulting fees paid to third parties;
•
expenses related to establishment and maintenance of our own manufacturing facilities;
•
expenses related to the manufacture of drug substance and drug product supplies for ongoing and future preclinical and clinical trials and other pre-commercial supplies;
•
expenses to support our product development and establish manufacturing capabilities to support potential future commercialization of any products for which we may obtain regulatory approval;
•
expenses related to license fees and milestone payments under in-licensing agreements;
•
expenses related to compliance with drug development regulatory requirements in the U.S., the European Union and other foreign jurisdictions; and
•
depreciation and other allocated expenses.
Our research and development expenses are subject to numerous uncertainties primarily related to the timing and cost needed to complete our respective projects. Further, the development timelines, probability of success and development expenses can differ materially from expectations, and the completion of clinical trials may take several years or more depending on the type, complexity, novelty and intended use of a product candidate. Accordingly, the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development. We expect our research and development expenses to maintain or increase as we continue our clinical development of DAXI for the treatment of facial wrinkles and other neuroscience indications, such as cervical dystonia, plantar fasciitis, adult upper limb spasticity, and migraine, any future new indications, and our biosimilar product candidate or if the FDA requires us to conduct additional clinical trials for approval.
Our research and development expenses fluctuate as projects transition from one development phase to the next. Depending on the stage of completion and level of effort related to each development phase undertaken, we may reflect variations in our research and development expenses. We expense both internal and external research and development expenses as they are incurred.

25


Our research and development expenses are summarized as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except percentages)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Clinical and regulatory
$
13,090

 
$
10,633

 
23
 %
 
$
38,204

 
$
34,408

 
11
 %
Manufacturing and quality
8,140

 
5,452

 
49
 %
 
23,229

 
17,958

 
29
 %
Other research and development expenses
2,511

 
3,927

 
(36
)%
 
7,497

 
8,975

 
(16
)%
Stock-based compensation
2,106

 
1,836

 
15
 %
 
6,438

 
5,627

 
14
 %
Total research and development expenses
$
25,847

 
$
21,848

 
18
 %
 
$
75,368

 
$
66,968

 
13
 %
Clinical and regulatory
Clinical and regulatory expenses include personnel costs, external clinical trial costs for clinical sites, clinical research organizations, central laboratories, data management, contractors and regulatory activities associated with the development of DAXI. For the three months ended September 30, 2019 and 2018, clinical and regulatory costs totaled $13.1 million, or 51%, and $10.6 million, or 49%, respectively, of the total research and development expenses for the respective periods. For the nine months ended September 30, 2019 and 2018, clinical and regulatory costs totaled $38.2 million, or 51%, and $34.4 million, or 51%, respectively, of the total research and development expenses for the respective periods.
For the three and nine months ended September 30, 2019, clinical and regulatory expenses increased by $2.5 million, or 23%, and $3.8 million, or 11%, respectively, compared to the same period in 2018. This increase is primarily due to increased costs related to hiring additional personnel and outside services to support BLA preparation activities. We expect to maintain or increase our clinical and regulatory expenses in the near term as we initiate and complete clinical trials and other associated programs related to DAXI for the treatment forehead lines, lateral canthal lines, cervical dystonia, plantar fasciitis, adult upper limb spasticity, and migraine, and our anticipated BLA submission for DAXI for the treatment of glabellar (frown) lines.
Manufacturing and quality
Manufacturing and quality expenses include personnel and occupancy expenses, external contract manufacturing costs and pre-approval manufacturing of drug product used in our research and development of DAXI. Manufacturing and quality expenses also include raw materials, lab supplies, and storage and shipment of our product to support quality control and assurance activities. These expenses do not include clinical expenses associated with the development of DAXI. For the three months ended September 30, 2019 and 2018, manufacturing and quality expenses were $8.1 million, or 31%, and $5.5 million, or 25%, respectively, of the total research and development expenses for the respective periods. For the nine months ended September 30, 2019 and 2018, manufacturing and quality expenses were $23.2 million, or 31%, and $18.0 million, or 27%, respectively, of the total research and development expenses for the respective periods.
For the three and nine months ended September 30, 2019, manufacturing and quality expenses increased by $2.7 million, or 49%, and $5.3 million, or 29%, respectively, compared to the same period in 2018, primarily due to increased costs related to pre-BLA manufacturing and quality activities, hiring additional personnel and outside services to address compliance requirements, and infrastructure build-out. We expect to increase our manufacturing and quality efforts as we approach commercialization.
Other research and development expenses
Other research and development expenses include expenses for personnel, contract research organizations, consultants, raw materials, and lab supplies used to conduct preclinical research and development of DAXI and our biosimilar product candidate. For the three months ended September 30, 2019 and 2018, other research and development expenses were $2.5 million, or 10%, and $3.9 million, or 18%, respectively, of the total research and development expenses for the respective periods. For the nine months ended September 30, 2019 and 2018, other research and development expenses were $7.5 million, or 10%, and $9.0 million, or 13%, respectively, of the total research and development expenses for the respective periods.

26


For the three and nine months ended September 30, 2019, other research and development expenses decreased by $1.4 million, or 36%, and $1.5 million, or 16%, respectively, compared to the same period in 2018, primarily due to the expenses related to the initial development activities from the Mylan Collaboration, which was completed in February 2019.
Stock-based compensation
For the three and nine months ended September 30, 2019, stock-based compensation included in research and development expenses increased by $0.3 million, or 15%, and $0.8 million, or 14%, respectively, compared to the same periods in 2018, primarily due to increased employee headcount, offset by an average decrease in fair value of stock options granted during these periods.
General and Administrative Expenses
General and administrative expenses consist primarily the following:
•
pre-commercial activities including market research, public relations, promotion and advertising;
•
personnel and service costs in our finance, information technology, commercial, investor relations, legal, human resources, and other administrative functions; and
•
professional fees for accounting and legal services, including legal services associated with obtaining and maintaining patents and litigation.
We expect that our general and administrative expenses will maintain or increase with the continued development of, and if approved, the commercialization of DAXI.
Our general and administration expenses are summarized as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except percentages)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
General and administrative expenses before stock-based compensation
$
14,542

 
$
11,899

 
22
 %
 
$
36,801

 
$
33,710

 
9
 %
Stock-based compensation
2,197

 
2,256

 
(3
)%
 
6,444

 
6,795

 
(5
)%
Total general and administrative expenses
$
16,739

 
$
14,155

 
18
 %
 
$
43,245

 
$
40,505

 
7
 %
General and administrative expenses before stock-based compensation
For the three months ended September 30, 2019, general and administrative expenses before stock-based compensation increased by $2.6 million, or 22%, compared to the same period in 2018, primarily due to increased personnel in administrative functions and costs related to infrastructure build-out. For the nine months ended September 30, 2019, general and administrative expenses before stock-based compensation increased by $3.1 million, or 9% compared to the same period in 2018, primarily due to increased personnel in administrative functions, costs related to first-year effort to comply with Sarbanes-Oxley 404(b) requirements, and costs related to infrastructure build-out.
Stock-based compensation
For the three and nine months ended September 30, 2019, stock-based compensation included in general and administrative expenses decreased by $0.1 million, or 3%, and $0.4 million, or 5%, respectively, compared to the same period in 2018, primarily due to an average decrease in fair value of stock option granted during the period, offset by higher employee headcount.

27


Net Non-Operating Income and Expense
Interest Income
Interest income primarily consists of interest income earned on our deposit, money market fund, and investment balances. We expect interest income to vary each reporting period depending on our average deposit, money market fund, and investment balances during the period and market interest rates.
Interest Expense
Interest expense primarily consists of the interest charges associated with our financing obligations and capitalized interest. Interest expense includes cash and non-cash components with the non-cash components consisting of effective interest recognized on the financing obligations, and interest capitalized for assets constructed for use in operations.
Change in Fair Value of Derivative Liability associated with the Medicis settlement
The product approval payment associated with the Medicis settlement is classified as a liability on our Condensed Consolidated Balance Sheet. This liability is remeasured to fair value at each balance sheet date with the corresponding gain or loss recorded. We will continue to record adjustments to the fair value of the Medicis settlement derivative liability until the product approval payment is paid.
Other Expense, net
Other expense, net primarily consists of miscellaneous tax and other expense items.
Our net non-operating income and expense are summarized as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except percentages)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Interest income
$
1,329

 
$
996

 
33
 %
 
$
4,495

 
$
3,099

 
45
 %
Interest expense
—

 
—

 
—
 %
 
—

 
(44
)
 
(100
)%
Change in fair value of derivative liability associated with the Medicis settlement
(68
)
 
(45
)
 
51
 %
 
(139
)
 
(150
)
 
(7
)%
Other expense, net
(130
)
 
(144
)
 
(10
)%
 
(170
)
 
(626
)
 
(73
)%
Total net non-operating income
$
1,131

 
$
807

 
40
 %
 
$
4,186

 
$
2,279

 
84
 %
For the three months ended September 30, 2019, our total net non-operating income increased by $0.3 million compared to the same period in 2018, primarily due to an increase in interest income of $0.3 million from our investments. For the nine months ended September 30, 2019, our total net non-operating income increased by $1.9 million compared to the same period in 2018, primarily due to our higher cash, cash equivalents, and investments balance and higher interest rates in 2019.
Liquidity and Capital Resources
Our financial condition is summarized as follows:
 
September 30,
 
December 31,
 
Increase
(in thousands)
2019
 
2018
 
Cash, cash equivalents, and investments
$
209,032

 
$
175,812

 
$
33,220

Working capital
$
186,414

 
$
175,952

 
$
10,462

Total stockholders’ equity
$
151,281

 
$
145,622

 
$
5,659


28


Sources and Uses of Cash
We hold our cash, cash equivalents, and investments in a variety of non-interest bearing bank accounts and interest-bearing instruments subject to investment guidelines allowing for holdings in money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements. Our investment portfolio is structured to provide for investment maturities and access to cash to fund our anticipated working capital needs.
As of September 30, 2019 and December 31, 2018, we had cash, cash equivalents and investments of $209.0 million and $175.8 million, respectively, which represented an increase of $33.2 million. The increase was primarily driven by the proceeds from issuance of common stock (net of commissions and discount) of $108.1 million in connection with the 2019 follow-on offering, the upfront payment (net of withholding tax) received under the Fosun License Agreement of $27.0 million, and the proceeds from maturity of investments of $183.0 million. These increases were primarily offset by cash used in other operating activities of $99.7 million, purchases of investments of $228.6 million, and purchases of property and equipment of $3.0 million.
Through September 30, 2019, we have funded substantially all of our operations through the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes. Since our inception, we have generated significant net loss due to our substantial research and development expenses. We expect to continue to incur net loss for at least the next several years as we advance DAXI through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization. As a result, we will need additional capital to fund our operations which we may obtain from additional financings, public offerings, or other sources.
We derived the following summary of our unaudited Condensed Consolidated Cash Flows for the periods indicated from Part I, Item 1, “Financial Information—Condensed Consolidated Financial Statements (Unaudited)” in this Form 10-Q:
 
Nine Months Ended September 30,
(in thousands)
2019
 
2018
Net cash provided by (used in):
 
 
 
Operating activities
$
(72,653
)
 
$
(73,105
)
Investing activities
$
(48,511
)
 
$
(166,127
)
Financing activities
$
106,830

 
$
1,618

Cash Flows from Operating Activities
Our cash used in operating activities is primarily driven by personnel, manufacturing costs, clinical development, and facility related expenditures. The changes in net cash used in operating activities are primarily related to our net loss, working capital fluctuations and changes in our non-cash expenses, all of which are highly variable. Our cash flows from operating activities will continue to be affected principally by our working capital requirements and the extent to which we increase spending on personnel and research and development activities as our business grows.
For the nine months ended September 30, 2019, net cash used in operating activities was $72.7 million, which was primarily due to clinical spend of approximately $25 million to advance our clinical programs toward commercialization; investing in our personnel and talent retention, which represents approximately $33 million; professional services and consulting of approximately $28 million; and rent, supplies and utilities of $14 million; offset by the upfront payment, net with withholding tax, received under the Fosun License Agreement of $27 million. The remaining balance of operating activities related primarily to other supplies.
For the nine months ended September 30, 2018, net cash used in operating activities was $73.1 million, which was primarily due to clinical spend of approximately $35 million to advance our clinical programs toward commercialization; investing in our personnel and talent retention, which represents approximately $30 million; and professional services and consulting of approximately $25 million, offset by cash receipts of $25 million from Mylan upfront payment and interest received of approximately $5 million. The remaining balance of operating activities related primarily to rent, utilities, supplies, and other general and administrative costs.

29


Cash Flows from Investing Activities
For the nine months ended September 30, 2019 and 2018, net cash used in investing activities was primarily due to purchases of property and equipment, and fluctuations in the timing of purchases and maturities of investments offset by the proceeds from sale of property and equipment.
Cash Flows from Financing Activities
For the nine months ended September 30, 2019, net cash provided by financing activities was primarily driven by proceeds from the issuance of our common stock in connection with the 2019 follow-on offering (as described below) and proceeds from the exercise of stock options and employee stock purchase plan, offset by net settlement of restricted stock awards for employee taxes and payment of offering costs. For the nine months ended September 30, 2018, net cash provided by financing activities was primarily driven by proceeds from the exercise of stock options and employee stock purchase plan, offset by net settlement of restricted stock awards for employee taxes, principal payments made on financing obligations, and payment of offering costs.
Follow-On Public Offering
In January 2019, we completed the 2019 follow-on public offering, pursuant to which we issued 6,764,705 shares of common stock at $17.00 per share, including the exercise of the underwriters’ over-allotment option to purchase 882,352 additional shares of common stock, for aggregate net proceeds of $107.6 million, after deducting underwriting discounts, commissions and other offering expenses.
ATM Offering
We entered into a Controlled Equity Offering sales agreement (the “2018 ATM Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) in March 2018, under which we may offer and sell common stock having aggregate proceeds of up to $125.0 million through Cantor Fitzgerald as our sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon with Cantor Fitzgerald. From time to time, Cantor Fitzgerald will sell the common stock based upon our instructions, and we will pay a commission to Cantor Fitzgerald of up to 3.0% of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the nine months ended September 30, 2019 and 2018, no common stock was sold under the 2018 ATM Agreement with Cantor Fitzgerald & Co.
Common Stock and Common Stock Equivalents
As of October 24, 2019, outstanding shares of common stock were 45,108,360, outstanding stock options were 4,816,118, outstanding common stock warrants were 34,113, unvested restricted stock awards were 1,786,305, and shares expected to be purchased on December 31, 2019 under the 2014 ESPP were 60,164.

30


Operating and Capital Expenditure Requirements
We have not achieved profitability on a quarterly or annual basis since our inception and we expect to continue to incur net losses for the foreseeable future. We expect to make additional capital outlays to increase operating expenditures to support the completion of the clinical trials and other associated programs relating to DAXI for the treatment of facial wrinkles, cervical dystonia, plantar fasciitis, adult upper limb spasticity, and migraine, seek regulatory approval, prepare for and, if approved, proceed to commercialization. We believe that our existing capital resources will be sufficient to fund our operations for at least the next 12 months following the filing of this Form 10-Q. However, we anticipate that we will need to raise substantial additional financing in the future to fund our operations. In order to meet these additional cash requirements, we may seek to sell additional equity or issue debt, convertible debt or other securities that may result in dilution to our stockholders. If we raise additional funds through the issuance of debt or convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations, and financial condition.

31


If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay clinical trials or other development activities for DAXI and our biosimilar product candidate, and any future product candidates, or delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, if we obtain marketing approval. We may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. Our future capital requirements depend on many factors, including:
•
the results of our clinical trials for DAXI and preclinical trials of DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
the timing of, and the costs involved in, obtaining regulatory approvals for DAXI, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar;
•
the number and characteristics of any additional product candidates we develop or acquire;
•
the scope, progress, results and costs of researching and developing and conducting preclinical and clinical trials of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
the cost of commercialization activities if DAXI or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar are approved for sale, including marketing, sales and distribution costs;
•
the cost of manufacturing DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates and any products we successfully commercialize and maintaining our related facilities;
•
our ability to establish and maintain strategic collaborations, licensing or other arrangements including the Mylan collaboration, Fosun licensing, and the terms of and timing such arrangements;
•
the degree and rate of market acceptance of any future approved products;
•
the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments;
•
any product liability or other lawsuits related to our products;
•
the expenses needed to attract and retain skilled personnel;
•
any litigation, including litigation costs and the outcome of such litigation;
•
the costs associated with being a public company;
•
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and
•
the timing, receipt and amount of sales of, or royalties on, future approved products, if any.
Please see Part II, Item 1A. “Risk Factors” for additional risks associated with our substantial capital requirements.
Critical Accounting Policies
For the nine months ended September 30, 2019, there have been no material changes in our critical accounting policies as compared to those disclosed in Item 7 in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019, except as described in Part I, Item 1, “Financial Information—Notes to Unaudited Condensed Consolidated Financial Statements (Unaudited)—Note 1—The Company and Summary of Significant Accounting Policies” in this Form 10-Q.

32


Contractual Obligations
Our minimum contractual commitments were reported in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on February 28, 2019. Our future minimum contractual commitments have not changed materially from the amounts previously reported.
Recent Accounting Pronouncements
Refer to “Recent Accounting Pronouncements” in Part I, Item 1, “Financial Information—Notes to Unaudited Condensed Consolidated Financial Statements (Unaudited)—Note 1—The Company and Summary of Significant Accounting Policies” in this Form 10-Q.
Off-Balance Sheet Arrangements
As of September 30, 2019, we did not have any off-balance sheet arrangements or any relationships with any entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange rates and interest rates. We do not hold or issue financial instruments for trading purposes. For the nine months ended September 30, 2019, our exposure to market risk has not changed materially since that disclosed in Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting

33


For the three months ended September 30, 2019, there were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

34


PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may be involved in litigation relating to claims arising out of our operations. We are not currently involved in any material legal proceedings. We may, however, be involved in material legal proceedings in the future. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.
ITEM 1A. RISK FACTORS
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as all other information included in this Form 10-Q, including our Condensed Consolidated Financial Statements, the notes thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before you decide to purchase shares of our common stock. If any of the following risks actually occurs, our business, prospects, financial condition and operating results could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and stock price.
We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2018.
Risks Related to Our Business and Strategy
We are substantially dependent on the clinical and commercial success of our product candidate DAXI.*
To date, we have invested substantial efforts and financial resources in the research and development of botulinum toxin-based product candidates. Our success as a company is substantially dependent on the clinical and commercial success of DAXI.
We completed Phase 3 clinical development for DAXI in North America for the treatment of glabellar lines. From 2016 to 2018, we conducted and announced results relating to multiple pivotal and safety trials in our SAKURA Phase 3 program. The SAKURA 1 and SAKURA 2 trials were designed to evaluate the safety and efficacy of a single administration of DAXI for the treatment of moderate-to-severe glabellar lines in adults. In addition to the two pivotal trials, the Phase 3 program includes a long-term open-label safety trial (SAKURA 3), which is designed to evaluate the long-term safety and duration of DAXI for the treatment of moderate to severe glabellar lines in adults following both single and repeat treatment administration. SAKURA 3 was designed to support a safety database adequate for both domestic and international marketing applications. We plan to file marketing applications for DAXI for the treatment of glabellar lines first in the U.S. in November 2019, followed by the European Union, Canada, and certain Latin American and Asian countries.
In 2015, we initiated a Phase 2 dose-escalating, open-label clinical study of DAXI for the treatment of cervical dystonia. The Phase 2 study evaluated the safety, preliminary efficacy, and duration of effect of DAXI in subjects with moderate to severe isolated cervical dystonia. Based on the Phase 2 safety and efficacy results and subsequent guidance from the FDA and EMA, in June 2018 we announced the initiation of patient dosing in our ASPEN Phase 3 clinical program. The ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DAXI for the treatment of cervical dystonia in adults including: a randomized, double-blind, placebo-controlled, parallel group trial and an open-label, long-term safety trial. In October 2019, we completed the ASPEN Phase 3 pivotal trial enrollment, and plan to release topline results in the second half of 2020.

35


In 2016, we also initiated a Phase 2 prospective, randomized, double-blinded, placebo-controlled trial of DAXI in the therapeutic indication of plantar fasciitis. This study evaluated the safety and efficacy of a single administration of DAXI in reducing the signs and symptoms of plantar fasciitis. The study’s primary efficacy endpoint is the improvement in the American Orthopedic Foot and Ankle Score. In January 2018, we announced interim 8-week results from this study. We completed the 16-week trial which showed a 58 percent reduction of pain from baseline along with a strong placebo response, with the difference between the treatment groups not being statistically significant. We initiated another Phase 2, double-blind, placebo-controlled trial utilizing two doses of DAXI in the fourth quarter of 2018. We expect to complete Phase 2 trial enrollment before the end of 2019 and release topline results in the second half of 2020.
In April 2018, we announced two new clinical programs for DAXI, including adult upper limb spasticity and migraine. We initiated the JUNIPER Phase 2 study in adult upper limb spasticity in the fourth quarter of 2018 and we expect to complete Phase 2 trial enrollment in the first half of 2020. In 2020, we may initiate a study with DAXI for the treatment of migraine.
In July 2019, we completed the enrollment in the Phase 2 clinical study of DAXI for forehead lines. In August 2019, we completed Phase 2 study enrollment of DAXI for lateral canthal lines (crow’s feet). Topline results for both studies are expected in the first half of 2020.

Our near-term prospects, including our ability to finance our company and generate revenue, will depend heavily on the successful development, regulatory approval and commercialization of DAXI. Our longer-term prospects will depend on the successful development, regulatory approval and commercialization of DAXI, as well as DaxibotulinumtoxinA Topical, biosimilar or any future product candidates. The preclinical, clinical and commercial success of our product candidates will depend on a number of factors, including the following:
•
timely completion of, or need to conduct additional, clinical trials, including our clinical trials for DAXI, DaxibotulinumtoxinA Topical, biosimilar and any future product candidates, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the number and design of such trials and the accurate and satisfactory performance of third-party contractors;
•
our ability to demonstrate the effectiveness and differentiation of our products on a consistent basis as compared to existing or future therapies;
•
our ability to demonstrate to the satisfaction of the FDA, the safety and efficacy of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates through clinical trials;
•
whether we are required by the FDA or other similar foreign regulatory agencies to conduct additional clinical trials to support the approval of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
our success in educating physicians and patients about the benefits, administration and use of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved;
•
the prevalence and severity of adverse events experienced with our product candidates or future approved products;
•
the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;
•
the ability to raise additional capital on acceptable terms and in the time frames necessary to achieve our goals;
•
achieving and maintaining compliance with all regulatory requirements applicable to DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates or approved products;
•
the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative treatments;

36


•
the effectiveness of our own or our current and any future potential strategic collaborators’ marketing, sales and distribution strategy and operations;
•
our ability to effectively and reliably manufacture clinical trial supplies of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices (“cGMP”);
•
our ability to successfully commercialize DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved for marketing and sale, whether alone or in collaboration with others;
•
our ability to enforce our intellectual property rights in and to DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
our ability to avoid third-party patent interference or intellectual property infringement claims;
•
acceptance of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved, as safe and effective by patients and the medical community;
•
the willingness of third-party payors to reimburse physicians or patients for DAXI and any future products we may commercialize for therapeutic indications;
•
the willingness of patients to pay out of pocket for DAXI and any future products we may commercialize for aesthetic indications; and
•
the continued acceptable safety profile of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates following approval.
If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we cannot assure you that we will be able to generate sufficient revenue through the sale of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidate to continue our business.
We may be unable to obtain regulatory approval for DAXI, topical product candidate, biosimilar product candidate or future product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business prospects, and our results of operations.
To gain approval to market a biologic product such as DAXI, DaxibotulinumtoxinA Topical or biosimilar, we must provide the FDA and foreign regulatory authorities with data that adequately demonstrate the safety, efficacy and quality of the product for the intended indication applied for in the BLA or other respective marketing applications. The development of such products is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, including in Phase 3 development, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, findings made while clinical trials were underway, safety or efficacy observations, including previously unreported adverse events; and the need to conduct further supportive or unanticipated studies, even after initiating Phase 3 trials. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful or that additional supportive studies will not be required, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.

37


For example, we completed DaxibotulinumtoxinA Topical clinical trials for the treatment of lateral canthal lines (“crow’s feet”) and primary axillary hyperhidrosis, but discontinued further clinical development in 2016 following the results from our REALISE 1 Phase 3 clinical trial for crow's feet. In 2016, we also initiated a Phase 2 trial of DAXI for the treatment of plantar fasciitis. In January 2018, we announced interim 8-week results from this study and subsequently completed the 16-week trial, which showed a strong placebo response, with the difference between the treatment groups not being statistically significant.
Our business currently depends substantially on the successful development, regulatory approval and commercialization of our product candidates. We are in the process of compiling the clinical data package required for submission of a BLA. In October 2019, we completed the enrollment for our pivotal ASPEN-1 Phase 3 clinical trial for DAXI for the treatment of cervical dystonia. The ASPEN-1 trial enrolled approximately 300 patients at multiple sites in the U.S., Canada, and Europe.
Such studies may increase the time, expense and uncertainty of our product development programs and potential approval and commercialization timelines, including, for example, because results of such studies may indicate to us a further need to refine the related product candidate.
We currently have no drug or biologic products approved for sale, and we may never obtain regulatory approval to commercialize DAXI, DaxibotulinumtoxinA Topical or biosimilar. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the U.S. until we receive approval of a BLA from the FDA. We are also not permitted to market our product candidates in any foreign countries until we receive the requisite approval from the regulatory authorities of such countries.
The FDA or any foreign regulatory body can delay, limit or deny approval of our product candidates for many reasons, including:
•
our inability to demonstrate to the satisfaction of the FDA or an applicable foreign regulatory body that DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates are safe and effective for the requested indication;
•
our inability to demonstrate preclinical proof of concept of DaxibotulinumtoxinA Topical, biosimilar or other products in future, new indications;
•
the FDA’s or an applicable foreign regulatory agency’s disagreement with the trial protocol or the interpretation of data from preclinical studies or clinical trials;
•
our inability to demonstrate that clinical and other benefits of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates outweigh any safety or other perceived risks;
•
the FDA’s or an applicable foreign regulatory agency’s requirement for additional preclinical or clinical studies;
•
the FDA’s or an applicable foreign regulatory agency’s non-approval of the formulation, labeling or the specifications of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
the FDA’s or an applicable foreign regulatory agency’s failure to approve our manufacturing processes or facilities, or the manufacturing processes or facilities of third-party manufacturers with which we contract; or
•
the potential for approval policies or regulations of the FDA or an applicable foreign regulatory agency to significantly change in a manner rendering our clinical data insufficient for approval.

38


Our business currently depends substantially on the successful development, regulatory approval and commercialization of our product candidates. Of the large number of drugs, including biologics, in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized.

Even if we eventually complete clinical testing and receive approval of any regulatory filing for DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA or the applicable foreign regulatory agency also may approve DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates, and DAXI in particular, would delay or prevent commercialization of DAXI and would materially adversely impact our business, results of operations and prospects.
Even if we receive regulatory approval for our product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review.
We and any third-party contract development and manufacturers or suppliers are required to comply with applicable cGMP regulations and other international regulatory requirements. The regulations require that our product candidates be manufactured and records maintained in a prescribed manner with respect to manufacturing, testing and quality control/quality assurance activities. Manufacturers and suppliers of materials must be named in a BLA submitted to the FDA for any product candidate for which we are seeking FDA approval. Additionally, third party manufacturers and suppliers and any manufacturing facility must undergo a pre-approval inspection before we can obtain marketing authorization for any of our product candidates. Even after a manufacturer has been qualified by the FDA, the manufacturer must continue to expend time, money and effort in the area of production and quality control to ensure full compliance with cGMP. Manufacturers are subject to regular, periodic inspections by the FDA following initial approval. Further, to the extent that we contract with third parties for the manufacture of our products, our ability to control third-party compliance with FDA requirements will be limited to contractual remedies and rights of inspection.
If, as a result of the FDA’s inspections, it determines that the equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may not approve the product or may suspend the manufacturing operations. If the manufacturing operations of any of the suppliers for our product candidates are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand, which would harm our business. In addition, if delivery of material from our suppliers were interrupted for any reason, we might be unable to ship our approved product for commercial supply or to supply our products in development for clinical trials. Significant and costly delays can occur if the qualification of a new supplier is required.
Failure to comply with regulatory requirements could prevent or delay marketing approval or require the expenditure of money or other resources to correct. Failure to comply with applicable requirements may also result in warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal of the government to renew marketing applications and criminal prosecution, any of which could be harmful to our ability to generate revenues and our stock price.
Any regulatory approvals that we receive for our product candidates are likely to contain requirements for post-marketing follow-up studies, which may be costly. Product approvals, once granted, may be modified based on data from subsequent studies or commercial use. As a result, limitations on labeling indications or marketing claims, or withdrawal from the market may be required if problems occur after approval and commercialization.

39


We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.
Since our inception, most of our resources have been dedicated to the research and preclinical and clinical development of our botulinum toxin product candidates, DAXI, DaxibotulinumtoxinA Topical or biosimilar. Our clinical programs for DAXI, DaxibotulinumtoxinA Topical or biosimilar will require substantial additional funds to complete. As of September 30, 2019, we had a working capital surplus of $186.4 million and an accumulated deficit of $798.9 million. Our recorded net losses were $41.4 million and $32.8 million, and $114.1 million and $102.0 million, for the three and nine months ended September 30, 2019 and 2018, respectively.
We have funded our operations primarily through the sale and issuance of convertible preferred stock, common stock, notes payable and convertible notes. As of September 30, 2019, we had capital resources consisting of cash and cash equivalents and investments of $209.0 million. We believe that we will continue to expend substantial resources for the foreseeable future for the clinical development of DAXI, DaxibotulinumtoxinA Topical or biosimilar and development of any other indications and product candidates that we may choose to pursue. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, and manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of DAXI and any future product candidates. In addition, we have formed strategic collaborations, licensing and similar arrangements with third parties, such as the Mylan Collaboration and Fosun License Agreement, that we believe can complement or augment our product offerings, and may continue to do so in the foreseeable future.
We believe that our existing cash, cash equivalents, and investments will allow us to fund our operations for at least 12 months following the filing of this Form 10-Q. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional capital sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future operating plans.
Our future capital requirements depend on many factors, including:
•
the results of our clinical trials for DAXI and preclinical trials of DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
the timing of, and the costs involved in, obtaining regulatory approvals for DAXI, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar;
•
the number and characteristics of any additional product candidates we develop or acquire;
•
the scope, progress, results and costs of researching and developing and conducting preclinical and clinical trials of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;
•
the cost of commercialization activities if DAXI or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar are approved for sale, including marketing, sales and distribution costs;
•
the cost of manufacturing DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates and any products we successfully commercialize and maintaining our related facilities;
•
our ability to establish and maintain strategic collaborations, licensing or other arrangements including the Mylan collaboration, Fosun licensing, and the terms of and timing such arrangements;

40


•
the degree and rate of market acceptance of any future approved products;
•
the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments;
•
our ability to establish our marketing, sales, and distribution functions if we receive regulatory approval for our product candidates;
•
any product liability or other lawsuits related to our products;
•
the expenses needed to attract and retain skilled personnel;
•
any litigation, including litigation costs and the outcome of such litigation;
•
the costs associated with being a public company;
•
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and
•
the timing, receipt and amount of sales of, or royalties on, future approved products, if any.
Additional capital may not be available when needed, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, research, development, manufacturing, sales, marketing or other commercial activities for DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidate.
If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted and the terms of any new equity securities may have a preference over our common stock. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our product candidates or operate as a business.

41


Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success.
The commercial success of DAXI, and any future product candidates including DaxibotulinumtoxinA Topical or biosimilar, if approved, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications. The degree and rate of physician adoption of DAXI and any future product candidates, if approved, will depend on a number of factors, including:
•
the effectiveness and duration of effect of our product as compared to existing and future therapies;
•
physician willingness to adopt a new therapy to treat glabellar lines, cervical dystonia, plantar fasciitis, adult upper limb spasticity, migraine or other aesthetic or therapeutic indications;
•
patient satisfaction with the results and administration of our product and overall treatment experience;
•
patient demand for the treatment of glabellar lines, cervical dystonia, plantar fasciitis or other aesthetic or therapeutic indications;
•
the willingness of third-party payors to reimburse physicians or patients for DAXI and any future products we may commercialize for therapeutic indications;
•
the willingness of patients to pay out of pocket for DAXI and any future products we may commercialize for aesthetic indications; and
•
the revenue and profitability that our product will offer a physician as compared to alternative therapies.
If DAXI or any future product candidates are approved for use but fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected.
Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.
We expect to enter highly competitive pharmaceutical and medical device markets. Successful competitors in the pharmaceutical and medical device markets have the ability to effectively discover therapies, obtain patents, develop, test and obtain regulatory approvals for products, and have the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. Numerous companies are engaged in the developing, patenting, manufacturing and marketing healthcare products which we expect will compete with those that we are developing. Many of these competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities.
Upon marketing approval, the first expected use of our products will be in aesthetic medicine. Competition in aesthetic products is significant and dynamic, and is characterized by rapid and substantial technological development and product innovations. Numerous competitors have obtained patents protecting what they consider to be their intellectual property.
In aesthetic medicine, we plan to seek regulatory approval of DAXI for the treatment of glabellar lines. We anticipate that DAXI, if approved, will face significant competition from existing injectable botulinum toxins as well as unapproved and off-label treatments. Further, if approved, in the future we may face competition for DAXI from biosimilar products and products based upon botulinum toxin. To compete successfully, we will have to demonstrate that the treatment of glabellar lines with DAXI is a worthwhile aesthetic treatment and has advantages over other therapies. Competition could result in reduced profit margins and limited sales, which would harm our business, financial condition and results of operations.

42


Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in a number of foreign countries than are approved for use in the U.S. There are also fewer limitations on the claims that our competitors in certain countries can make about the effectiveness of their products and the manner in which they can market them.
We currently make our DAXI clinical drug product exclusively in one internal manufacturing facility. We plan to utilize internal and external facilities, including through one or more third-party contractors, in the future to support commercial production if our product candidates are approved. If these or any future facility or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business would be materially harmed.
We currently manufacture our own clinical drug product to support DAXI development in one internal manufacturing facility. In March 2017, we entered into an Althea Services Agreement. Under the Althea Services Agreement, Althea will provide us commercial fill/finish services and will serve as a second source of manufacturing for DAXI. We plan to utilize our internal and external Althea facility to support commercial production of DAXI, if approved. If these or any future facility were to be damaged, destroyed or otherwise unable to operate, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of such manufacturing facilities is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved, jeopardize our ability to manufacture our products as promptly as our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our customers’ expectations, our business, prospects, financial results and reputation could be materially harmed.
We recognize revenue in accordance with complex accounting standards and changes in the interpretation or application of generally accepted accounting principles may materially affect our financial statements.
In May 2014, the Financial Accounting Standards Board (the “FASB”) issued an accounting standard for revenue recognition, Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASC 606”). Further, in April 2016, the FASB amended ASC 606 to provide additional guidance on revenue recognition as it pertains to licenses of intellectual property. We adopted ASC 606 and its related amendments on January 1, 2018.
The nature of our business requires the application of complex revenue recognition rules. Significant judgment is required in the interpretation and application of complex accounting guidance such as ASC 606. Our judgments and assumptions are based on the facts and circumstances of the underlying revenue transactions. The SEC, the American Institute of Certified Public Accountants (“AICPA”), the FASB and various other regulatory or accounting bodies may issue new positions, interpretive views or updated accounting standards on the treatment of complex accounting matters such as revenue recognition that may materially affect our financial statements.
Impairment in the carrying value of long-lived assets could negatively affect our operating results.*
There were no indicators of impairment for the year ended December 31, 2018 or for the nine months ended September 30, 2019. Under U.S. GAAP, long-lived assets, such as our fill/finish line, are required to be reviewed for impairment whenever adverse events or changes in circumstances indicate a possible impairment. If business conditions or other factors indicate that the carrying value of the asset may not be recoverable, we may be required to record additional non-cash impairment charges. Additionally, if the carrying value of our capital equipment exceeds current fair value as determined based on the discounted future cash flows of the related product, the capital equipment would be considered impaired and would be reduced to fair value by a non-cash charge to earnings, which could negatively affect our operating results. Events and conditions that could result in impairment in the value of our long-lived assets include adverse clinical trial results, changes in operating plans, unfavorable changes in competitive landscape, adverse changes in the regulatory environment, or other factors leading to reduction in expected long-term sales or profitability. We will evaluate the recoverability and fair value of our long-lived assets, including those related to other components of the fill/finish line, each reporting period to determine the extent to which further non-cash charges to earnings are appropriate. Additional impairment in the value of our long-lived assets may materially and negatively impact our operating results.

43


We have incurred significant losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future. Currently, we have only one product candidate in clinical trials and no commercial sales, which make it difficult to assess our future viability.*
Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We are not profitable and have incurred losses in each year since we commenced operations in 2002. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. To date, we have not obtained any regulatory approvals for any of our product candidates or generated any revenue from product sales relating to DAXI, DaxibotulinumtoxinA Topical or biosimilar. We continue to incur significant research and development and other expenses related to our ongoing clinical trials and operations, and we expect to incur substantial expenses in building out our sales, marketing and distribution function if we receive regulatory approval to pursue commercialization of DAXI. As of September 30, 2019, we had a working capital surplus of $186.4 million and an accumulated deficit of $798.9 million. Our recorded net losses were $41.4 million and $32.8 million, and $114.1 million and $102.0 million for the three and nine months ended September 30, 2019 and 2018, respectively. We have funded our operations primarily through the sale and issuance of convertible preferred stock, common stock, notes payable and convertible notes. Our capital requirements to implement our business strategy are substantial, including our capital requirements to develop and commercialize DAXI. We believe that our currently available capital is sufficient to fund our operations through at least the next 12 months following the filing of this Form 10-Q.
We expect to continue to incur losses for the foreseeable future, and we anticipate that these losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize DAXI. Our ability to achieve revenue and profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals and manufacture, market and commercialize our products successfully. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.

44


Even if DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates obtain regulatory approval, they may never achieve market acceptance or commercial success.
Even if we obtain FDA or other regulatory approvals, DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates may not achieve market acceptance among physicians and patients, and may not be commercially successful.
The degree and rate of market acceptance of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates for which we receive approval depends on a number of factors, including:
•
the safety and efficacy of the product as demonstrated in clinical trials;
•
the clinical indications for which the product is approved;
•
acceptance by physicians, major operators of clinics and patients of the product as a safe and effective treatment;
•
the proper training and administration of our products by physicians and medical staff;
•
the potential and perceived advantages of our products over alternative treatments;
•
the cost of treatment in relation to alternative treatments and willingness to pay for our products, if approved, on the part of payors and patients;
•
the willingness of patients to pay for DAXI, DaxibotulinumtoxinA Topical, and other aesthetic treatments in general, relative to other discretionary items, especially during economically challenging times;
•
the willingness of third-party payors to reimburse physicians or patients for DAXI and any future products we may commercialize for therapeutic indications;
•
the willingness of patients to pay out of pocket for DAXI and any future products we may commercialize for aesthetic indications;
•
the relative convenience and ease of administration;
•
the prevalence and severity of adverse events; and
•
the effectiveness of our sales and marketing efforts.
Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue and continue our business.

45


Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Furthermore, we rely on contract research organizations, or CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements governing the committed activities of our CROs, we have limited influence over their actual performance. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. The results of preclinical studies and clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Furthermore, final results may differ from interim results. For example, any positive results generated to date in clinical trials for DAXI do not ensure that later clinical trials, including any DAXI clinical trials for the treatment of glabellar lines, will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety profile and efficacy despite having progressed through preclinical studies and initial clinical trials.
A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials. We have suffered similar setbacks with the clinical development of DaxibotulinumtoxinA Topical and we cannot be certain that we will not face other similar setbacks in the future for DAXI or other clinical development programs. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.
We have in the past and may in the future experience delays in our ongoing clinical trials, and we do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of subjects on time or be completed on schedule, if at all. Clinical trials can be delayed or aborted for a variety of reasons, including delay or failure to:
•
obtain regulatory approval to commence a trial;
•
reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•
obtain IRB, approval at each site;
•
recruit suitable subjects to participate in a trial;
•
have subjects complete a trial or return for post-treatment follow-up;
•
ensure clinical sites observe trial protocol or continue to participate in a trial;
•
address any patient safety concerns that arise during the course of a trial;
•
address any conflicts with new or existing laws or regulations;
•
add a sufficient number of clinical trial sites; or
•
manufacture sufficient quantities of product candidate for use in clinical trials.
Subject enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.

46


We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the data safety monitoring board, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, failure of inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, discovery of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.
If we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.
We have no experience manufacturing our product candidates at full commercial scale. If our product candidates are approved, we will face certain risks associated with scaling up our manufacturing capabilities to support commercial production.
We have developed an integrated manufacturing, research and development facility located at our corporate headquarters. We manufacture drug substance and finished dose forms of the drug product at this facility that we use for research and development purposes and clinical trials. We do not have experience in manufacturing our product candidates at commercial scale. If our product candidates are approved, we may need to expand our manufacturing facilities, add manufacturing personnel and ensure that validated processes are consistently implemented in our facilities and potentially enter into additional relationships with third-party manufacturers. The upgrade and expansion of our facilities will require additional regulatory approvals. In addition, it will be costly and time-consuming to expand our facilities and recruit necessary additional personnel. If we are unable to expand our manufacturing facilities in compliance with regulatory requirements or to hire additional necessary manufacturing personnel, we may encounter delays or additional costs in achieving our research, development and commercialization objectives, including obtaining regulatory approvals of our product candidates, which could materially damage our business and financial position.
We currently contract with third-party manufacturers for certain components and services necessary to produce DAXI and expect to continue to do so to support further clinical trials and commercial scale production if DAXI is approved. This increases the risk that we will not have sufficient quantities of DAXI or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
We currently rely on third-party manufacturers for certain components such as bulk peptide and services such as fill/finish services, necessary to produce DAXI for our clinical trials, and we expect to continue to rely on these or other manufacturers to support our commercial requirements if DAXI is approved. In particular, in March 2017, we entered into the Althea Services Agreement. We plan to utilize our internal and external Althea facility to support commercial production of DAXI, if approved. Some of our contracts with our manufacturers contain minimum order and pricing provisions and provide for early termination based on regulatory approval milestones.
Reliance on third-party manufacturers entails additional risks, including the reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third- party manufacturers may not be able to comply with cGMP or Quality System Regulation, or QSR, or similar regulatory requirements outside the U.S. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of DAXI, or any other product candidates or products that we may develop. Any failure or refusal to supply the components or services for DAXI or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.

47


We depend on single-source suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.
We and our manufacturers purchase the materials necessary to produce DAXI for our clinical trials from single-source third-party suppliers. There are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, and we may need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials and, if approved, ultimately for commercial sale. In particular, we outsource the manufacture of bulk peptide through American Peptide Company, Inc., or American Peptide, which was acquired by Bachem.
We do not have any control over the process or timing of the acquisition of raw materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe that we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of DAXI or any future product candidates, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party supplier could considerably delay completion of our clinical trials, product testing and potential regulatory approval of DAXI or any future product candidates. If we or our manufacturers are unable to purchase these raw materials on acceptable terms and at sufficient quality levels or in adequate quantities if at all, the development of DAXI and any future product candidates, or the commercial launch of any approved products, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.
Furthermore, if there is a disruption to our or our third-party suppliers’ relevant operations, we will have no other means of producing DAXI or any future product candidates until they restore the affected facilities or we or they procure alternative facilities. Additionally, any damage to or destruction of our or our third party or suppliers’ facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.
We currently have limited marketing and sales capabilities and no field sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize DAXI or any other future product candidates, if approved, or generate product revenue.
We currently have limited marketing and sales capabilities and no field sales organization. To commercialize DAXI or any other future product candidates, if approved, in the U.S., Europe and other jurisdictions we seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If DAXI receives regulatory approval, we expect to market DAXI through our own sales force in North America, and in Europe and other countries through either our own sales force or a combination of our internal sales force and distributors or partners, which may be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize DAXI or any future product candidates. We also have to compete with other pharmaceutical and life sciences companies to recruit, hire, train and retain sales and marketing personnel, and turnover in our sales force and marketing personnel could negatively affect the commercialization of DAXI, if it receives regulatory approval. If we are not successful in commercializing DAXI or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.
As we evolve from a company primarily involved in research and development to a company potentially involved in the commercialization of our products, we will need to increase the size of our organization and we may experience difficulties in managing this growth.*

48


If we are successful in advancing DAXI through the development stage towards commercialization, we will need to expand our organization, including adding marketing, managerial, operational and sales capabilities, or contracting with third parties to provide these capabilities for us. Our management, personnel, systems and facilities currently in place are not adequate to support the potential commercialization of DAXI and any other product candidates, if they are approved. Effectively executing our growth strategy requires that we:
•
identify recruit, train, integrate, incentivize and retain adequate numbers of effective sales and marketing personnel;
•
generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team;
•
achieve, maintain and grow market, physician, patient and healthcare payor acceptance of, and demand for our products;
•
manage our clinical trials and manufacturing operations effectively;
•
manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and
•
continue to improve our operational, financial and management controls, reporting systems and procedures.
As our operations expand, we expect that we will also need to manage additional relationships with various collaborative partners, suppliers and other third parties. Future growth will impose significant added responsibilities on our organization, in particular on management. Our future financial performance and our ability to commercialize DAXI and to compete effectively will depend, in part, on our ability to manage any future growth effectively. Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations.
We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
Our corporate headquarters and other facilities, including our internal manufacturing facility, are located in the San Francisco Bay Area, which has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.
If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facility, enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because we manufacture botulinum toxin in our facilities, we would be required to obtain further clearance and approval by state, federal or other applicable authorities to continue or resume manufacturing activities. The disaster recovery and business continuity plans we have in place currently are limited and may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.
Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, thereby increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

49


We currently rely on third parties and consultants to conduct all our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize DAXI or any future product candidates.
We do not have the ability to independently conduct preclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as CROs and clinical data management organizations, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our preclinical studies and clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred to as good clinical practices, or GCPs, and good laboratory practices, or GLPs, for conducting, monitoring, recording and reporting the results of clinical and preclinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on consultants to assist in the execution, including data collection and analysis, of our clinical trials.
In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. These third parties may terminate their agreements with us upon as little as 30 days’ prior written notice of a material breach by us that is not cured within 30 days. Many of these agreements may also be terminated by such third parties under certain other circumstances, including our insolvency or our failure to comply with applicable laws. In general, these agreements require such third parties to reasonably cooperate with us at our expense for an orderly winding down of services of such third parties under the agreements. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. We may be unable to recover unused funds from these third-parties. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for, and will not be able to, or may be delayed in our efforts to, successfully commercialize the product candidate being tested in such trials.
If any products we develop are not accepted by the market or if regulatory agencies limit our labeling indications, require labeling content that diminishes market uptake of our products or limits our marketing claims, we may be unable to generate significant revenues, if any.
Even if we obtain regulatory approval for our product candidates and are able to commercialize them, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.
The degree of market acceptance of any of our approved products will depend upon a number of factors, including:
•
the indication for which the product is approved and its approved labeling;
•
the presence of other competing approved treatments and therapies;
•
the potential advantages of the product over existing and future treatment products;
•
the relative convenience and ease of administration of the product;
•
the strength of our sales, marketing and distribution support;

50


•
the willingness of third-party payors to provide adequate reimbursement for our approved products, and the willingness of payments to pay for our approved products in the absence of third-party reimbursement; and
•
the price and cost-effectiveness of the product.
The FDA or other regulatory agencies could limit the labeling indication for which our product candidates may be marketed or could otherwise limit marketing efforts for our products. If we are unable to achieve approval or successfully market any of our product candidates, or marketing efforts are restricted by regulatory limits, our ability to generate revenues could be significantly impaired.
If DAXI is approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, and sanctions, product liability claims, and our image and reputation within the industry and marketplace could be harmed.
The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products, such as DAXI, if approved. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.
Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. Furthermore, the use of our products for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
Any of these events could harm our business and results of operations and cause our stock price to decline.
Even if DAXI or any future product candidate is approved for commercialization, if there is not sufficient patient demand for such procedures, our financial results and future prospects will be harmed.
Treatment of glabellar lines or other aesthetic indications with DAXI is an elective procedure, the cost of which must be borne by the patient, and we do not expect it to be reimbursable through government or private health insurance. The decision by a patient to elect to undergo the treatment of glabellar lines with DAXI or the treatment of other aesthetic indications we may pursue may be influenced by a number of factors, including:
•
the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience;
•
the extent to which physicians recommend DAXI to their patients;
•
the extent to which DAXI satisfies patient expectations;

51


•
our ability to properly train physicians in the use of DAXI or such that their patients do not experience excessive discomfort during treatment or adverse side effects;
•
the cost, safety and effectiveness of DAXI versus other treatments;
•
consumer sentiment about the benefits and risks of aesthetic procedures generally and DAXI in particular;
•
the success of any direct-to-consumer marketing efforts we may initiate; and
•
general consumer confidence, which may be impacted by general economic and political conditions.
Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient demand for DAXI or for any other future product candidate, once approved.
We are subject to uncertainty relating to third-party reimbursement policies which, if not favorable for DAXI or any future product candidates, could hinder or prevent their commercial success.*
Our ability to commercialize DAXI or any future product candidates for therapeutic indications such as cervical dystonia, adult upper limp spasticity, plantar fasciitis or migraine will depend in part on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. Third-party payors also are increasingly challenging the effectiveness of and prices charged for medical products and services. We may not obtain adequate third-party coverage or reimbursement for DAXI or any future product candidates for therapeutic indications, or we may be required to sell them at a discount.
We expect that third-party payors will consider the efficacy, cost effectiveness and safety of DAXI in determining whether to approve reimbursement for DAXI for therapeutic indications and at what level. Our business would be materially adversely affected if we do not receive coverage and adequate reimbursement of DAXI for therapeutic indications from private insurers on a timely or satisfactory basis. No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S.; therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, coverage under certain government programs, such as Medicare and Medicaid, may not be available for certain of our product candidates. As a result, the coverage determination process will likely be a time-consuming and costly process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our business could also be adversely affected if third-party payors limit the indications for which DAXI will be reimbursed to a smaller patient set than we believe they are effective in treating.
In some foreign countries, particularly Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products, including DAXI, to other available therapies. If reimbursement for our product is unavailable in any country in which reimbursement is sought, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

52


If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop.
We face an inherent risk of product liability lawsuits as a result of the clinical testing of our product candidates and we will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
•
decreased demand for DAXI or any future product candidates or products we develop;
•
injury to our reputation and significant negative media attention;
•
withdrawal of clinical trial participants or cancellation of clinical trials;
•
costs to defend the related litigation;
•
a diversion of management’s time and our resources;
•
substantial monetary awards to trial participants or patients;
•
regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
•
loss of revenue;
•
an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage; and
•
the inability to commercialize any products we develop.
Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of DAXI or any future products we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing DAXI we intend to expand our insurance coverage to include the sale of DAXI as applicable; however, we may be unable to obtain this liability insurance on commercially reasonable terms.

53


We have been, and in the future may be, subject to securities class action and stockholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business.
We have been, and may in the future be, the target of securities class actions or stockholder derivative claims. On May 1, 2015, a securities class action complaint was filed on behalf of City of Warren Police and Fire Retirement System against us and certain of our directors and executive officers at the time of our follow-on public offering, and the investment banking firms that acted as the underwriters in our follow-on public offering. The Court granted final approval of the Settlement, as set forth in the Stipulation of Settlement, on July 28, 2017. While the litigation has ended, we may be subject to future securities class action and shareholder derivation actions, which may adversely impact our business, results of operations, financial position or cash flows and divert management’s time and attention from the business.
If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, conduct our clinical trials and commercialize DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future products we develop.*
Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly Mark J. Foley, our President and Chief Executive Officer, Abhay Joshi, Ph.D., our Chief Operating Officer, Caryn G. McDowell, our Senior Vice President, General Counsel & Corporate Secretary, and Tobin C. Schilke, our Chief Financial Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, the completion of our planned clinical trials or the commercialization of DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future products we develop.
Leadership transitions can be inherently difficult to manage. Resignations of executive officers may cause disruption in our business, strategic and employee relationships, which may significantly delay or prevent the achievement of our business objectives. Leadership changes may also increase the likelihood of turnover in other key officers and employees and may cause declines in the productivity of existing employees. The search for a replacement officer may take many months or more, further exacerbating these factors. Identifying and hiring an experienced and qualified executive officer are typically difficult. Periods of transition in senior management leadership are often difficult as the new executives gain detailed knowledge of our operations and may result in cultural differences and friction due to changes in strategy and style. During the transition periods, there may be uncertainty among investors, employees, creditors and others concerning our future direction and performance.
We could experience problems attracting and retaining qualified employees. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense and the turnover rate can be high due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their previous research output.
If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.*
Although a substantial amount of our effort will focus on the continued clinical testing and potential approval of DAXI, a key element of our strategy is to discover, develop and commercialize a portfolio of botulinum toxin products for both aesthetic and therapeutic indications. We are seeking to do so through our internal research programs and may explore strategic collaborations for the development or acquisition of new products.
While DAXI is in the clinical development stage, DaxibotulinumtoxinA Topical and all of our other potential product candidates remain in the discovery or preclinical stage. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our

54


research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:
•
the research methodology used may not be successful in identifying potential product candidates;
•
competitors may develop alternatives that render our product candidates obsolete or less attractive;
•
product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;
•
a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
•
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;
•
a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and
•
intellectual property rights of third parties may potentially block our entry into certain geographies or make such entry economically impracticable.
If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will be more vulnerable to problems that we encounter in developing and commercializing DAXI.
The requirements of being a public company may strain our resources, divert management's attention and affect our ability to attract and retain qualified members of our board of directors.
We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Dodd-Frank Act, the Nasdaq listing rules and other applicable securities rules and regulations. Compliance with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly, and increase demand on our systems and resources. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management's attention may be diverted from other business concerns, which could harm our business and operating results. Although we have hired additional employees to comply with these requirements, we may need to hire more employees in the future, which will increase our costs and expenses.
In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.
As a public company that is subject to these rules and regulations we may find it is more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and qualified executive officers.

55


We need to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, and the failure to do so could have a material adverse effect on our business and stock price.
The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. We are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, or Section 404. Beginning with the 2018 Annual Report on Form 10-K, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. If we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could decline and we could be subject to actions or investigations by the SEC, or other regulatory authorities, which would require additional financial and management resources.
We may experience difficulties maintaining our new enterprise resource planning system.*
In the second quarter of 2019, we implemented a new enterprise resource planning (“ERP”) system. ERP implementations are complex and time-consuming, and involve substantial expenditures on system software and implementation activities. The ERP system will be critical to our ability to provide important information to our management, obtain and deliver our products, provide services and customer support, send invoices and track payments, fulfill contractual obligations, accurately maintain books and records, provide accurate, timely and reliable reports on our financial and operating results or otherwise operate our business. ERP implementations also require transformation of business and financial processes in order to reap the benefits of the ERP system; any such transformation involves risks inherent in the conversion to a new computer system, including loss of information and potential disruption to our normal operations. The implementation and maintenance of the new ERP system has required, and will continue to require, the investment of significant financial and human resources. Any disruptions, delays or deficiencies in the design or the ongoing maintenance of the new ERP system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations, accurately maintain books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Additionally, if the system does not operate as intended, the effectiveness of our internal control over financial reporting could be adversely affected or our ability to assess it adequately could be delayed.
Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Our research and development and manufacturing activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including botulinum toxin type A, a key component of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We are licensed with the Centers for Disease Control and Prevention and with the California Department of Health, Food and Drug Branch for use of botulinum toxin and to manufacture both the active pharmaceutical ingredient, or API, and the finished product in topical and injectable dose forms. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.

56


We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.*
We may continue to license or selectively pursue strategic collaborations for the development, validation and commercialization of DAXI, DaxibotulinumtoxinA Topical, biosimilar and any future product candidates. For instance, in February 2018, we and Mylan entered into the Mylan Collaboration, pursuant to which we and Mylan will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize our biosimilar product candidate. In addition, in December 2018, we and Fosun entered into the Fosun License Agreement pursuant to which we have granted Fosun the exclusive rights to develop and commercialize DAXI in the Fosun Territory and certain sublicense rights. In any third-party collaboration, we are dependent upon the success of the collaborators to perform their responsibilities with continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. We cannot control the amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses. Our collaboration with Mylan is for the development of a biosimilar product, which is subject to risks inherent with the relatively short history of biosimilar product approvals in the U.S. The biosimilar product would be subject to similar commercial risks as our DAXI and DaxibotulinumtoxinA Topical product candidates. In February 2019, we and Mylan participated in a Biosimilar Initial Advisory Meeting (“BIAM”) with the FDA to discuss the feasibility of a 351(k) biosimilar submission and the necessary development pathway for the biosimilar product candidate. While we believe that such a pathway is viable, the successful development and commercialization of a biosimilar product in any indications of BOTOX® or BOTOX Cosmetic® would be subject to FDA requirements that would need to be assessed by us and Mylan in determining the development of the biosimilar product candidate. In August 2019, we announced an amendment to the Mylan Collaboration pursuant to which, among other things, we agreed to extend the period of time for Mylan to make a decision under the Collaboration Agreement as to whether to continue the development and commercialization of a biosimilar to the branded biologic product (DaxibotulinumtoxinA) marketed as BOTOX® beyond the initial development plan, for which both parties prepared and conducted the BIAM with the FDA. Such amendment to the Mylan Collaboration and the FDA requirements may also limit our ability to begin Phase 3 development of the biosimilar in 2020, as presently planned or at all. Even if successfully developed, the biosimilar product would be subject to similar commercial risks as our DAXI and DaxibotulinumtoxinA Topical product candidates.
Unfavorable global economic conditions or trade relations could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the demand for aesthetic or therapeutic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect sales of DAXI for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, demand for the first indications of each of our product candidates will be tied to discretionary spending levels of our targeted patient population. Future global financial crises may cause extreme volatility and disruptions in capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services.

57


In addition, changes in U.S. and foreign trade policies could trigger retaliatory actions by affected countries, resulting in “trade wars”, which may reduce customer demand for goods exported out of the U.S. if the parties having to pay those retaliatory tariffs increase their prices, or if trading partners limit their trade with the U.S. If these consequences are realized, the price to the consumer of aesthetic or therapeutic medical procedures from products exported out of the U.S. may increase, resulting in a material reduction in the demand for our future product candidates.  Such a reduction may materially and adversely affect our potential sales and our business. In particular, under our Fosun License Agreement, we are responsible for manufacturing DAXI and supplying it to Fosun, which would then develop commercialize, market and sell it in mainland China, Hong Kong and Macau. If this arrangement is restricted in any way due to the US-China trade relation, the contingent payments we are entitled to receive under the agreement, which are based on product sales, among other things, may be adversely affected.
Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current or future economic climate and financial market conditions could adversely impact our business.
Adverse tax laws or regulations could be enacted or existing laws could be applied to us or our customers, which could increase the costs of our services and adversely impact our business.
The application of federal, state, local and international tax laws to services provided electronically is evolving. New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time (possibly with retroactive effect), and could be applied solely or disproportionately to services provided over the internet. These enactments could adversely affect our sales activity due to the inherent cost increase the taxes would represent and ultimately result in a negative impact on our operating results and cash flows.
In addition, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us (possibly with retroactive effect), which could require us or our customers to pay additional tax amounts, as well as require us or our customers to pay fines or penalties and interest for past amounts. If we are unsuccessful in collecting such taxes from our customers, we could be held liable for such costs, thereby adversely impacting our operating results and cash flows.
Further, we have undertaken certain transactions to realize potential tax efficiencies in support of our expected global business expansion. These transactions are meant to align the global economic ownership of our intellectual property rights with our current and future business operations. We are uncertain as to whether the tax efficiencies sought by this alignment will materialize and may choose to unwind these transactions in the future.
On December 22, 2017, legislation that significantly revised the Internal Revenue Code of 1986 was signed into law. The legislation, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law changes is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. 

58


Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition.
We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. For example, in January 2019, we discovered that our e-mail server suffered unauthorized intrusions in which proprietary business information was accessed. Although we do not believe that we have experienced any material losses related to security breaches, including recent cybersecurity incidents, there can be no assurance that we will not suffer such losses in the future.  Breaches and other inappropriate access can be difficult to detect and any delay in identifying them could increase their harm. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Any such breaches of security and inappropriate access could disrupt our operations, harm our reputation or otherwise have a material adverse effect on our business, financial condition and results of operations.
The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical study data from completed or ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media or individuals pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, if applicable. For example, these may include the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, U.S. state breach notification laws and the EU General Data Protection Regulation (EU) 2016/679, or GDPR. We would also be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims or litigation and potential civil or criminal liability, which could materially adversely affect our business, results of operations and financial condition.

59


Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.*
We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal data, such as information that we collect about patients and healthcare providers in connection with clinical trials in the U.S. and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our vendors’ ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.
In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. California enacted the California Consumer Privacy Act (CCPA) on June 28, 2018, which takes effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In the event that we are subject to HIPAA, the CCPA or other U.S. privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our customers, or our vendors must comply. For example, the EU has adopted the GDPR, which went into effect in May 2018 and introduces strict requirements for processing the personal information of EU subjects, including clinical trial data. The GDPR is likely to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for more robust regulatory enforcement and fines of up to €20 million or 4 percent of the annual global revenue of the noncompliant company, whichever is greater. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.
Risks Related to Our Intellectual Property
If our efforts to protect our intellectual property related to DAXI, or any future product candidates, including DaxibotulinumtoxinA Topical and biosimilar, are not adequate, we may not be able to compete effectively.
We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to DAXI, DaxibotulinumtoxinA Topical, biosimilar, and our development programs. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thereby eroding our competitive position.

60


The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or license may fail to result in issued patents in the U.S. or foreign countries. Competitors in the field of cosmetics, pharmaceuticals, and botulinum toxin have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Our European Patent EP 2 661 276 for “Topical composition comprising botulinum toxin and a dye” was opposed in the European Patent Office by Allergan plc on May 2, 2018, and although this patent is not material to our business, we will continue to take appropriate measures to defend the patent. On May 10, 2019 our European Patent No. EP 2 490 986 B1 for “Methods and Systems For Purifying Non-Complexed Botulinum Neurotoxin” was opposed. We are vigorously defending this patent in the European Patent Office. We were informed in May 2019 that our patent application NC2018/0005351 pending in Colombia for “Injectable Botulinum Toxin Formulations And Methods of Use Thereof Having Long Duration of Therapeutic Effect” was opposed. We have responded to this pre-grant opposition. Furthermore, even if our patents and applications are unchallenged, they may not adequately protect our intellectual property or prevent others from designing around our claims.
In addition, the patent laws of the U.S. provide procedures for third parties to challenge the validity of issued patents. Patents issued from applications filed after March 15, 2013 may be challenged by third parties using the post-grant review procedure which allows challenges for a number of reasons, including prior art, sufficiency of disclosure, and subject matter eligibility. Under the inter partes review procedure, any third party may challenge the validity of any issued U.S. Patent in the U.S. Patent and Trademark Office, or USPTO, on the basis of prior art patents or printed publications. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings as compared to the evidentiary standard relied on in U.S. federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates is challenged, then it could threaten our ability to commercialize DAXI, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, and could threaten our ability to prevent competitive products from being marketed. Further, if we encounter delays in our clinical trials, the period of time during which we could market DAXI, or any future product candidates under patent protection would be reduced. The results of our REALISE 1 Phase 3 clinical trial may be relevant to our patent strategy for our DaxibotulinumtoxinA Topical program.
Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the U.S. transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to “first-to-file” from “first-to-invent” is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act signed into law on September 16, 2011. Among some of the other changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO.

61


Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios and financial resources than we have.
We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain or enforce and any other elements of our product development and manufacturing processes that involve proprietary know-how, information or technology that is not covered by patents.
In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, collaborators and advisers to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. A breach of confidentiality could significantly affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisers have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Also, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and other confidential information.
If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.
Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. Competitors in the field of cosmetics, pharmaceuticals and botulinum toxin have developed large portfolios of patents and patent applications in fields relating to our business. For example, there are patents held by third parties that relate to the treatment with botulinum toxin-based products for indications we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.
As a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product based on our current or future indications, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

62


There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.
Competitors may infringe upon our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied.
An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.
Interference, derivation, inter partes review, post-grant review or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patents or patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, either alone or with our licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

63


Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws.

Risks Related to Government Regulation
Our business and products are subject to extensive government regulation.
We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the U.S., principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control, and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act (“FFDCA”), the PHSA, and Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs.
After our products receive regulatory approval, we, and our direct and indirect suppliers, will remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in the implementation of Risk Evaluation and Mitigation Strategies (“REMS”) programs, completion of government mandated clinical trials, and government enforcement action relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls noted above.
The regulatory approval process is highly uncertain and we may not obtain regulatory approval for the commercialization of DAXI or any future product candidates.
The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries, which regulations differ from country to country. Neither we nor any collaboration partner are permitted to market DAXI or any future product candidates in the U.S. until we receive approval of a BLA from the FDA. We have not submitted an application or obtained marketing approval for DAXI anywhere in the world. We expect to submit the BLA for DAXI in November 2019, but may experience delays in filing due to unexpected chemistry, manufacturing and control issues, delay from third-party contractors or lack of available personnel resources required to complete the BLA application within the expected submission timeline. After we submit a BLA for DAXI, the FDA may refuse to file the application if it determines that the application is not sufficiently complete to permit substantive review. Even if filed by FDA, our BLA may receive a Complete Response Letter identifying deficiencies that must be addressed, rather than an approval. Obtaining regulatory approval of a BLA can be a lengthy, expensive and uncertain process.

64


In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:
•
warning letters;
•
civil and criminal penalties;
•
injunctions;
•
withdrawal of approved products;
•
product seizure or detention;
•
product recalls;
•
total or partial suspension of production; and
•
refusal to approve pending BLAs or supplements to approved BLAs.
Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we or our collaborators must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical and clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.
Regulatory approval of a BLA or BLA supplement is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including the following:
•
a product candidate may not be deemed safe, effective, or of required quality;
•
FDA officials may not find the data from preclinical studies and clinical trials sufficient;
•
the FDA might not approve our third-party manufacturers’ processes or facilities; or
•
the FDA may change its approval policies or adopt new regulations.
If DAXI or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed.

65


Even if we receive regulatory approval for DAXI or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, may limit or delay regulatory approval and may subject us to penalties if we fail to comply with applicable regulatory requirements.
Once regulatory approval has been granted, DAXI or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.
Any regulatory approvals that we or our collaborators receive for DAXI or any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the applicable regulatory agency approves DAXI or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with DAXI or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
•
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
•
fines, warning letters or holds on clinical trials;
•
refusal by the FDA to approve pending applications or supplements to approved applications submitted by us or our strategic collaborators, or suspension or revocation of product license approvals;
•
product seizure or detention, or refusal to permit the import or export of products; and
•
injunctions or the imposition of civil or criminal penalties.
Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.
If we fail to obtain regulatory approvals in foreign jurisdictions for DAXI, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar, we will be unable to market our products outside of the U.S.

66


In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, or the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive the necessary approvals to commercialize our products in geographies outside of the U.S.
If approved, DAXI or any other products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business.
Some participants in our clinical trials have reported adverse events after being treated with DAXI. If we are successful in commercializing DAXI, or any other products including DaxibotulinumtoxinA Topical or biosimilar, the FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.
We may in the future be subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties.
While we do not expect that DAXI, if approved for the treatment of glabellar lines, will subject us to all of the various U.S. federal and state laws intended to prevent healthcare fraud and abuse, we may in the future become subject to such laws for treatment of other indications. The federal anti-kickback statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state healthcare programs as well as private payors. Violations of the anti-kickback laws can result in exclusion from federal healthcare programs and the levying of substantial civil and criminal penalties.
The federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal healthcare program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA, then our revenues could be adversely affected, which would likely harm our business, financial condition, and results of operations.
HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

67


The federal Physician Payments Sunshine Act, and its implementing regulations, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to Centers for Medicare & Medicaid Services information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members.
We may also be subject to analogous state laws and regulations, including: state anti-kickback and false claims laws, state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities, and state and local laws that require the registration of our pharmaceutical sales representatives.
State and federal authorities have aggressively targeted pharmaceutical manufacturers for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with physicians and other healthcare professionals, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans, and have often become subject to consent decrees severely restricting the manner in which they conduct business. Further, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.
Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.
Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of DAXI, topical, or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. In addition, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of, or affect the price that we may charge for, DAXI, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could require, among other things:
•
changes to manufacturing methods;
•
recall, replacement, or discontinuance of one or more of our products; and
•
additional recordkeeping.

68


Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.
Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.*
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Risks Related to the Ownership of Our Common Stock
The trading price of our common stock is volatile, and purchasers of our common stock could incur substantial losses.
The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock markets in general and the markets for pharmaceutical biopharmaceutical and biotechnology stocks in particular have experienced extreme volatility that may have been for reasons that are related or unrelated to the operating performance of the issuer. The market price for our common stock may be influenced by many factors, including:
•
regulatory or legal developments in the U.S. and foreign countries;
•
results from or delays in clinical trials of our product candidates, including our ongoing ASPEN Phase 3 clinical program in cervical dystonia and our Phase 2 programs in plantar fasciitis, adult upper limb spasticity, forehead lines, and lateral canthal lines all with DAXI;
•
announcements of regulatory approval or disapproval of DAXI or any future product candidates;
•
FDA or other U.S. or foreign regulatory actions or guidance affecting us or our industry;
•
introductions and announcements of new products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;
•
variations in our financial results or those of companies that are perceived to be similar to us;
•
changes in the structure of healthcare payment systems;
•
announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;
•
market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts’ reports or recommendations;
•
quarterly variations in our results of operations or those of our future competitors;
•
changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;

69


•
sales of substantial amounts of our stock by insiders and large stockholders, or the expectation that such sales might occur;
•
general economic, industry and market conditions;
•
additions or departures of key personnel;
•
intellectual property, product liability or other litigation against us;
•
expiration or termination of our potential relationships with customers and strategic partners;
•
the occurrence of trade wars or barriers, or the perception that trade wars or barriers will occur; and
•
other factors described in this “Risk Factors” section.
These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In addition, in the past, stockholders have initiated class actions against pharmaceutical companies, including us, following periods of volatility in their stock prices. Such litigation instituted against us could cause us to incur substantial costs and divert management’s attention and resources.
If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may cease to publish research on our company at any time in their discretion. A lack of research coverage may adversely affect the liquidity and market price of our common stock. We will not have any control of the equity research analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company, or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.
Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to drop significantly, even if our business is doing well.*
Sales of a substantial number of shares of our common stock in the public market could occur at any time. In March 2018, we entered into the 2018 ATM Agreement. Under the 2018 ATM Agreement, we may offer and sell common stock having aggregate proceeds of up to $125.0 million from time to time through Cantor Fitzgerald as our sales agent. No sales of our common stock have taken place under the 2018 ATM Agreement as of September 30, 2019. In January 2019, we completed the 2019 follow-on public offering, pursuant to which we issued 6,764,705 shares of common stock at $17.00 per share, including the exercise of the underwriters’ over-allotment option to purchase 882,352 additional shares of common stock, for aggregate net proceeds of $107.6 million, after deducting underwriting discounts, commissions and other offering expenses.
If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. Any sales of securities by stockholders could have a material adverse effect on the trading price of our common stock.
Provisions in our corporate charter documents and under Delaware law could discourage takeover attempts and lead to management entrenchment, and the market price of our common stock may be lower as a result.

70


Certain provisions in our amended and restated certificate of incorporation and amended and restated bylaws may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock. Our board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.
Our charter documents also contain other provisions that could have an anti-takeover effect, including:
•
only one of our three classes of directors will be elected each year;
•
no cumulative voting in the election of directors;
•
the ability of our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;
•
the exclusive right of our board of directors to elect a director to fill a vacancy or newly created directorship;
•
stockholders will not be permitted to take actions by written consent;
•
stockholders cannot call a special meeting of stockholders;
•
stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;
•
the ability of our board of directors, by a majority vote, to amend the bylaws; and
•
the requirement for the affirmative vote of at least 66 2/3 percent or more of the outstanding common stock to amend many of the provisions described above.
In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that certain investors are willing to pay for our stock.
Our amended and restated certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders.
A relatively small number of existing stockholders have substantial control over us, which could limit your ability to influence the outcome of key transactions, including a change of control.*
As of September 30, 2019, our directors, executive officers and each of our stockholders who own greater than 5 percent of our outstanding common stock and their affiliates, in the aggregate, beneficially owned a majority of our common stock. As a result, these stockholders, if acting together, would be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may have interests that differ from yours and may vote in a way with which you disagree and that may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might affect the market price of our common stock.

71


Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.
In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:
•
We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
•
We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.
•
We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.
•
We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.
•
The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.
•
We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.
We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent Sales of Unregistered Securities
For the three months ended September 30, 2019, there were no sales of unregistered securities.

72


Issuer Purchases of Equity Securities
We have not and do not currently intend to retire or repurchase any of our shares other than providing our employees with the option to withhold shares to satisfy tax withholding amounts due from employees upon the vesting of restricted stock awards in connection with our 2014 Equity Incentive Plan.
Period
Total Number of Shares Purchased (i)
 
Weighted-Average Price Paid per Share (ii)
 
Total Number of Share Purchased as Part of Publicly Announced Plan or Programs
 
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan or Programs (in thousands)
July 1 through July 31, 2019
2,336

 
$
12.55

 
—

 
$
—

August 1 through August 31, 2019
2,757

 
10.90

 
—

 
—

September 1 through September 30, 2019
1,671

 
12.97

 
—

 
—

Total
6,764

 
$
11.97

 
—

 
$
—

(i)
Consists solely of shares that were withheld to satisfy tax withholding amounts due from employees upon the vesting of previously issued restricted stock awards.
(ii)
The weighted-average price paid per share is the weighted-average of the fair market prices at which we calculated the number of shares withheld to cover tax withholdings for the employees.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.

73


ITEM 6. EXHIBITS
The following exhibits are included herein or incorporated herein by reference:
Exhibit Number
 
Exhibit Description
 
Incorporated by Reference
 
Filed Herewith
Form
 
File No.
 
Exhibit
 
Filling Date
3.1
 
 
8-K
 
001-36297
 
3.1
 
February 11, 2014
 
—
3.2
 
 
S-1
 
333-193154
 
3.4
 
December 31, 2013
 
—
4.1
 
 
S-1/A
 
333-193154
 
4.4
 
February 3, 2014
 
—
10.1+
 
 
—
 
—
 
—
 
—
 
X
10.2
 
 
—
 
—
 
—
 
—
 
X
10.3
 
 
—
 
—
 
—
 
—
 
X
10.4
 
 
—
 
—
 
—
 
—
 
X
10.5
 
 
—
 
—
 
—
 
—
 
X
31.1
 
 
—
 
—
 
—
 
—
 
X
31.2
 
 
—
 
—
 
—
 
—
 
X
32.1†
 
 
—
 
—
 
—
 
—
 
X
32.2†
 
 
—
 
—
 
—
 
—
 
X
101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
—
 
—
 
—
 
—
 
X
101.SCH
 
XBRL Taxonomy Extension Schema Document
 
—
 
—
 
—
 
—
 
X
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
—
 
—
 
—
 
—
 
X
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
 
—
 
—
 
—
 
—
 
X
101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document
 
—
 
—
 
—
 
—
 
X
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
—
 
—
 
—
 
—
 
X
104
 
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)
 
—
 
—
 
—
 
—
 
X
+
Portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.
†
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, and shall not be deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Exchange Act. Such certifications shall not be deemed incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

74


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
REVANCE THERAPEUTICS, INC.
 
 
 
Date: November 4, 2019
By:
 
/s/ Tobin C. Schilke
 
 
 
Tobin C. Schilke
 
 
 
Chief Financial Officer
 
 
 
(Duly Authorized Principal Financial Officer and Principal Accounting Officer)





 EX-10.1 2 ex101q31910qmylan.htm EXHIBIT 10.1 Exhibit




Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REVANCE THERAPEUTICS, INC., IF PUBLICLY DISCLOSED.

AMENDMENT #1 TO THE
COLLABORATION AND LICENSE AGREEMENT

THIS AMENDMENT #1 TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment #1”) is made and entered into effective as of August 22, 2019 (the “Amendment #1 Effective Date”), by and among Revance Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having principal offices at 7555 Gateway Blvd., Newark, CA 94560 (together with its successors and assigns, “Revance”), and Mylan Ireland Ltd., a company organized and existing under the laws of Ireland, having principal offices at South Bank House, Barrow Street, 6th Floor, Dublin, Ireland (together with its successors and assigns, “Mylan”).

WHEREAS, pursuant to the Collaboration and License Agreement between Revance and Mylan dated 28 February 2018 (the “Agreement”), the Parties agreed to collaborate to develop a biosimilar version of the branded biologic product marketed as Botox® in certain countries, and Revance licensed certain intellectual property rights to Mylan on an exclusive basis for Mylan to develop, manufacture and commercialize Product in the Mylan Territory;

WHEREAS, the Parties now wish to amend the Agreement as set forth below; unless otherwise defined herein, all capitalized terms used herein and defined in the Agreement shall have the respective meaning given to those terms in the Agreement.

NOW, THEREFORE, for good and valuable consideration (the receipt and sufficiency of which are acknowledged by the Parties), the Parties agree as follows:

1.    Amendment to Agreement.

a.
Following the Amendment #1 Effective Date, Revance shall issue to Mylan an invoice for, and Mylan shall pay to Revance within 45 days of receipt thereof, a payment equal to Five Million Dollars ($5,000,000) for extending the period of time under the Agreement for Mylan to send a Continuation Notice.

b.
The following two sentences are added to the end of Section 5.2(a):

“In addition to performing the Initial Development Plan, Revance shall complete the [*] studies as described and set forth in Schedule 1 hereto (“[*] Studies”) as soon as practicable. Revance shall use Commercially Reasonable Efforts to complete the activities set forth in Schedule 1 in accordance with

1

this Agreement and Applicable Law, and shall report its progress of such studies, including all results, to the JSC pursuant to Section 4.4(b).”

c.
Section 5.2(b) of the Agreement is hereby deleted in its entirety and replaced by the following:

“Initial Development Costs.  Notwithstanding anything to the contrary contain herein, [*] Development Costs incurred in conducting the Initial Development Plan, including the [*] Studies.”;

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REVANCE THERAPEUTICS, INC., IF PUBLICLY DISCLOSED.

2



and all references to the “Initial Development Cost Cap” shall be removed from the Agreement.

d.
Section 5.2(c) of the Agreement is hereby deleted in its entirety and replaced by the following:

“Continuation Decision. Mylan shall make a continuation decision as to whether to continue the Development and commercialization of the Product pursuant to this Agreement, as set forth in this Section 5.2(c) (the “Continuation Decision”) following Revance’s completion of the [*] Studies. Mylan shall notify Revance in writing of Mylan’s decision to either continue or not to continue the Development and commercialization of the Product pursuant to this Agreement on or before the later of (i) April 30, 2020, or (ii) thirty (30) calendar days from the date that Revance completes the [*] Studies and provides Mylan with the results thereof (the “Continuation Notice”). If Mylan’s Continuation Decision is that it will continue Development and commercialization of the Product pursuant to this Agreement, Revance shall submit an invoice to Mylan for the FDA Advisory Milestone Payment upon receipt of the Continuation Notice. If Mylan’s Continuation Decision is that it will not continue Development and commercialization of the Product pursuant to this Agreement, either Party may terminate this Agreement upon written notice to the other Party provided within [*] days of receipt of Mylan’s Continuation Decision; provided that if neither Party terminates pursuant to this sentence, the Parties shall promptly meet to discuss in good faith whether there is a path forward for the Product in the Mylan Territory hereunder, including any necessary changes to this Agreement, the Development Plan and Development Budget. The Parties agree that prior to the commencement of the thirty (30) calendar day period provided for above, the Parties shall collaborate on (y) development of a preliminary strategy for Legal Clearance Activities for consideration by the JSC in creating the Development Plan and (z) development of a Development Plan that includes a detailed regulatory strategy for the Product in the U.S. and Europe in accordance with Section 5.3(b) below.”

e.
In Section 5.3(a) the words “(and [*] of Excess Revance Costs, if any)” are hereby deleted.

f.
In Section 5.3(d)(i) the words “[*]” are hereby deleted and replaced with “[*]” and the proviso at the end of Section 5.3(d)(i) is hereby deleted in its entirety.
g.
In Section 8.2 the words “(plus Mylan’s share of any Excess Revance Costs)” are hereby deleted.
h.
In Exhibit 1.31, Section 2, the words “as well as an amount equal to [*] of any Excess Revance Costs,” are hereby deleted.

2.    Complete Agreement / Ratification. Except to the extent expressly amended hereby, the terms and conditions of the Agreement will continue to apply. In the event of a conflict between this Amendment #1 and the Agreement, this Amendment #1 will prevail. This Amendment #1 will be governed by and construed in accordance with the substantive laws of the State of New York (without regard to any conflicts of law provisions) and the provisions of Article 15 of the Agreement will apply to any dispute hereunder. This Amendment #1 may not be amended except by agreement in writing signed by both Parties. The Agreement as amended hereby constitutes the entire agreement of the Parties with respect the matters described therein and herein and supersede any prior agreement or understanding with respect thereto. As amended hereby, the Agreement is ratified and affirmed in all respects.

[SIGNATURES FOLLOW ON NEXT PAGE]

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REVANCE THERAPEUTICS, INC., IF PUBLICLY DISCLOSED.

3

IN WITNESS WHEREOF, the Parties have caused this Amendment #1 to be executed effective as of the Amendment #1 Effective Date.


REVANCE THERAPEUTICS INC.
 
MYLAN IRELAND LTD.
 
 
 
By:
/s/ Dan Browne
 
By:
/s/ Peter McCormick
Name:
Dan Browne
 
Name:
Peter McCormick
Title
President & Chief Executive Officer
 
Title:
Global Head OSD Operations & Science





CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REVANCE THERAPEUTICS, INC., IF PUBLICLY DISCLOSED.

4


SCHEDULE 1

[*] STUDIES

[*]





































CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REVANCE THERAPEUTICS, INC., IF PUBLICLY DISCLOSED.

5
 EX-10.2 3 ex102q31910qseparation.htm EXHIBIT 10.2 Exhibit

Exhibit 10.2
October 10, 2019
Via Email
L. Daniel Browne
Revance Therapeutics, Inc.
Re:    Separation Agreement
Dear Dan:
This letter sets forth the substance of the separation agreement (the “Agreement”) that Revance Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
1.SEPARATION DATE. Your last day of work as the Company’s Chief Executive Officer and your employment termination date will be October 11, 2019 (the “Separation Date”). On the Separation Date, the Company will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to these payments regardless of whether or not you sign this Agreement.
2.    BOARD RESIGNATION. As part of this Agreement, you hereby resign your position as a director on the Company’s Board of Directors, and the Board accepts your resignation, effective as of the Separation Date.
3.    SEVERANCE BENEFITS. Pursuant to the Revance Therapeutics, Inc. Third Amended and Restated Executive Severance Plan, if you sign this Agreement, allow the releases set forth herein to become effective, and comply with all of your legal and contractual obligations to the Company, then the Company will provide you with the following severance benefits::
(a)Cash Severance. The Company will pay you severance in an amount equal to fifteen (15) months of you base salary, paid in equal installments on the Company’s regular payroll schedule over the fifteen (15) month period following the Separation Date; provided, however, that no payments will be made prior to the first business day to occur on or after the 60th day following the Separation Date. On the first business day to occur on or after the 60th day following the Separation Date, you will receive in a lump sum the cash severance you would have received on or prior to such date under the original schedule, with the balance being paid as originally scheduled.
(b)    Health Care Continuation Coverage.
(i)    COBRA. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense. Later, you may be able to convert to an individual policy through the provider of the Company’s health insurance, if you wish.




(ii)    COBRA Premiums. If you timely elect continued coverage under COBRA, the Company will pay your COBRA premiums to continue your coverage (including coverage for eligible dependents, if applicable) (“COBRA Premiums”) through the period (the “COBRA Premium Period”) starting on the Separation Date and ending on the earliest to occur of: (i) the date that is fifteen (15) months after the Separation Date; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer's group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company in writing of such event.
(iii)    Special Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to you, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including premiums for you and your eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for the remainder of the COBRA Premium Period. You may, but are not obligated to, use such Special Cash Payments toward the cost of COBRA premiums. On the thirtieth (30th) day following your Separation from Service, the Company will make the first payment to you under this paragraph, in a lump sum, equal to the aggregate Special Cash Payments that the Company would have paid to you through such date had the Special Cash Payments commenced on the first day of the first month following the Separation from Service through such thirtieth (30th) day, with the balance of the Special Cash Payments paid thereafter on the schedule described above.
4.    STOCK OPTIONS. Vesting of your equity awards will cease on the Separation Date. Your right to exercise any vested shares, and all other rights and obligations with respect to your equity awards will be as set forth in the applicable award agreement and plan documents. Your options shall continue to be governed by the terms of the applicable grant notices, stock option agreements and the applicable plan documents. The Company will also extend the post-termination exercise period for all of the vested stock options you hold through the earlier to occur of a Change in Control (as defined in the Company’s 2014 Equity Incentive Plan), or January 31, 2021.
5.    OTHER COMPENSATION OR BENEFITS. You acknowledge that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance or benefits after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account).
6.    EXPENSE REIMBURSEMENTS. You agree that, within ten (10) days after the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice.



7.    RETURN OF COMPANY PROPERTY. By no later than the close of business on the Separation Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control. You agree that you will make a diligent search to locate any such documents, property and information within the timeframe referenced above. In addition, if you have used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you must provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part); and you agree to provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done. Your timely compliance with the provisions of this paragraph is a precondition to your receipt of the severance benefits provided hereunder.
8.    PROPRIETARY INFORMATION OBLIGATIONS. Both during and after your employment you acknowledge your continuing obligations under your Proprietary Information and Inventions Agreement, including your obligations not to use or disclose any confidential or proprietary information of the Company. A copy of your Proprietary Information and Inventions Agreement is attached hereto as Exhibit A.
9.    NONDISPARAGEMENT. You agree not to disparage the Company and its officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations; provided that you may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. In addition, nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or regulation. The Company shall instruct its directors and officers to refrain from disparaging you in any manner likely to be harmful to you or your business or personal reputation; provided that the Company (and its directors and officers) may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation; and provided further that the Company’s press release announcing your departure shall not violate this section.
10.    NO VOLUNTARY ADVERSE ACTION; AND COOPERATION. You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall you induce or encourage any person or entity to bring any such claims; provided that you may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. In addition, you agree to voluntarily cooperate with the Company if you have knowledge of facts relevant to any



existing or future litigation or arbitration initiated by or filed against the Company by making yourself reasonably available without further compensation for interviews with the Company or its legal counsel, for preparing for and providing deposition testimony, and for preparing for and providing trial testimony.
11.    NO ADMISSIONS. You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.
12.    RELEASE OF CLAIMS.
(a)    General Release. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).
(b)    Scope of Release. The Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation, paid time off, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the “ADEA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).
(c)    ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA (“ADEA Waiver”), and that the consideration given for the waiver and release in this Section is in addition to anything of value to which you are already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (i) your waiver and release do not apply to any rights or claims that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it earlier); (iv) you have seven (7) days following the date you sign this Agreement to revoke the ADEA Waiver (by providing written notice of



your revocation to me); and (v) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after you sign this Agreement (“Effective Date”). Nevertheless, your general release of claims, except for the ADEA Waiver, is effective immediately, and not revocable.
(d)    Section 1542 Waiver. YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows:
“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”
You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of any unknown or unsuspected claims herein.
(e)    Excluded Claims. Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are a party or under applicable law; (ii) any rights which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement. You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims. You understand that nothing in this Agreement limits your ability to file a charge or complaint with any Government Agency. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.
13.    REPRESENTATIONS. You hereby represent that you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.
14.    SECTION 409A. Notwithstanding anything herein to the contrary, (i) if at the time of your termination of employment with the Company, you are a “specified employee” as defined in Section 409A of the Code and the applicable guidance and regulations thereunder (collectively, “Section 409A”), and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then the Company will



defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to you) until the first business day to occur following the date that is six (6) months following your termination of employment with the Company (or the earliest date as is permitted under Section 409A); and (ii) if any other payments of money or other benefits due to you hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Company’s Board of the Directors, that does not cause such an accelerated or additional tax. In the event that payments under this Agreement are deferred pursuant to this Section 14 in order to prevent any accelerated tax or additional tax under Section 409A, then such payments shall be paid at the time specified under this Section 14 without any interest thereon. The Company shall consult with you in good faith regarding the implementation of this Section 14; provided, that neither the Company nor any of its employees or representatives shall have any liability to you with respect thereto. Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. For purposes of Section 409A, each payment made under this Agreement shall be designated as a “separate payment” within the meaning of the Section 409A. Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement or in-kind benefit provided pursuant to this Agreement does not constitute a “deferral of compensation” within the meaning of Section 409A, (A) the amount of expenses eligible for reimbursement or in-kind benefits provided to you during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to you in any other calendar year; (B) the reimbursements for expenses for which you are entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred; and (C) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.
15.    DISPUTE RESOLUTION. To ensure the timely and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, your employment, or the termination of your employment, including but not limited to statutory claims, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, conducted by JAMS, Inc. (“JAMS”) under the then applicable JAMS rules (which can be found at the following web address: https://www.jamsadr.com/rules-employment-arbitration/). By agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The Company acknowledges that you will have the right to be



represented by legal counsel at any arbitration proceeding. In addition, all claims, disputes, or causes of action under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to an action or claim brought in court pursuant to the California Private Attorneys General Act of 2004, as amended. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required of you if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.
16.    MISCELLANEOUS. This Agreement, including Exhibit A, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the subject matter hereof. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and signatures transmitted by PDF shall be equivalent to original signatures.
If this Agreement is acceptable to you, please sign below and return the original to me within twenty-one (21) days. The Company’s offer contained herein will automatically expire if we do not receive the fully signed Agreement within this timeframe.



I wish you good luck in your future endeavors.
Sincerely,
REVANCE THERAPEUTICS, INC.
By:
 
/s/Angus Russell
 
 
Angus Russel
 
 
Chairman
 
 
Board of Directors
Exhibit A – Proprietary Information and Inventions Agreement

ACCEPTED AND AGREED:
By:
 
/s/ L. Daniel Browne
 
 
L. Daniel Browne
 
 
 
 
 
October 13, 2019
 
 
Date




EXHIBIT A
PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT




 EX-10.3 4 ex103q31910qseverancep.htm EXHIBIT 10.3 Exhibit


Exhibit 10.3
REVANCE THERAPEUTICS, INC.
EXECUTIVE SEVERANCE BENEFIT PLAN
Amended and Restated Effective October 13, 2019
1. INTRODUCTION. This Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”) is established by Revance Therapeutics, Inc. (the “Company”). The Plan was originally adopted by the Board on December 17, 2013; became effective without further action on the IPO Date (as defined below) (the “Effective Date”); was amended by the Board on May 7, 2015 to clarify that the Plan applies to all stock awards, including without limitation stock options, restricted stock awards and restricted stock units; was amended by the Board again on February 16, 2017 to extend benefits to Senior Vice President-level and Vice President-level employees; was amended again on February 12, 2019 to change the definition of Resignation for Good Reason and clarify that this Plan replaces individual employment or severance agreements only where this Plan provides superior benefits, which amendment effective February 12, 2019 shall be effective with regard to the definition of Resignation for Good Reason only for individuals who become Participants after February 12, 2019; and was amended again on October 13, 2019 to change the definition of Severance Multiplier for a Participant who is the Chief Executive Officer of the Company.
The Plan provides for severance benefits to the Chief Executive Officer, other executive officers, senior vice presidents and vice presidents, and key employees of the Company designated by the Board. This document constitutes the Summary Plan Description for the Plan.
2. DEFINITIONS. For purposes of the Plan, the following terms are defined as follows:
(a) “Accrued Amounts” means any unpaid annual base salary accrued through the date of a Participant’s Qualifying Termination and any accrued but unpaid vacation pay.
(b) “Annual Bonus” means the annual cash bonus that a Participant is eligible to earn, if any, pursuant to the Participant’s Executive Employment Agreement with the Company, as it may be amended from time to time.
(c) “Annual Bonus Target” means a Participant’s Annual Bonus with respect to performance for the year in which the Qualifying Termination occurs, calculated assuming the Participant achieves the maximum possible annual target bonus percentage for that year.
(d) “Board” means the Board of Directors of the Company.
(e) “Cause”, as determined by the Board in its sole discretion, means: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct.
(f) “Change in Control” shall have the meaning set forth in the Company’s 2014 Equity Incentive Plan. The definition of Change in Control is intended to conform to the definitions of “change in ownership of a corporation” and “change in ownership of a substantial portion of a corporation’s assets” provided in Treasury Regulation Sections 1.409A-3(i)(5)(v) and (vii).
(g) “Change in Control Termination” means (i) a Participant’s dismissal or discharge by the Company for a reason other than death, disability, or Cause, or (ii) a Resignation for Good Reason, either of which occurs in connection with or within twelve (12) months following the effective date of a Change in Control, provided that any such termination is a Separation from Service. In no event will a Participant’s Separation from Service due to death, disability or Cause, or a resignation by a Participant without Good Reason, constitute a Change in Control Termination.
(h) “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended and any analogous provisions of applicable state law.

1



(i) “Code” means the Internal Revenue Code of 1986, as amended.
(j) “Common Stock” means the common stock of the Company.
(k) “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
(l) “IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.
(m) “Monthly Annual Bonus Target” means a Participant’s Annual Bonus Target, divided by 12.
(n) “Monthly Base Salary” means the Participant’s annual base salary, ignoring any decrease in annual base salary that forms the basis for a Resignation for Good Reason, as in effect on the date of the Qualifying Termination, divided by 12.
(o) “Non-Change in Control Termination” means a Participant’s dismissal or discharge by the Company resulting in a Separation from Service, for a reason other than death, disability, or Cause, other than in connection with or within twelve (12) months following the effective date of a Change in Control. In no event will a Participant’s Separation from Service due to death, disability or Cause, or a resignation by a Participant for any reason, constitute a Non-Change in Control Termination.
(p) “Participant” means each individual who (i) is employed by the Company as an executive officer, senior vice president, vice president, or key employee designated by the Board, and (ii) has received and returned a signed Participation Notice.
(q) “Participation Notice” means the latest notice delivered by the Company to a Participant informing the Participant that he or she is eligible to participate in the Plan, in substantially the form of EXHIBIT A to the Plan.
(r) “Plan Administrator” means the Board or any committee of the Board duly authorized to administer the Plan. The Plan Administrator may be, but is not required to be, the Compensation Committee of the Board. The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board has previously appointed a committee to act as the Plan Administrator.
(s) “Qualifying Termination” means either a Change in Control Termination or a Non-Change in Control Termination.
(t) “Resignation for Good Reason” means a Participant’s resignation from all positions the Participant then holds with the Company, resulting in a Separation from Service, within ninety (90) days after the expiration of the cure period set forth below, provided the Participant has given the Board written notice of the occurrence of any of the following events taken without the Participant’s written consent within thirty (30) days after the first occurrence of such event and the Company has not cured such event, to the extent curable, within thirty (30) days thereafter:
(i) Relocation of the Participant’s principal place of employment to a place that increases the Participant’s one-way commute by more than thirty-five (35) miles as compared to the Participant’s then-current principal place of employment immediately prior to such relocation; or
(ii) The failure of any successor-in-interest to assume a material written contractual obligation to Participant, which (in either case) adversely affects the Participant.
(u) “Separation from Service” means a “separation from service” within the meaning of Treasury Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder.
(v) “Severance Multiplier” means:
(i) for a Participant who is the Chief Executive Officer of the Company at the time of the Qualifying Termination, (A) eighteen (18), for a Non-Change in Control Termination, and (B) twenty-four (24), for a Change in Control Termination;

2


(ii) for a Participant who is an executive officer of the Company (but not the Chief Executive Officer) or, as applicable, a key employee designated by the Board, (A) nine (9), for a Non-Change in Control Termination, and (B) twelve (12), for a Change in Control Termination; and
(iii) for a Participant who is a senior vice president or vice president of the Company at the time of the Qualifying Termination or, as applicable, a key employee designated by the Board, (A) six (6), for a Non-Change in Control Termination, and (B) nine (9), for a Change in Control Termination; and
(w) “Severance Period” means a period of months commencing on the date of a Participant’s Qualifying Termination, with the number of months being equal to a Participant’s applicable Severance Multiplier.
(x) “Stock Awards” means outstanding stock awards for shares of the Company’s common stock granted to a Participant by the governing plan documents, grant notices and award agreements, including without limitation stock options, restricted stock awards and restricted stock units.
3. ELIGIBILITY FOR BENEFITS.
(a) Eligibility; Exceptions to Benefits. Subject to the terms and conditions of the Plan, the Company will provide the benefits described in Section 4 to the affected Participant. A Participant will not receive benefits under the Plan in the following circumstances, as determined by the Plan Administrator, in its sole discretion:
(i) The Participant is a party to an effective written employment, change in control or severance arrangement with the Company that provides for equal or superior severance benefits, separation or similar post-termination payments pursuant to the Participant’s termination of employment.
(ii) The Participant’s employment is terminated by either the Company or the Participant for any reason other than a Qualifying Termination.
(iii) The Participant has not entered into the Employee Proprietary Information and Inventions Agreement or any similar or successor document (the “Proprietary Information Agreement”).
(iv) The Participant has failed to execute and allow to become effective the Release (as defined and described below) within sixty (60) days following the Participant’s Separation from Service.
(v) The Participant has failed to return all Company Property. For this purpose, “Company Property” means all paper and electronic Company documents (and all copies thereof) created and/or received by the Participant during his or her period of employment with the Company and other Company materials and property that the Participant has in his or her possession or control, including, without limitation, Company files, correspondence, emails, memoranda, notes, notebooks, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, without limitation, leased vehicles, computers, computer equipment, software programs, facsimile machines, mobile telephones, servers), credit and calling cards, entry cards, identification badges and keys, and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof, in whole or in part). As a condition to receiving benefits under the Plan, a Participant must not make or retain copies, reproductions or summaries of any such Company documents, materials or property and must make a diligent search to locate any such documents, property and information. If the Participant has used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10) business days after the Separation from Service, the Participant must provide the Company with a computer-useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. However, a Participant is not required to return his or her personal copies of documents evidencing the Participant’s hire, termination, compensation, benefits and stock awards and any other documentation received as a stockholder of the Company. A Participant’s failure to return Company Property that is neither confidential nor material, such as an identification badge or calling card, will not, in and of itself, disqualify such Participant from receiving benefits under the Plan; provided, that any such items of Company Property are subsequently returned to the Company upon request.
(vi) The Participant has failed to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any existing or future litigation, arbitrations, mediations,

3


claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts, or failures to act that occurred during the time period in which the Participant was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice, without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation and testimony. As a condition of receiving benefits under the Plan, the Participant must also promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by the Participant in connection with any such legal proceedings, unless the Participant is expressly prohibited by law from so doing. The Company will reimburse the Participant for reasonable out-of-pocket expenses incurred in connection with any such cooperation (excluding foregone wages, salary, or other compensation) within thirty (30) days after the Participant’s timely presentation of appropriate documentation thereof, in accordance with the Company’s standard reimbursement policies and procedures, and will make reasonable efforts to accommodate the Participant’s scheduling needs.
(b) Termination of Benefits. A Participant’s right to receive benefits under the Plan will terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits under the Plan, the Participant, without the prior written approval of the Plan Administrator:
(i) willfully breaches a material provision of the Participant’s Proprietary Information Agreement and/or any obligations of confidentiality, non-solicitation, non-disparagement, no conflicts or non-competition provision set forth in any other agreement between the Company and a Participant (including, without limitation, the Participant’s employment agreement or offer letter) or under applicable law;
(ii) encourages or solicits any of the Company’s then current employees to leave the Company’s employ for any reason or interferes in any other manner with employment relationships at the time existing between the Company and its then current employees; or
(iii) induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees, or other third party to terminate their existing business relationship with the Company or interferes in any other manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor, licensor, licensee, or other third party.
4. PAYMENTS & BENEFITS. Except as may otherwise be provided in a Participant’s Participation Notice, in the event of a Qualifying Termination, the Company will pay the Participant the Accrued Amounts, if any, on the date of such Qualifying Termination. In addition, subject to Sections 5 and 6 and a Participant’s continued compliance with the provisions of any agreement with the Company, including, without limitation, the Participant’s Proprietary Information Agreement, in the event of a Qualifying Termination, the Participant shall be entitled to the payments and benefits described in this Section 4, subject to the terms and conditions of the Plan.
(a) Cash Severance.
(i) Change in Control Termination. Upon a Change in Control Termination, the Participant will receive as severance an amount equal to the product of (i) the sum of the Participant’s Monthly Base Salary and Monthly Annual Bonus Target, and (ii) the Participant’s applicable Severance Multiplier (the “Change in Control Cash Severance”). The Change in Control Cash Severance will be paid in a single lump sum, less all applicable withholdings and deductions; provided, however, that no payments will be made prior to the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination.
(ii) Non-Change in Control Termination. Upon a Non-Change in Control Termination, the Participant will receive as severance an amount equal to the product of (i) the Participant’s Monthly Base Salary, and (ii) the Participant’s applicable Severance Multiplier (the “Non-Change in Control Cash Severance”). The Non-Change in Control Cash Severance will be paid in equal installments on the Company’s regular payroll schedule over the Severance Period, less all applicable withholdings and deductions; provided, however, that no payments will be made prior to the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination. On the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination, the Company will pay the Participant in a lump sum the Non-Change in Control Cash Severance that the Participant would have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance with Section 409A of the Code and the effectiveness of the Release referenced in Section 5(a) below, with the balance of the Non-Change in Control Cash Severance being paid as originally scheduled.

4


(b) COBRA Benefits.
(i) If the Participant is eligible and has made the necessary elections for continuation coverage pursuant to COBRA under a health, dental, or vision plan sponsored by the Company, the Company will pay, as and when due directly to the COBRA carrier, the COBRA premiums necessary to continue the COBRA coverage for the Participant and his or her eligible dependents until the earliest to occur of (i) the end of the applicable Severance Period, (ii) the date on which the Participant becomes eligible for coverage under the group health insurance plans of a subsequent employer, and (iii) the date on which the Participant is no longer eligible for continuation coverage under COBRA (such period from the date of the Qualifying Termination through the earliest of (i) through (iii), the “COBRA Payment Period”).
(ii) Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment of COBRA premiums hereunder is likely to result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will instead pay the Participant, on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings and deductions. To the extent applicable, on the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination, the Company will make the first payment under this Section 4(b)(ii) in a lump sum equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the original schedule. The Participant may, but is not obligated to, use such payments toward the cost of COBRA premiums.
(iii) If the Participant becomes eligible for coverage under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the applicable Severance Period, the Participant must immediately notify the Company of such event, and all payments and obligations under this section 4(b) will cease. For purposes of this Section 4(b), references to COBRA also refer to analogous provisions of state law. Any applicable insurance premiums that are paid by the Company will not include any amounts payable by the Participant under a Code Section 125 health care reimbursement plan, which are the sole responsibility of the Participant.
(C) Accelerated Vesting. Upon a Change in Control Termination, the vesting and exercisability (if applicable) of all outstanding and unvested Stock Awards that are held by the Participant on the effective date of the Change in Control Termination will, as of the date of the Change in Control Termination, accelerate in full as to one hundred percent (100%) of the shares subject to the Stock Awards.
5. CONDITIONS AND LIMITATIONS ON BENEFITS.
(a) Release. To be eligible to receive any benefits under the Plan, a Participant must sign a general waiver and release in substantially the form attached hereto as EXHIBIT B, EXHIBIT C, or EXHIBIT D, as appropriate (the “Release”), and such release must become effective in accordance with its terms, in each case within sixty (60) days following the Qualifying Termination. The Plan Administrator, in its sole discretion, may modify the form of the required Release to comply with applicable law, and any such Release may be incorporated into a termination agreement or other agreement with the Participant.
(b) Prior Agreements; Certain Reductions. The Plan Administrator will reduce a Participant’s benefits under the Plan by any other statutory severance obligations or contractual severance benefits, obligations for pay in lieu of notice, and any other similar benefits payable to the Participant by the Company that are due in connection with the Participant’s Qualifying Termination and that are in the same form as the benefits provided under the Plan (e.g., equity award vesting credit). Without limitation, this reduction includes a reduction for any benefits required pursuant to (i) any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”), (ii) a written employment, change in control, severance or equity award agreement with the Company, (iii) any Company policy or practice providing for the Participant to remain on the payroll for a limited period of time after being given notice of the termination of the Participant’s employment, and (iv) any required salary continuation, notice pay, statutory severance payment, or other payments either required by local law, or owed pursuant to a collective labor agreement, as a result of the termination of the Participant’s employment. The benefits provided under the Plan are intended to satisfy, to the greatest extent possible, and not to provide benefits duplicative of, any and all statutory, contractual and collective agreement obligations of the Company in respect of the form of benefits provided under the Plan that may arise out of a Qualifying Termination,

5


and the Plan Administrator will so construe and implement the terms of the Plan. Reductions may be applied on a retroactive basis, with benefits previously provided being recharacterized as benefits pursuant to the Company’s statutory or other contractual obligations. The payments pursuant to the Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or employee welfare benefits to which a Participant may be entitled for the period ending with the Participant’s Qualifying Termination.
(c) Mitigation. Except as otherwise specifically provided in the Plan, a Participant will not be required to mitigate damages or the amount of any payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan be reduced by any compensation earned by a Participant as a result of employment by another employer or any retirement benefits received by such Participant after the date of the Participant’s termination of employment with the Company (except as provided for in Section 5(b)).
(d) Indebtedness of Participants. To the extent permitted under applicable law, if a Participant is indebted to the Company on the effective date of a Participant’s Qualifying Termination, the Company reserves the right to offset the payment of any benefits under the Plan by the amount of such indebtedness. Such offset will be made in accordance with all applicable laws. The Participant’s execution of the Participation Notice constitutes knowing written consent to the foregoing.
(e) Parachute Payments.
(i) Except as otherwise expressly provided in an agreement between a Participant and the Company, if any payment or benefit the Participant would receive in connection with a Change in Control from the Company or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (B) the largest portion, up to and including the total, of the Payment, whichever amount ((A) or (B)), after taking into account all applicable federal, state, provincial, foreign, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of stock awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to the Participant. Within any such category of Payments (that is, (1), (2), (3) or (4)), a reduction will occur first with respect to amounts that are not “deferred compensation” within the meaning of Section 409A of the Code and then with respect to amounts that are “deferred compensation.” In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant’s applicable type of stock award (i.e., earliest granted stock awards are cancelled last). If Section 409A of the Code is not applicable by law to a Participant, the Company will determine whether any similar law in the Participant’s jurisdiction applies and should be taken into account.
(ii) The professional firm engaged by the Company for general tax purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section 5(e). If the professional firm so engaged by the Company is serving as an accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such professional firm required to be made hereunder. Any good faith determinations of the professional firm made hereunder shall be final, binding and conclusive upon the Company and the Participant.
6. TAX MATTERS.
(a) Application of Code Section 409A. Notwithstanding anything herein to the contrary, (i) if at the time of Participant’s termination of employment with the Company, the Participant is a “specified employee” as defined in Section 409A of the Code and the applicable guidance and regulations thereunder (collectively, “Section 409A”), and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then the Company will defer the commencement of the payment of any such payments or benefits hereunder

6


(without any reduction in such payments or benefits ultimately paid or provided to Participant) until the first business day to occur following the date that is six (6) months following Participant’s termination of employment with the Company (or the earliest date as is permitted under Section 409A); and (ii) if any other payments of money or other benefits due to Participant hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that does not cause such an accelerated or additional tax. In the event that payments under the Plan are deferred pursuant to this Section 6 in order to prevent any accelerated tax or additional tax under Section 409A, then such payments shall be paid at the time specified under this Section 6 without any interest thereon. The Company shall consult with Participant in good faith regarding the implementation of this Section 6; provided, that neither the Company nor any of its employees or representatives shall have any liability to Participant with respect thereto. Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of the Plan providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. For purposes of Section 409A, each payment made under the Plan shall be designated as a “separate payment” within the meaning of the Section 409A. Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement or in-kind benefit provided pursuant to the Plan does not constitute a “deferral of compensation” within the meaning of Section 409A, (A) the amount of expenses eligible for reimbursement or in-kind benefits provided to a Participant during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to a Participant in any other calendar year; (B) the reimbursements for expenses for which a Participant is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred; and (C) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.
(b) Withholding. All payments and benefits under the Plan will be subject to all applicable deductions and withholdings, including, without limitation, obligations to withhold for federal, state, provincial, foreign and local income and employment taxes.
(c) Tax Advice. By becoming a Participant in the Plan, the Participant agrees to review with the Participant’s own tax advisors the federal, state, provincial, local, and foreign tax consequences of participation in the Plan. The Participant will rely solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that Participant (and not the Company) will be responsible for his or her own tax liability that may arise as a result of becoming a Participant in the Plan.
7. REEMPLOYMENT. In the event of a Participant’s reemployment by the Company during the period of time in respect of which severance benefits have been provided (that is, benefits as a result of a Qualifying Termination), the Company, in its sole and absolute discretion, may require such Participant to repay to the Company all or a portion of such severance benefits as a condition of reemployment.
8. CLAWBACK; RECOVERY. All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in the Participation Notice, as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to Resignation for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company.
9. RIGHT TO INTERPRET PLAN; AMENDMENT AND TERMINATION.
(a) Exclusive Discretion. The Plan Administrator will have the exclusive discretion and authority to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the operation of the Plan, including, without limitation, the eligibility to participate in the Plan, the amount of benefits paid under the Plan and any adjustments that need to be made in accordance with the laws applicable to a

7


Participant. The rules, interpretations, computations and other actions of the Plan Administrator will be binding and conclusive on all persons.
(b) Amendment or Termination. The Company reserves the right to amend or terminate the Plan, any Participation Notice issued pursuant to the Plan or the benefits provided hereunder at any time; provided, however, that no such amendment or termination will apply to any Participant who would be adversely affected by such amendment or termination unless such Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan or any Participation Notice will be in writing and executed by a duly authorized officer of the Company.
10. NO IMPLIED EMPLOYMENT CONTRACT. The Plan will not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company, or (ii) to interfere with the right of the Company to discharge any employee or other person at any time, with or without Cause, and with or without advance notice, which right is hereby reserved.
11. LEGAL CONSTRUCTION. The Plan will be governed by and construed under the laws of the State of California (without regard to principles of conflict of laws), except to the extent preempted by ERISA.
12. CLAIMS, INQUIRIES AND APPEALS.
(A) Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or inquiries about present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is set forth in Section 14(d).
(b) Denial of Claims. In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s right to review the denial. Any electronic notice will comply with the regulations of the U.S. Department of Labor. The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following:
(1) the specific reason or reasons for the denial;
(2) references to the specific Plan provisions upon which the denial is based;
(3) a description of any additional information or material that the Plan Administrator needs to complete the review and an explanation of why such information or material is necessary; and
(4) an explanation of the Plan’s review procedures and the time limits applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in Section 12(d).
The notice of denial will be given to the applicant within ninety (90) days after the Plan Administrator receives the application, unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for processing is required, written notice of the extension will be furnished to the applicant before the end of the initial ninety (90) day period.
The notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application.
(c) Request for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied, in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application is denied. A request for a review will be in writing and will be addressed to:
Revance Therapeutics, Inc.
Attn: Human Resources
7555 Gateway Boulevard
Newark, CA 94560

8


A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent. The applicant (or his or her representative) will have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating to his or her claim. The applicant (or his or her representative) will be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim. The review will take into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.
(d) Decision on Review. The Plan Administrator will act on each request for review within sixty (60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for review is required, written notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor. In the event that the Plan Administrator confirms the denial of the application for benefits, in whole or in part, the notice will set forth, in a manner designed to be understood by the applicant, the following:
(1) the specific reason or reasons for the denial;
(2) references to the specific Plan provisions upon which the denial is based;
(3) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her claim; and
(4) a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA.
(e) Rules and Procedures. The Plan Administrator will establish rules and procedures, consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in connection with an appeal from the denial of benefits to do so at the applicant’s own expense.
(f) Exhaustion of Remedies. No legal action for benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 12(a), (ii) has been notified by the Plan Administrator that the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 12(c), and (iv) has been notified that the Plan Administrator has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an applicant’s claim or appeal within the relevant time limits specified in this Section 12, the applicant may bring legal action for benefits under the Plan pursuant to Section 502(a) of ERISA.
13. BASIS OF PAYMENTS TO AND FROM PLAN. All benefits under the Plan will be paid by the Company. The Plan will be unfunded, and benefits hereunder will be paid only from the general assets of the Company.
14. OTHER PLAN INFORMATION.
(a) Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan Sponsor” as that term is used in ERISA) by the Internal Revenue Service is 77-055-1645. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 503.
(b) Ending Date for Plan’s Fiscal Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s records is December 31.
(c) Agent for the Service of Legal Process. The agent for the service of legal process with respect to the Plan is:
Revance Therapeutics, Inc.
Attn: Chief Financial Officer

9


7555 Gateway Boulevard
Newark, CA 94560
(d) Plan Sponsor and Administrator. The “Plan Sponsor” and the “Plan Administrator” of the Plan is:
Revance Therapeutics, Inc.
Attn: Human Resources
7555 Gateway Boulevard
Newark, CA 94560
The Plan Sponsor’s and Plan Administrator’s telephone number is (510) 742-3400. The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan.
15. STATEMENT OF ERISA RIGHTS.
Participants in the Plan (which is a welfare benefit plan sponsored by Revance Therapeutics, Inc.) are entitled to certain rights and protections under ERISA. For the purposes of this Section 15, and under ERISA, Participants are entitled to:
Receive Information About the Plan and Benefits
(a) Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration;
(b) Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Plan Administrator may make a reasonable charge for the copies; and
(c) Receive a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report.
Prudent Actions By Plan Fiduciaries
In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of each Plan Participant and their beneficiaries. No one, including a Participant’s employer, a Participant’s union or any other person, may fire a Participant or otherwise discriminate against a Participant in any way to prevent a Participant from obtaining a Plan benefit or exercising a Participant’s rights under ERISA.
Enforcement of Participant Rights
If a Participant’s claim for a Plan benefit is denied or ignored, in whole or in part, a Participant has a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.
Under ERISA, there are steps a Participant can take to enforce the above rights. For instance, if a Participant request a copy of Plan documents or the latest annual report from the Plan, if applicable, and does not receive them within thirty (30) days, the Participant may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay the Participant up to $110 a day until the Participant receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.
If a Participant has a claim for benefits that is denied or ignored, in whole or in part, the Participant may file suit in a state or federal court.
If a Participant is discriminated against for asserting the Participant’s rights, the Participant may seek assistance from the U.S. Department of Labor, or the Participant may file suit in a federal court. The court will

10


decide who should pay court costs and legal fees. If the Participant is successful, the court may order the person the Participant has sued to pay these costs and fees. If the Participant loses, the court may order the Participant to pay these costs and fees, for example, if it finds the Participant’s claim is frivolous.
Assistance With Questions
If a Participant has any questions about the Plan, the Participant should contact the Plan Administrator. If a Participant has any questions about this statement or about the Participant’s rights under ERISA, or if a Participant needs assistance in obtaining documents from the Plan Administrator, the Participant should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in the telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. A Participant may also obtain certain publications about the Participant’s rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.
16. GENERAL PROVISIONS.
(a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant pursuant to the terms of the Plan will be in writing and will be deemed given when delivered personally, when received electronically (including email addressed to the Participant’s Company email account and to the Company email account of the Company’s Chief Financial Officer), or deposited in the U.S. Mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address set forth in Section 14(d), in the case of a Participant, at the address as set forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by notifying the other in writing.
(b) Transfer and Assignment. The rights and obligations of a Participant under the Plan may not be transferred or assigned without the prior written consent of the Company. The Plan will be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder.
(c) Waiver. Any party’s failure to enforce any provision or provisions of the Plan will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Plan. The rights granted to the parties herein are cumulative and will not constitute a waiver of any party’s right to assert all other legal remedies available to it under the circumstances.
(d) Severability. Should any provision of the Plan be declared or determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired.
(e) Section Headings. Section headings in the Plan are included only for convenience of reference and will not be considered part of the Plan for any other purpose.


11


EXHIBIT A
REVANCE THERAPEUTICS, INC.
EXECUTIVE SEVERANCE BENEFIT PLAN
PARTICIPATION NOTICE
To: Revance Human Resources
Date:
Revance Therapeutics, Inc. (the “Company”) has adopted the Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”). The Company is providing you this Participation Notice to inform you that you have been designated as a Participant in the Plan. A copy of the Plan document is attached to this Participation Notice. The terms and conditions of your participation in the Plan are as set forth in the Plan and this Participation Notice, which together constitute the Summary Plan Description for the Plan.
You understand that the Plan does not provide duplication of any severance benefits with any benefits provided to you under any other contract or agreement with the Company; you will only receive the severance benefits under this Plan if this Plan provides superior benefits to any other agreements you have with the Company. You also understand that by accepting your status as a Participant in the Plan, your stock options that have been considered to be “incentive stock options” prior to the date hereof may cease to qualify as “incentive stock options” as a result of the vesting acceleration benefit provided in the Plan. By accepting participation, you represent that you have either consulted your personal tax or financial planning advisor about the tax consequences of your participation in the Plan, or you have knowingly declined to do so.
Please return a signed copy of this Participation Notice to the Company’s Human Resources at the Company’s offices and retain a copy of this Participation Notice, along with the Plan document, for your records.
REVANCE THERAPEUTICS, INC.:

 
                                                                
(Signature)
 
By:
 
Title:
 

PARTICIPANT:

 
                                                                
(Signature)
 
By:




EXHIBIT B
RELEASE AGREEMENT
[EMPLOYEES AGE 40 OR OVER; INDIVIDUAL TERMINATION]
I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”).
I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan.
I hereby acknowledge and reaffirm my obligations under my Employee Proprietary Information and Inventions Agreement.
Except as otherwise set forth in this Release, I hereby generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock awards, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) (“ADEA”), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended) (“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).
Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release (the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws, or operating agreements of the Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I sign this Release. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against the Released Parties that are not included in the Released Claims.
I understand that nothing in this release limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). I further understand this release does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights waived by signing this release.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and that the consideration given under the Plan for the waiver and release in the preceding paragraphs hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise



after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may choose voluntarily not do so); (c) I have twenty-one (21) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days following the date I sign this Release to revoke the Release by providing written notice of my revocation to an officer of the Company; and (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign this Release.
In giving the releases set forth in this Release, which include claims which may be unknown or unsuspected by me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Release.
I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked; (b) I have received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one (21) days following the date it is provided to me, and I must not subsequently revoke the Release.
PARTICIPANT:

 
                                                                
(Signature)
 
Printed Name:
Date:
 





EXHIBIT C
RELEASE AGREEMENT
[EMPLOYEES AGE 40 OR OVER; GROUP TERMINATION]
I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”).
I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan.
I hereby acknowledge and reaffirm my obligations under my Employee Proprietary Information and Inventions Agreement.
Except as otherwise set forth in this Release, I hereby generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock awards, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Age Discrimination in Employment Act (as amended) (“ADEA”), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended) (“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).
Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release (the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws, or operating agreements of the Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I sign this Release. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against the Released Parties that are not included in the Released Claims.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and that the consideration given under the Plan for the waiver and release in the preceding paragraphs hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may choose voluntarily not to do so); (c) I have forty-five (45) days to consider this Release (although I may choose voluntarily to sign this Release earlier); (d) I have seven (7) days following the date I sign this Release to revoke the Release by providing written notice of my revocation to an office of the Company; (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign this Release; and (f) I have received with this Release a written disclosure under 29 U.S. Code Section 626(f)(1)(H) that includes certain information relating to the Company’s group termination.
I understand that nothing in this release limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and



Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). I further understand this release does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights waived by signing this release.
In giving the releases set forth in this Release, which include claims which may be unknown or unsuspected by me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Release.
I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked; (b) I have received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than forty-five (45) days following the date it is provided to me, and I must not subsequently revoke the Release.
PARTICIPANT:

 
                                                                
(Signature)
 
Printed Name:
Date:





EXHIBIT D
RELEASE AGREEMENT
[EMPLOYEES UNDER AGE 40]
I have reviewed, I understand, and I agree completely to the terms set forth in the Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”).
I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company, affiliates of the Company, and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company or an affiliate of the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan.
I hereby acknowledge and reaffirm my obligations under my Employee Proprietary Information and Inventions Agreement.
Except as otherwise set forth in this Release, I hereby generally and completely release the Company and its affiliates, and its and their parents, subsidiaries, successors, predecessors and affiliates, and its and their partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (collectively, the “Released Parties”), of and from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time prior to or on the date I sign this Release (collectively, the “Released Claims”). The Released Claims include, but are not limited to: (a) all claims arising out of or in any way related to my employment with the Company and its affiliates, or their affiliates, or the termination of that employment; (b) all claims related to my compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock awards, or any other ownership interests in the Company and its affiliates, or their affiliates; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, provincial and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Employee Retirement Income Security Act of 1974 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”), the California Family Rights Act (as amended) (“CFRA”), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).
Notwithstanding the foregoing, I understand that the following rights or claims are not included in my Release (the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any fully executed indemnification agreement with the Company or its affiliate to which I am a party; the charter, bylaws, or operating agreements of the Company or its affiliate; or under applicable law; (b) any rights or claims which cannot be waived as a matter of law; or (c) any claims for breach of the Plan arising after the date that I sign this Release. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against the Released Parties that are not included in the Released Claims.
I understand that nothing in this release limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). I further understand this release does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights waived by signing this release.
In giving the releases set forth in this Release, which include claims which may be unknown or unsuspected by me at present, I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as



follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected claims granted in this Release.
I hereby represent and warrant that: (a) I have been paid all compensation owed and for all time worked; (b) I have received all the leave and leave benefits and protections for which I am eligible pursuant to FMLA, CFRA, the Company’s policies, or applicable law; and (c) I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than fourteen (14) days following the date it is provided to me.
PARTICIPANT:

 
                                                                
(Signature)
 
Printed Name:
Date:

 EX-10.4 5 ex104q31910qmarkfoley.htm EXHIBIT 10.4 Exhibit

Exhibit 10.4

EXECUTIVE EMPLOYMENT AGREEMENT
for
Mark Foley
This Executive Employment Agreement (the “Agreement”), made between Revance Therapeutics, Inc. (the “Company”) and Mark Foley (“Executive”) (collectively, the “Parties”), is effective as of October 13, 2019 (the “Start Date”).
WHEREAS, the Company desires for Executive to provide services to the Company; and
WHEREAS, Executive is willing to engage in employment by the Company on the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:
1.Employment by the Company.
1.1    Position. Executive shall serve as the Company’s Chief Executive Officer. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation periods, approved non-company business and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies.
1.2    Duties and Location. Executive shall perform such duties as are required by the Company’s Board of Directors (the “Board”), to whom Executive will report. Executive’s primary office location will be the Company’s office located in Newark, California. The Company reserves the right to reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location from time to time, and to require reasonable business travel. The Company may modify Executive’s job title and duties as it deems necessary and appropriate in light of the Company’s needs and interests from time to time.
1.3    Policies and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.
2.    Compensation.
2.1    Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of $650,000 per year (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. Executive’s base salary shall be reviewed by the Board of Directors (the “Board”) for possible adjustment annually.

1.
 


2.2    Bonus. Executive will be eligible for a discretionary annual bonus, with Executive’s target bonus to be equal to 75% of Executive’s Base Salary. Executive’s target bonus shall be reviewed by the Board for possible adjustment annually. Whether Executive receives an annual bonus for any given year, and the amount of any such annual bonus, will be determined by the Board in its sole discretion based upon the Company’s and Executive’s achievement of objectives and milestones to be determined on an annual basis by the Board in consultation with Executive. Bonuses are generally paid by March 15 following the applicable bonus year, and Executive must be an active employee on the date any annual bonus is paid in order to earn any such annual bonus. Executive will not be eligible for, and will not earn, any annual bonus (including a prorated bonus) if Executive’s employment terminates for any reason before the date annual bonuses are paid.
2.3    Standard Company Benefits. Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees. Executive will receive up to twenty (20) days of paid vacation per calendar year. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time.
2.4    Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy and requirements of the Internal Revenue Service as in effect from time to time.
2.5    Equity.
(i)    Effective as of the Start Date, the Company will grant Executive 200,000 shares of restricted common stock awards (“RSA”) and an option to purchase 740,000 shares of the Company’s common stock (the “Option”) with an exercise price equal to the fair market value of the Company’s common stock as of the Start Date, as determined under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”). Subject to Executive’s continuing service with the Company: (i) the Option will vest over a period of four years, with 25% vesting one year after the Start Date and 1/48th vesting each month thereafter over the remaining three years; and (ii) the RSA will vest over a period of three years, with 1/3 vesting one year after the Start Date and 1/3 vesting on each of the second and third anniversaries of the Start Date. The Option and RSA will be governed in all respects by the terms of the 2014 Plan, and restricted stock award and stock option agreements thereunder, which Executive will be required to sign as a condition of receiving the awards.
(ii)    In addition, effective as of the Start Date, the Company will grant Executive 860,000 shares of performance-based common stock awards (“PSA”) that will vest based on the Company’s performance and achievement of the following milestones: (1) 25% of the PSA shares will vest upon the approval by the Food and Drug Administration (FDA) of the Company’s biologics license application (BLA) for DAXI for the treatment of glabellar lines on or before December 31, 2020; (2) 35% of the PSA

2.
 

shares will vest upon the earlier of: (a) the date that the closing share price of the Company’s common stock is at least $25/share on any day after the grant date and remains at or above $25/share during any 90 day period on a volume weighted average price (VWAP) basis; or (b) upon a Change in Control (as defined in the 2014 Plan) in which the purchase price of the Company’s common stock is at or above $25/share; and (3) 40% of the PSA will vest upon the earlier of: (a) the date that the closing share price of the Company’s common stock is at least $40/share on any day after the grant date and remains at or above $40/share during any 90 day period on a volume weighted average price (VWAP) basis; or (b) upon a Change in Control (as defined in the 2014 Plan) in which the purchase price of the Company’s common stock is at or above $40/share. All per share prices referenced above shall be adjusted for any stock splits, combinations and the like. The PSA will be governed in all respects by the terms of the 2014 Plan, and performance stock award agreement thereunder, which Executive will be required to sign as a condition of receiving the PSA.
(iii)    In addition, upon approval by the Board or Compensation Committee of the Board in connection with the Company’s assessment of 2020 executive compensation, expected in the first quarter of 2020, the Company will grant Executive an additional 200,000 shares of restricted common stock awards (the “Additional RSA”) under the 2014 Plan. Subject to Executive’s continuing service with the Company, the Additional RSA will vest over a period of three years, with 1/3 vesting one year after the Start Date and 1/3 vesting on each of the second and third anniversaries of the Start Date. The Additional RSA will be governed in all respects by the terms of the Company’s 2014 Equity Incentive Plan, and performance stock award agreements thereunder, which Executive will be required to sign as a condition of receiving the award.
3.    Termination of Employment; Severance. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause or advance notice. Executive will be eligible for severance under the Company’s Executive Severance Benefit Plan as adopted by the Board and as it may be amended from time to time (the “Severance Plan”). As of the Start Date, Executive’s Severance Multiplier (as defined in the Severance Plan) is eighteen (18) for a Non-Change in Control Termination and twenty-four (24) for a Change in Control Termination.

4.    Proprietary Information Obligations. As a condition of employment, Executive shall be required to execute the Company’s standard form of Employee Proprietary Information and Inventions Agreement.
5.    Conflicts. Executive represents that Executive has full authority to accept this position and perform the duties of the position without conflict with any other obligations and that Executive is not involved in any situation that might create, or appear to create, a conflict of interest with respect to Executive’s loyalty to or duties for the Company. Executive specifically warrants that Executive is not subject to an employment agreement or restrictive covenant preventing full performance of Executive’s duties for the Company. Executive agrees not to bring to the Company or use in the performance of Executive’s responsibilities any materials or documents of a former employer that are not generally available to the public unless Executive has obtained express written

3.
 

authorization from the former employer. Executive further agrees to honor all obligations to former employers during the course of Executive’s employment with the Company.
6.    Outside Activities During Employment; Dispute Resolution
6.1    Non-Company Business. Except with the prior written consent of the Board, Executive will not during the term of Executive’s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor; provided, however, that Executive may (i) engage in activities that do not interfere with his duties and obligations under this Agreement or create an actual or potential conflict of interest with the Company as reasonably determined by the Board, and (ii) serve as a member of the Board of Directors on a maximum one (1) publicly traded company subject to the approval of the Board with such approval not to be unreasonably withheld; provided that Executive may maintain his two (2) current public company Board affiliations through December 31, 2020. Executive may serve as a member of the Board of Directors of private companies and/or engage in civic and not-for-profit activities so long as such service or activities do not materially interfere with the performance of Executive’s duties hereunder.
6.2    No Adverse Interests. Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.
6.3    Dispute Resolution. To ensure timely and economical resolution of any disputes that may arise in connection with Executive’s employment with the Company, as a condition of Executive’s employment, Executive and the Company hereby agree that any and all claims, disputes or controversies of any nature whatsoever arising out of, or relating to, this letter, or its interpretation, enforcement, breach, performance or execution, Executive’s employment with the Company, or the termination of such employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted before a single arbitrator by JAMS or its successor, under the then applicable JAMS arbitration rules (which can be found at http://www.jamsadr.com/rules-clauses/). The arbitration shall take place in San Jose, California; provided, however, that if the arbitrator determines there will be an undue hardship to Executive to have the arbitration in such location, the arbitrator will choose an alternative appropriate location. Executive and the Company each acknowledge that by agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding. Executive will have the right to be represented by legal counsel at Executive’s expense at any arbitration proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this paragraph apply to a dispute, controversy, or claim sought to be resolved in accordance

4.
 

with these arbitration procedures. The Company shall pay all costs and fees in excess of the amount of court fees that Executive would be required to incur if the dispute were filed or decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.
7.    General Provisions.
7.1    Contingencies. The Company reserves the right to conduct a background investigation and/or reference check on Executive. Executive may also be required to go through a Security Risk Assessment (SRA) via the CDC which includes a Bioterrorism Act background check and FBI fingerprinting. This job offer is contingent upon SRA approval (including FBI clearance) as well as a satisfactory background investigation and/or reference check. In accordance with federal immigration law, Executive will also be required to provide to the Company documentary evidence of Executive’s identity and eligibility for employment in the United States. This employment offer is contingent upon such documentation being provided to the Company within three (3) business days after Executive’s hire date.
7.2    Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.
7.3    Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.
7.4    Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.
7.5    Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.

5.
 


7.6    Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.
7.7    Headings. The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
7.8    Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and he may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.
7.9    Tax Withholding and Indemnification. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.
7.10    Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.
[Remainder of Page Intentionally Left Blank]

6.
 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the day and year first written above.
REVANCE THERAPEUTICS, INC.
By:
 
/s/Angus Russell
 
 
Angus Russel
 
 
Chairman of the Board of Directors

EXECUTIVE

By:
 
/s/ Mark Foley
 
 
Mark Foley


7.
 
 EX-10.5 6 ex105q319nonemployeedi.htm EXHIBIT 10.5 Exhibit



Exhibit 10.5
Revance Therapeutics, Inc.
Amended and Restated
Non-Employee Director Compensation Policy
 
Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Revance Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy for his or her Board service. This policy is effective as of October 10, 2019 (the “Effective Date”) and may be amended at any time in the sole discretion of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.

1.Annual Board Service Retainer:
a.
All Eligible Directors: $40,000
b.
Chairman of the Board Service Retainer (including Eligible Director Service Retainer): $75,000

2.Annual Committee Member Service Retainer:
a.
Member of the Audit Committee: $10,000
b.
Member of the Brand Strategy Committee: $6,000
c.
Member of the Compensation Committee: $6,000
d.
Member of the Nominating & Governance Committee: $4,500
e.
Member of the Science & Technology Committee: $6,000

3.
Annual Committee Chair Service Retainer (including Committee Member Service Retainer):
a.
Chairman of the Audit Committee: $20,000
b.
Chairman of the Brand Strategy Committee: $12,500
c.
Chairman of the Compensation Committee: $12,500
d.
Chairman of the Nominating & Governance Committee: $8,000
e.
Chairman of the Science & Technology Committee: $12,500
 
Equity Compensation
 
The equity compensation set forth below will be granted under the Revance Therapeutics, Inc. 2014 Equity Incentive Plan (the “Plan”), and will be documented on the applicable form of stock option agreement most recently approved for use by the Board (or a duly authorized committee thereof) for Eligible Directors. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).

1.
Initial Option Grant: On the date of the Eligible Director’s initial election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading

1.




day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 18,000 shares (an “Initial Option Grant”). The shares subject to each Initial Option Grant will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date.
 
2.
Initial Restricted Stock Award: On the date of the Eligible Director’s initial election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a restricted stock award for 9,000 shares (an “Initial RSA”). The shares underlying the Initial RSA will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date.

3.
Annual Option Grant: On the date of each Company’s annual stockholder meeting held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 9,000 shares (an “Annual Option Grant”). The shares subject to the Annual Option Grant will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date.
 
4.
Annual Restricted Stock Award: On the date of each Company’s annual stockholder meeting held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a restricted stock award for 4,500 shares (an “Annual RSA”). The shares underlying the Annual RSA will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date.
 

2.

 EX-31.1 7 rvnc-q319exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS
I, Mark J. Foley, certify that:
1.
I have reviewed this Form 10-Q of Revance Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2019
 
 
/s/ Mark J. Foley
 
Mark J. Foley
 
President and Chief Executive Officer
 
(Duly Authorized Principal Executive Officer)




 EX-31.2 8 rvnc-q319exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATIONS
I, Tobin C. Schilke, certify that:
1.
I have reviewed this Form 10-Q of Revance Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2019
 
 
/s/ Tobin C. Schilke
 
Tobin C. Schilke
 
Chief Financial Officer
 
(Duly Authorized Principal Financial Officer and Principal Accounting Officer)



 EX-32.1 9 rvnc-q319exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Mark J. Foley, Chief Executive Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:
1.
The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 4, 2019
IN WITNESS WHEREOF, the undersigned has set his hands hereto as of the 4th day of November, 2019.
 
 
/s/ Mark J. Foley
 
Mark J. Foley
 
President and Chief Executive Officer
 
(Duly Authorized Principal Executive Officer)
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



EX-32.2 10 rvnc-q319exhibit322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Tobin C. Schilke, Chief Financial Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:
1.
The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 4, 2019
IN WITNESS WHEREOF, the undersigned has set his hands hereto as of the 4th day of November, 2019.
 
 
/s/ Tobin C. Schilke
 
Tobin C. Schilke
 
Chief Financial Officer
 
(Duly Authorized Principal Financial Officer and Principal Accounting Officer)
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



EX-101.SCH 11 rvnc-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Cash Equivalents and Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Cash Equivalents and Investments - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - The Company and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Leases Leases - Aggregate Future Noncancelable Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Leases Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Leases Leases - Operating Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Leases Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Medicis Settlement link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Medicis Settlement - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Stockholders' Equity Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 rvnc-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 rvnc-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 rvnc-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Leases [Abstract] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Extended term of lease Lessee, Operating Lease, Renewal Term Income Statement [Abstract] Revenue Revenues Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Interest income Investment Income, Nonoperating Interest expense Interest Expense Change in fair value of derivative liability associated with the Medicis settlement Gain (Loss) on Derivative Instruments, Contract, Net, Pretax Gain (Loss) on Derivative Instruments, Contract, Net, Pretax Other expense, net Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Unrealized gain (loss) and adjustment on securities included in net loss Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basic and diluted net loss Net Income Loss Available To Common Stockholders, Basic And Diluted Net Income Loss Available To Common Stockholders, Basic And Diluted Basic and diluted net loss (in dollar per share) Earnings Per Share, Basic and Diluted Basic and diluted weighted-average number of shares used in computing net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Restricted Stock [Member] Performance-based Common Stock Performance Shares [Member] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] President, Chief Executive Officer and Principal Executive Officer President, Chief Executive Officer and Principal Executive Officer [Member] President, Chief Executive Officer and Principal Executive Officer [Member] Former President and Chief Executive Officer Former President and Chief Executive Officer [Member] Former President and Chief Executive Officer [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Annual base salary Salary and Wage, Officer, Excluding Cost of Good and Service Sold Annual target bonus as percent of base salary Annual Target Bonus as Percent of Base Salary Annual Target Bonus as Percent of Base Salary Options granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted, exercise price per share (in USD) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Equity awards other than options granted (shares)Shares granted -based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Severance payment, months of salary Severance Payment, Months of Salary Severance Payment, Months of Salary Organization, Consolidation and Presentation of Financial Statements [Abstract] Revenue Collaborative Arrangement Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Investments, Debt and Equity Securities [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Money market funds Money Market Funds [Member] U.S. treasury securities US Treasury Securities [Member] U.S. government agency obligations US Government Agencies Debt Securities [Member] Commercial paper Commercial Paper [Member] Overnight repurchase agreements Repurchase Agreements [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cash equivalents Cash Equivalents [Member] Short-term investments Other Current Assets [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Cost Debt Securities, Available-for-sale, Amortized Cost Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Value Debt Securities, Available-for-sale Other-than-temporary impairments on available-for-sale securities Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Loss Contingencies [Table] Loss Contingencies [Table] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Service Agreements Service Agreements [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Botulinum Toxin Research Associates, Inc. Botulinum Toxin Research Associates, Inc. [Member] Botulinum Toxin Research Associates, Inc. [Member] Other Current Liabilities Other Current Liabilities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Ajinomoto Althea, Inc. Ajinomoto Althea, Inc. [Member] Ajinomoto Althea, Inc. [Member] List Laboratories List Laboratories [Member] List Laboratories [Member] BioSentinel, Inc. BioSentinel, Inc. [Member] BioSentinel, Inc. [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Product Approval Payment Derivative Credit Risk Contract [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Prepaid purchase obligations Prepaid Purchase Obligations Prepaid Purchase Obligations Accrued milestone obligations Accrued Milestone Obligations Accrued Milestone Obligations Fair value of assets acquired Fair Value of Assets Acquired Indemnification liability recorded during the period Indemnification Liability Recorded during Period Indemnification Liability Recorded during Period Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Development Milestones Development Milestones [Member] Development Milestones [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Development Services Development Services [Member] Development Services [Member] Mylan Mylan Ireland Limited [Member] Mylan Ireland Limited [Member] Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member] Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Non-refundable upfront payment Contract with Customer, Liability Contingent payments Contingent Licensing Royalty Revenue Contingent Licensing Royalty Revenue Revenue maximum for receipt of tiered milestone payments Revenue Recognition, Milestone Method, Maximum Revenue Revenue Recognition, Milestone Method, Maximum Revenue Revenue maximum for waiver of royalties Revenue, Maximum, for Waiver of Royalties Revenue, Maximum, for Waiver of Royalties Additional one-time payment receivable Contract with Customer, Asset, Gross, Current Transaction price Contract Receivable Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Contract with customer, liability, revenue recognized (less than $0.1 million for the three months ended sept. 30, 2019) Contract with Customer, Liability, Revenue Recognized Deferred revenue, current portion Contract with Customer, Liability, Current Contract with customer, refund liability, noncurrent Contract with Customer, Refund Liability, Noncurrent Contract with customer, asset, before allowance for credit loss Contract with Customer, Asset, before Allowance for Credit Loss Foreign withholding tax, amount Foreign Withholding Tax, Amount Foreign Withholding Tax, Amount Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Operating Lease Costs Lease, Cost [Table Text Block] Operating Lease Liability Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Supplemental Cash Flow Information Lessee, Supplemental Cash Flow Information [Table Text Block] Lessee, Supplemental Cash Flow Information [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2018-07 Accounting Standards Update 2018-07 [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Other Accumulated Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance (in shares) Common Stock, Shares, Outstanding Beginning Balance Stockholders' Equity Attributable to Parent Cumulative-effect adjustment from adoption of ASU 2018-07 New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Issuance of common stock in connection with the 2019 follow-on offering (in shares) Stock Issued During Period Shares New Issues Follow On Offering Stock Issued During Period Shares New Issues Follow On Offering Issuance of common stock in connection with the 2019 follow-on offering Stock Issued During Period Value New Issues Follow On Offering Stock Issued During Period Value New Issues Follow On Offering Issuance of common stock upon exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of restricted stock awards, net of cancellation (in shares) Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased Net settlement of restricted stock awards for employee taxes (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Issuance of common stock relating to employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Net settlement of restricted stock awards for employee taxes Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of common stock relating to employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Unrealized gain (loss) and adjustment on securities included in net loss Net loss Ending Balance (in shares) Ending Balance Operating lease cost Operating Lease, Cost Variable lease cost (1) Variable Lease, Cost Total operating lease costs Lease, Cost Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Operating lease right of use assets Operating Lease, Right-of-Use Asset Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other non-current assets Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accruals and other current liabilities Accrued Liabilities, Current Operating lease liabilities, current portion Operating Lease, Liability, Current Total current liabilities Liabilities, Current Derivative liability associated with the Medicis settlement Derivative Liability, Noncurrent Deferred revenue, net of current portion Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Deferred rent Deferred Rent Credit, Noncurrent TOTAL LIABILITIES Liabilities Commitments and Contingencies (Note 7) Commitments and Contingencies STOCKHOLDERS’ EQUITY Stockholders' Equity Attributable to Parent [Abstract] Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2019 and December 31, 2018 Preferred Stock, Value, Issued Common stock, par value $0.001 per share — 95,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 44,108,407 and 36,975,203 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of discount on investments Accretion (Amortization) of Discounts and Premiums, Investments Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Gain on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Other non-cash operating activities Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Operating lease right of use assets Increase (Decrease) in Operating Lease Right of Use Assets Increase (Decrease) in Operating Lease Right of Use Assets Other non-current assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accruals and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of investments Payments to Acquire Short-term Investments Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from maturities of investments Proceeds from Maturities, Prepayments and Calls of Short-term Investments Proceeds from sales of property and equipment Proceeds from Sale of Property, Plant, and Equipment Payment for acquisition of in-process research and development Payments to Acquire in Process Research and Development Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from issuance of common stock in connection with the 2019 follow-on offering, net of commissions and discount Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount Proceeds from the exercise of stock options and employee stock purchase plan Proceeds from Stock Options Exercised Net settlement of restricted stock awards for employee taxes Payment, Tax Withholding, Share-based Payment Arrangement Payment of offering costs Payment of Financing and Stock Issuance Costs Principal payments made on financing obligations Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: Noncash Investing and Financing Items [Abstract] Property and equipment purchases included in accounts payable and accruals Capital Expenditures Incurred but Not yet Paid Equity [Abstract] Schedule of Stock-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Cash and Cash Equivalents [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] J.P. Morgan Securities LLC J.P. Morgan Securities LLC [Member] J.P. Morgan Securities LLC [Member] JPMorgan Chase & Co. and Wholly-owned Subsidiaries JPMorgan Chase & Co. and Wholly-owned Subsidiaries [Member] JPMorgan Chase & Co. and Wholly-owned Subsidiaries [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related party transactions Related Party Transaction, Amounts of Transaction Common stock outstanding, held by JP Morgan Chase (in shares) Common Stock, Outstanding, Held by Related Party Common Stock, Outstanding, Held by Related Party Percent of outstanding common stock held by JP Morgan Chase during the period (less than 10$ at Sept. 30, 2019) Common Stock, Outstanding, Held during Period, Percent Common Stock, Outstanding, Held during Period, Percent Cash, cash equivalents and investments, held by JP Morgan Chase Cash, Cash Equivalents and Investments, Held by Related Party Cash, Cash Equivalents and Investments, Held by Related Party Medicis Settlement Contingencies Disclosure [Text Block] Fair Value Disclosures [Abstract] Schedule of Fair Value of Financial Instruments Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Changes in Fair Value of Financial Instruments Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Follow On Offering Follow On Offering [Member] Follow On Offering [Member] Payments of Stock Issuance Costs Payments of Stock Issuance Costs Convertible preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Convertible preferred stock authorized (shares) Preferred Stock, Shares Authorized Convertible preferred stock issued (shares) Preferred Stock, Shares Issued Convertible preferred stock outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollar per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Entity Credit Risk Measurement Input, Entity Credit Risk [Member] Medicis Pharmaceutical Corporation Medicis Pharmaceutical Corporation [Member] Medicis Pharmaceutical Corporation [Member] Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. [Member] Valeant Pharmaceuticals International, Inc. [Member] Proceeds Sharing Arrangement Proceeds Sharing Arrangement [Member] Proceeds Sharing Arrangement [Member] Settlement And Termination [Line Items] Settlement And Termination [Line Items] Settlement And Termination [Line Items] Settlement consideration payable Settlement Agreement Amount Settlement Agreement Amount Upfront payment paid Agreement Settlement Upfront Payment Agreement Settlement Upfront Payment Settlement agreement, payable Loss Contingency Accrual Settlement payment Payments for Legal Settlements Derivative liability for the product approval payment Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Fair value, measurement input, duration Fair Value, Measurement Input, Duration Fair Value, Measurement Input, Duration Fair value, measurement input Fair Value, Measurement Input Fair Value, Measurement Input Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Derivative Liability Associated with the Medicis Settlement Derivative Liability Settlement [Member] Derivative Liability Settlement [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value as of December 31, 2018 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair value as of September 30, 2019 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Derivative liability associated with the Medicis settlement Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total assets measured at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total liabilities measured at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Leases Lessee, Operating Leases [Text Block] Cash Equivalents and Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and Development Research and Development Expense [Member] General and Administrative Selling, General and Administrative Expenses [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock based compensation expense Share-based Payment Arrangement, Expense The Company and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Fair Value Measurements Fair Value Disclosures [Text Block] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total payments Operating Leases, Future Minimum Payments Due Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Weighted Average Weighted Average [Member] Employee Stock Option and Restricted Stock Awards Employee Stock Option and Restricted Stock Awards [Member] Employee Stock Option and Restricted Stock Awards [Member] Employee Stock Option Share-based Payment Arrangement, Option [Member] Employee Stock Employee Stock [Member] Common Stock Warrant Warrant [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Over-Allotment Option Over-Allotment Option [Member] At the Market Offering At the Market Offering [Member] At the Market Offering [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2014 Equity Incentive Plan Two Thousand And Fourteen Equity Incentive Plan [Member] Two Thousand And Fourteen Equity Incentive Plan [Member] 2014 Inducement Plan Two Thousand And Fourteen Inducement Plan [Member] Two Thousand And Fourteen Inducement Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares available for purchase under common stock warrants (in shares) Class of Warrant or Right, Outstanding Exercise price per share (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Shares underlying stock options granted (in shares) Shares granted under restricted stock awards (shares) Shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Stock issued during period, shares, new issues (in shares) Stock Issued During Period, Shares, New Issues Share price (in dollar per share) Share Price Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Stock issuance sales agreement, authorized offering price, maximum Stock Issuance Sales Agreement, Authorized Offering Price, Maximum Stock Issuance Sales Agreement, Authorized Offering Price, Maximum Stock issuance sales agreement, commission rate (percent) Sale of Stock, Issuance Costs, Commission, Percentage, Maximum Sale of Stock, Issuance Costs, Commission, Percentage, Maximum 2019 remaining three months Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total operating lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest (1) Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of operating lease payments Operating Lease, Liability Weighted average discount rate (percent) Operating Lease, Weighted Average Discount Rate, Percent Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding common stock options Outstanding common stock warrants Unvested restricted stock awards Shares of common stock expected to be purchased on December 31 under the 2014 ESPP ESPP Purchases [Member] ESPP Purchases [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Subsequent Events [Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] CALIFORNIA CALIFORNIA Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Increase in NOL due to change in apportionment model Increase (Decrease) in Net Operating Loss due to Change in Apportionment Model Increase (Decrease) in Net Operating Loss due to Change in Apportionment Model Increase in deferred tax assets Increase (Decrease) in Deferred Tax Assets Increase (Decrease) in Deferred Tax Assets Available-for-sale Securities Debt Securities, Available-for-sale [Table Text Block] Net loss Working capital surplus Working Capital Surplus Working Capital Surplus Accumulated deficit Contract with customer, liability, net Contract with Customer, Liability, Net Contract with Customer, Liability, Net Cash and cash equivalents, and investments, expected funding term for operating plan (in months) Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum Operating lease liabilities Deferred rent liabilities Deferred Rent Credit Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] EX-101.PRE 15 rvnc-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 16 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
 9 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
California State Apportionment
In 2018, the Company petitioned the California Franchise Tax Board for an alternative apportionment percentage due to the insignificant apportionment percentage derived from the single sales factor methodology for California. In January 2019, the California Franchise Tax Board approved the use of an alternative apportionment method. The Company’s net operating losses (“NOL”) in California is estimated to increase by approximately $219 million as a result of the change in apportionment model. The Company has increased its deferred tax assets by $15 million with a corresponding offsetting adjustment to its valuation allowance. There is no impact to the Company’s net loss in the period as a result of the adjustment.
XML 17 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company determines the fair value of certain financial assets and liabilities using three levels of inputs as follows:
•
Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities;
•
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
•
Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.
The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:
 
September 30, 2019
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
40,153

 
$
40,153

 
$
—

 
$
—

U.S. treasury securities
75,353

 
75,353

 
—

 
—

U.S. government agency obligations
32,882

 
—

 
32,882

 
—

Commercial paper
43,873

 
—

 
43,873

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

Total assets measured at fair value
$
206,762

 
$
115,506

 
$
91,256

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,892

 
$
—

 
$
—

 
$
2,892

Total liabilities measured at fair value
$
2,892

 
$
—

 
$
—

 
$
2,892

 
December 31, 2018
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
38,354

 
$
38,354

 
$
—

 
$
—

U.S. treasury securities
80,844

 
80,844

 
—

 
—

U.S. government agency obligations
52,578

 
—

 
52,578

 
—

Total assets measured at fair value
$
171,776

 
$
119,198

 
$
52,578

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,753

 
$
—

 
$
—

 
$
2,753

Total liabilities measured at fair value
$
2,753

 
$
—

 
$
—

 
$
2,753


The Company classifies U.S. government agency obligations, commercial paper, and overnight repurchase agreements within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair values.
The following table summarizes the change in the fair value of the Company’s Level 3 financial instrument:
(in thousands)
Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2018
$
2,753

Change in fair value
139

Fair value as of September 30, 2019
$
2,892


The fair value of the derivative liability associated with the Medicis settlement was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (Note 3). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
CURRENT ASSETS    
Cash and cash equivalents $ 58,922 $ 73,256
Short-term investments 150,110 102,556
Accounts receivable 5,000 27,000
Prepaid expenses and other current assets 6,536 5,110
Total current assets 220,568 207,922
Property and equipment, net 14,917 14,449
Operating lease right of use assets 27,078  
Restricted cash 730 730
Other non-current assets 2,519 3,247
TOTAL ASSETS 265,812 226,348
CURRENT LIABILITIES    
Accounts payable 6,902 8,434
Accruals and other current liabilities 18,694 14,948
Deferred revenue, current portion 5,241 8,588
Operating lease liabilities, current portion 3,317  
Total current liabilities 34,154 31,970
Derivative liability associated with the Medicis settlement 2,892 2,753
Deferred revenue, net of current portion 50,707 42,684
Operating lease liabilities, net of current portion 26,778  
Deferred rent   3,319
TOTAL LIABILITIES 114,531 80,726
Commitments and Contingencies (Note 7)
STOCKHOLDERS’ EQUITY    
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2019 and December 31, 2018 0 0
Common stock, par value $0.001 per share — 95,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 44,108,407 and 36,975,203 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively 44 37
Additional paid-in capital 950,073 830,368
Accumulated other comprehensive income (loss) 42 (8)
Accumulated deficit (798,878) (684,775)
TOTAL STOCKHOLDERS’ EQUITY 151,281 145,622
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 265,812 $ 226,348
XML 19 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases - Operating Lease Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Leases [Abstract]    
Operating lease cost $ 1,425 $ 4,193
Variable lease cost (1) 298 886
Total operating lease costs $ 1,723 $ 5,079
XML 20 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies - Additional Information (Detail)
 9 Months Ended
Sep. 30, 2019
USD ($)
Loss Contingencies [Line Items]  
Indemnification liability recorded during the period $ 0
List Laboratories | Product Approval Payment Derivative  
Loss Contingencies [Line Items]  
Accrued milestone obligations 2,000,000.0
Botulinum Toxin Research Associates, Inc.  
Loss Contingencies [Line Items]  
Accrued milestone obligations 16,000,000.0
BioSentinel, Inc.  
Loss Contingencies [Line Items]  
Accrued milestone obligations 300,000
Other Current Liabilities  
Loss Contingencies [Line Items]  
Fair value of assets acquired 1,000,000.0
Service Agreements | Ajinomoto Althea, Inc.  
Loss Contingencies [Line Items]  
Prepaid purchase obligations $ 1,300,000
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Follow On Offering  
Payments of Stock Issuance Costs $ 521
XML 22 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2019
USD ($)
Income Tax Contingency [Line Items]  
Increase in deferred tax assets $ 15
CALIFORNIA  
Income Tax Contingency [Line Items]  
Increase in NOL due to change in apportionment model $ 219
XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 193 294 1 false 59 0 false 4 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.revance.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) Sheet http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement Sheet http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement Statements 5 false false R6.htm 1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - The Company and Summary of Significant Accounting Policies Sheet http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies The Company and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Medicis Settlement Sheet http://www.revance.com/role/MedicisSettlement Medicis Settlement Notes 9 false false R10.htm 2102100 - Disclosure - Revenue Sheet http://www.revance.com/role/Revenue Revenue Notes 10 false false R11.htm 2103100 - Disclosure - Cash Equivalents and Investments Sheet http://www.revance.com/role/CashEquivalentsAndInvestments Cash Equivalents and Investments Notes 11 false false R12.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.revance.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2105100 - Disclosure - Leases Sheet http://www.revance.com/role/Leases Leases Notes 13 false false R14.htm 2106100 - Disclosure - Commitments and Contingencies Sheet http://www.revance.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2107100 - Disclosure - Stockholders' Equity Sheet http://www.revance.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2108100 - Disclosure - Income Taxes Sheet http://www.revance.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2112100 - Disclosure - Subsequent Event Sheet http://www.revance.com/role/SubsequentEvent Subsequent Event Notes 17 false false R18.htm 2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) Sheet http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies The Company and Summary of Significant Accounting Policies (Policies) Policies http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 2303301 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.revance.com/role/CashEquivalentsAndInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://www.revance.com/role/CashEquivalentsAndInvestments 19 false false R20.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.revance.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.revance.com/role/FairValueMeasurements 20 false false R21.htm 2305301 - Disclosure - Leases Leases (Tables) Sheet http://www.revance.com/role/LeasesLeasesTables Leases Leases (Tables) Tables 21 false false R22.htm 2307301 - Disclosure - Stockholders' Equity Stockholders' Equity (Tables) Sheet http://www.revance.com/role/StockholdersEquityStockholdersEquityTables Stockholders' Equity Stockholders' Equity (Tables) Tables 22 false false R23.htm 2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail) Sheet http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail The Company and Summary of Significant Accounting Policies- Additional Information (Detail) Details 23 false false R24.htm 2402401 - Disclosure - Medicis Settlement - Additional Information (Detail) Sheet http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail Medicis Settlement - Additional Information (Detail) Details 24 false false R25.htm 2402401 - Disclosure - Revenue (Details) Sheet http://www.revance.com/role/RevenueDetails Revenue (Details) Details http://www.revance.com/role/Revenue 25 false false R26.htm 2403402 - Disclosure - Cash Equivalents and Investments (Detail) Sheet http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail Cash Equivalents and Investments (Detail) Details http://www.revance.com/role/CashEquivalentsAndInvestmentsTables 26 false false R27.htm 2403403 - Disclosure - Cash Equivalents and Investments - Related Party Transactions (Details) Sheet http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails Cash Equivalents and Investments - Related Party Transactions (Details) Details 27 false false R28.htm 2404402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) Sheet http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) Details 28 false false R29.htm 2404403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) Sheet http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) Details 29 false false R30.htm 2405402 - Disclosure - Leases Leases (Details) Sheet http://www.revance.com/role/LeasesLeasesDetails Leases Leases (Details) Details http://www.revance.com/role/LeasesLeasesTables 30 false false R31.htm 2405403 - Disclosure - Leases Leases - Operating Lease Costs (Details) Sheet http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails Leases Leases - Operating Lease Costs (Details) Details 31 false false R32.htm 2405404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details) Sheet http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails Leases Leases - Operating Lease Liability Maturities (Details) Details 32 false false R33.htm 2405405 - Disclosure - Leases Leases - Aggregate Future Noncancelable Lease Payments (Details) Sheet http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails Leases Leases - Aggregate Future Noncancelable Lease Payments (Details) Details 33 false false R34.htm 2405406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details) Sheet http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails Leases Leases - Supplemental Cash Flow Information (Details) Details 34 false false R35.htm 2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 35 false false R36.htm 2407402 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details) Sheet http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details) Details 36 false false R37.htm 2407403 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) Sheet http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) Details 37 false false R38.htm 2407404 - Disclosure - Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) Sheet http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) Details 38 false false R39.htm 2408401 - Disclosure - Income Taxes (Details) Sheet http://www.revance.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.revance.com/role/IncomeTaxes 39 false false R40.htm 2412402 - Disclosure - Subsequent Event (Details) Sheet http://www.revance.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://www.revance.com/role/SubsequentEvent 40 false false All Reports Book All Reports rvncq31910q.htm ex101q31910qmylan.htm ex102q31910qseparation.htm ex103q31910qseverancep.htm ex104q31910qmarkfoley.htm ex105q319nonemployeedi.htm rvnc-20190930.xsd rvnc-20190930_cal.xml rvnc-20190930_def.xml rvnc-20190930_lab.xml rvnc-20190930_pre.xml rvnc-q319exhibit311.htm rvnc-q319exhibit312.htm rvnc-q319exhibit321.htm rvnc-q319exhibit322.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 24 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rvncq31910q.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 193, "dts": { "calculationLink": { "local": [ "rvnc-20190930_cal.xml" ] }, "definitionLink": { "local": [ "rvnc-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "rvncq31910q.htm" ] }, "labelLink": { "local": [ "rvnc-20190930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rvnc-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rvnc-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 385, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 20, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 25 }, "keyCustom": 32, "keyStandard": 262, "memberCustom": 22, "memberStandard": 33, "nsprefix": "rvnc", "nsuri": "http://www.revance.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.revance.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue", "role": "http://www.revance.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Cash Equivalents and Investments", "role": "http://www.revance.com/role/CashEquivalentsAndInvestments", "shortName": "Cash Equivalents and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Fair Value Measurements", "role": "http://www.revance.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Leases", "role": "http://www.revance.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Commitments and Contingencies", "role": "http://www.revance.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Stockholders' Equity", "role": "http://www.revance.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Income Taxes", "role": "http://www.revance.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Subsequent Event", "role": "http://www.revance.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "The Company and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Cash Equivalents and Investments (Tables)", "role": "http://www.revance.com/role/CashEquivalentsAndInvestmentsTables", "shortName": "Cash Equivalents and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.revance.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Leases Leases (Tables)", "role": "http://www.revance.com/role/LeasesLeasesTables", "shortName": "Leases Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Stockholders' Equity Stockholders' Equity (Tables)", "role": "http://www.revance.com/role/StockholdersEquityStockholdersEquityTables", "shortName": "Stockholders' Equity Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail)", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "The Company and Summary of Significant Accounting Policies- Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "lang": "en-US", "name": "rvnc:CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2102Q4October_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:SettlementAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Medicis Settlement - Additional Information (Detail)", "role": "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail", "shortName": "Medicis Settlement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2102Q4October_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:SettlementAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Revenue (Details)", "role": "http://www.revance.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Cash Equivalents and Investments (Detail)", "role": "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "shortName": "Cash Equivalents and Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Cash Equivalents and Investments - Related Party Transactions (Details)", "role": "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails", "shortName": "Cash Equivalents and Investments - Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)", "role": "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2018Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)", "role": "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2018Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Leases Leases (Details)", "role": "http://www.revance.com/role/LeasesLeasesDetails", "shortName": "Leases Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Leases Leases - Operating Lease Costs (Details)", "role": "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails", "shortName": "Leases Leases - Operating Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details)", "role": "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails", "shortName": "Leases Leases - Operating Lease Liability Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405405 - Disclosure - Leases Leases - Aggregate Future Noncancelable Lease Payments (Details)", "role": "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails", "shortName": "Leases Leases - Aggregate Future Noncancelable Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rvnc:LesseeSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails", "shortName": "Leases Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rvnc:LesseeSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:IndemnificationLiabilityRecordedduringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:IndemnificationLiabilityRecordedduringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details)", "role": "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails", "shortName": "Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)", "role": "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)", "role": "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "shortName": "Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "first": true, "lang": null, "name": "rvnc:IncreaseDecreaseinDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Income Taxes (Details)", "role": "http://www.revance.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "first": true, "lang": null, "name": "rvnc:IncreaseDecreaseinDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2019Q4Oct13_srt_TitleOfIndividualAxis_rvnc_PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Subsequent Event (Details)", "role": "http://www.revance.com/role/SubsequentEventDetails", "shortName": "Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "D2019Q4Oct13_srt_TitleOfIndividualAxis_rvnc_PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - The Company and Summary of Significant Accounting Policies", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies", "shortName": "The Company and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Medicis Settlement", "role": "http://www.revance.com/role/MedicisSettlement", "shortName": "Medicis Settlement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rvncq31910q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "rvnc_AccruedMilestoneObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Milestone Obligations", "label": "Accrued Milestone Obligations", "verboseLabel": "Accrued milestone obligations" } } }, "localname": "AccruedMilestoneObligations", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_AgreementSettlementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Agreement Settlement Upfront Payment", "label": "Agreement Settlement Upfront Payment", "terseLabel": "Upfront payment paid" } } }, "localname": "AgreementSettlementUpfrontPayment", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_AjinomotoAltheaInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ajinomoto Althea, Inc. [Member]", "label": "Ajinomoto Althea, Inc. [Member]", "terseLabel": "Ajinomoto Althea, Inc." } } }, "localname": "AjinomotoAltheaInc.Member", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_AnnualTargetBonusasPercentofBaseSalary": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual Target Bonus as Percent of Base Salary", "label": "Annual Target Bonus as Percent of Base Salary", "terseLabel": "Annual target bonus as percent of base salary" } } }, "localname": "AnnualTargetBonusasPercentofBaseSalary", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "percentItemType" }, "rvnc_AttheMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At the Market Offering [Member]", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "localname": "AttheMarketOfferingMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_BioSentinelInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioSentinel, Inc. [Member]", "label": "BioSentinel, Inc. [Member]", "terseLabel": "BioSentinel, Inc." } } }, "localname": "BioSentinelInc.Member", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_BotulinumToxinResearchAssociatesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Botulinum Toxin Research Associates, Inc. [Member]", "label": "Botulinum Toxin Research Associates, Inc. [Member]", "terseLabel": "Botulinum Toxin Research Associates, Inc." } } }, "localname": "BotulinumToxinResearchAssociatesInc.Member", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_CashCashEquivalentsandInvestmentsHeldbyRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash, Cash Equivalents and Investments, Held by Related Party", "label": "Cash, Cash Equivalents and Investments, Held by Related Party", "terseLabel": "Cash, cash equivalents and investments, held by JP Morgan Chase" } } }, "localname": "CashCashEquivalentsandInvestmentsHeldbyRelatedParty", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum", "label": "Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum", "terseLabel": "Cash and cash equivalents, and investments, expected funding term for operating plan (in months)" } } }, "localname": "CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "rvnc_CommonStockOutstandingHeldbyRelatedParty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Outstanding, Held by Related Party", "label": "Common Stock, Outstanding, Held by Related Party", "terseLabel": "Common stock outstanding, held by JP Morgan Chase (in shares)" } } }, "localname": "CommonStockOutstandingHeldbyRelatedParty", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "rvnc_CommonStockOutstandingHeldduringPeriodPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Outstanding, Held during Period, Percent", "label": "Common Stock, Outstanding, Held during Period, Percent", "terseLabel": "Percent of outstanding common stock held by JP Morgan Chase during the period (less than 10$ at Sept. 30, 2019)" } } }, "localname": "CommonStockOutstandingHeldduringPeriodPercent", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rvnc_ContingentLicensingRoyaltyRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Licensing Royalty Revenue", "label": "Contingent Licensing Royalty Revenue", "terseLabel": "Contingent payments" } } }, "localname": "ContingentLicensingRoyaltyRevenue", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_ContractwithCustomerLiabilityNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Liability, Net", "label": "Contract with Customer, Liability, Net", "terseLabel": "Contract with customer, liability, net" } } }, "localname": "ContractwithCustomerLiabilityNet", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_DerivativeLiabilitySettlementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Liability Settlement [Member]", "label": "Derivative Liability Settlement [Member]", "terseLabel": "Derivative liability associated with the Medicis settlement", "verboseLabel": "Derivative Liability Associated with the Medicis Settlement" } } }, "localname": "DerivativeLiabilitySettlementMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "rvnc_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development Milestones [Member]", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_DevelopmentServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development Services [Member]", "label": "Development Services [Member]", "terseLabel": "Development Services" } } }, "localname": "DevelopmentServicesMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_ESPPPurchasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ESPP Purchases [Member]", "label": "ESPP Purchases [Member]", "terseLabel": "Shares of common stock expected to be purchased on December 31 under the 2014 ESPP" } } }, "localname": "ESPPPurchasesMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rvnc_EmployeeStockOptionandRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock Option and Restricted Stock Awards [Member]", "label": "Employee Stock Option and Restricted Stock Awards [Member]", "terseLabel": "Employee Stock Option and Restricted Stock Awards" } } }, "localname": "EmployeeStockOptionandRestrictedStockAwardsMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_FairValueMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement Input", "label": "Fair Value, Measurement Input", "terseLabel": "Fair value, measurement input" } } }, "localname": "FairValueMeasurementInput", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "rvnc_FairValueMeasurementInputDuration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement Input, Duration", "label": "Fair Value, Measurement Input, Duration", "terseLabel": "Fair value, measurement input, duration" } } }, "localname": "FairValueMeasurementInputDuration", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "rvnc_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follow On Offering [Member]", "label": "Follow On Offering [Member]", "terseLabel": "Follow On Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_ForeignWithholdingTaxAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Foreign Withholding Tax, Amount", "label": "Foreign Withholding Tax, Amount", "terseLabel": "Foreign withholding tax, amount" } } }, "localname": "ForeignWithholdingTaxAmount", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_FormerPresidentandChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former President and Chief Executive Officer [Member]", "label": "Former President and Chief Executive Officer [Member]", "terseLabel": "Former President and Chief Executive Officer" } } }, "localname": "FormerPresidentandChiefExecutiveOfficerMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "rvnc_GainLossonDerivativeInstrumentsContractNetPretax": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (Loss) on Derivative Instruments, Contract, Net, Pretax", "label": "Gain (Loss) on Derivative Instruments, Contract, Net, Pretax", "terseLabel": "Change in fair value of derivative liability associated with the Medicis settlement" } } }, "localname": "GainLossonDerivativeInstrumentsContractNetPretax", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Deferred Tax Assets", "label": "Increase (Decrease) in Deferred Tax Assets", "terseLabel": "Increase in deferred tax assets" } } }, "localname": "IncreaseDecreaseinDeferredTaxAssets", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinNetOperatingLossduetoChangeinApportionmentModel": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Net Operating Loss due to Change in Apportionment Model", "label": "Increase (Decrease) in Net Operating Loss due to Change in Apportionment Model", "terseLabel": "Increase in NOL due to change in apportionment model" } } }, "localname": "IncreaseDecreaseinNetOperatingLossduetoChangeinApportionmentModel", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseinOperatingLeaseLiabilities", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Right of Use Assets", "label": "Increase (Decrease) in Operating Lease Right of Use Assets", "negatedLabel": "Operating lease right of use assets" } } }, "localname": "IncreaseDecreaseinOperatingLeaseRightofUseAssets", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IndemnificationLiabilityRecordedduringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Indemnification Liability Recorded during Period", "label": "Indemnification Liability Recorded during Period", "terseLabel": "Indemnification liability recorded during the period" } } }, "localname": "IndemnificationLiabilityRecordedduringPeriod", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_J.P.MorganSecuritiesLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "J.P. Morgan Securities LLC [Member]", "label": "J.P. Morgan Securities LLC [Member]", "terseLabel": "J.P. Morgan Securities LLC" } } }, "localname": "J.P.MorganSecuritiesLLCMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rvnc_JPMorganChaseCo.andWhollyownedSubsidiariesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "JPMorgan Chase & Co. and Wholly-owned Subsidiaries [Member]", "label": "JPMorgan Chase & Co. and Wholly-owned Subsidiaries [Member]", "terseLabel": "JPMorgan Chase & Co. and Wholly-owned Subsidiaries" } } }, "localname": "JPMorganChaseCo.andWhollyownedSubsidiariesMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rvnc_LesseeSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Supplemental Cash Flow Information [Table Text Block]", "label": "Lessee, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "rvnc_ListLaboratoriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "List Laboratories [Member]", "label": "List Laboratories [Member]", "terseLabel": "List Laboratories" } } }, "localname": "ListLaboratoriesMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_MedicisPharmaceuticalCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicis Pharmaceutical Corporation [Member]", "label": "Medicis Pharmaceutical Corporation [Member]", "terseLabel": "Medicis Pharmaceutical Corporation" } } }, "localname": "MedicisPharmaceuticalCorporationMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_MylanIrelandLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mylan Ireland Limited [Member]", "label": "Mylan Ireland Limited [Member]", "terseLabel": "Mylan" } } }, "localname": "MylanIrelandLimitedMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income Loss Available To Common Stockholders, Basic And Diluted", "label": "Net Income Loss Available To Common Stockholders, Basic And Diluted", "verboseLabel": "Basic and diluted net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_PrepaidPurchaseObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Purchase Obligations", "label": "Prepaid Purchase Obligations", "terseLabel": "Prepaid purchase obligations" } } }, "localname": "PrepaidPurchaseObligations", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "President, Chief Executive Officer and Principal Executive Officer [Member]", "label": "President, Chief Executive Officer and Principal Executive Officer [Member]", "terseLabel": "President, Chief Executive Officer and Principal Executive Officer" } } }, "localname": "PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount", "label": "Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount", "terseLabel": "Proceeds from issuance of common stock in connection with the 2019 follow-on offering, net of commissions and discount" } } }, "localname": "ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_ProceedsSharingArrangementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Proceeds Sharing Arrangement [Member]", "label": "Proceeds Sharing Arrangement [Member]", "terseLabel": "Proceeds Sharing Arrangement" } } }, "localname": "ProceedsSharingArrangementMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_RevenueMaximumforWaiverofRoyalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue, Maximum, for Waiver of Royalties", "label": "Revenue, Maximum, for Waiver of Royalties", "terseLabel": "Revenue maximum for waiver of royalties" } } }, "localname": "RevenueMaximumforWaiverofRoyalties", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Milestone Method, Maximum Revenue", "label": "Revenue Recognition, Milestone Method, Maximum Revenue", "terseLabel": "Revenue maximum for receipt of tiered milestone payments" } } }, "localname": "RevenueRecognitionMilestoneMethodMaximumRevenue", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Issuance Costs, Commission, Percentage, Maximum", "label": "Sale of Stock, Issuance Costs, Commission, Percentage, Maximum", "terseLabel": "Stock issuance sales agreement, commission rate (percent)" } } }, "localname": "SaleofStockIssuanceCostsCommissionPercentageMaximum", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvnc_SettlementAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Settlement Agreement Amount", "label": "Settlement Agreement Amount", "terseLabel": "Settlement consideration payable" } } }, "localname": "SettlementAgreementAmount", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_SettlementAndTerminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Settlement And Termination [Line Items]", "label": "Settlement And Termination [Line Items]", "terseLabel": "Settlement And Termination [Line Items]" } } }, "localname": "SettlementAndTerminationLineItems", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rvnc_SeverancePaymentMonthsofSalary": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Severance Payment, Months of Salary", "label": "Severance Payment, Months of Salary", "terseLabel": "Severance payment, months of salary" } } }, "localname": "SeverancePaymentMonthsofSalary", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "durationItemType" }, "rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]", "label": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]", "terseLabel": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd." } } }, "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issuance Sales Agreement, Authorized Offering Price, Maximum", "label": "Stock Issuance Sales Agreement, Authorized Offering Price, Maximum", "terseLabel": "Stock issuance sales agreement, authorized offering price, maximum" } } }, "localname": "StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_StockIssuedDuringPeriodSharesNewIssuesFollowOnOffering": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Shares New Issues Follow On Offering", "label": "Stock Issued During Period Shares New Issues Follow On Offering", "terseLabel": "Issuance of common stock in connection with the 2019 follow-on offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesFollowOnOffering", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased", "label": "Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased", "terseLabel": "Issuance of restricted stock awards, net of cancellation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "rvnc_StockIssuedDuringPeriodValueNewIssuesFollowOnOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Value New Issues Follow On Offering", "label": "Stock Issued During Period Value New Issues Follow On Offering", "terseLabel": "Issuance of common stock in connection with the 2019 follow-on offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesFollowOnOffering", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "rvnc_TwoThousandAndFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_TwoThousandAndFourteenInducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand And Fourteen Inducement Plan [Member]", "label": "Two Thousand And Fourteen Inducement Plan [Member]", "terseLabel": "2014 Inducement Plan" } } }, "localname": "TwoThousandAndFourteenInducementPlanMember", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_ValeantPharmaceuticalsInternationalInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valeant Pharmaceuticals International, Inc. [Member]", "label": "Valeant Pharmaceuticals International, Inc. [Member]", "terseLabel": "Valeant Pharmaceuticals International, Inc." } } }, "localname": "ValeantPharmaceuticalsInternationalInc.Member", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_WorkingCapitalSurplus": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Working Capital Surplus", "label": "Working Capital Surplus", "terseLabel": "Working capital surplus" } } }, "localname": "WorkingCapitalSurplus", "nsuri": "http://www.revance.com/20190930", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r35", "r79" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r98", "r145", "r149", "r277", "r278" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r99", "r233" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CALIFORNIA", "terseLabel": "CALIFORNIA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201807Member": { "auth_ref": [ "r166", "r167", "r168", "r169", "r170" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-07 Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.", "label": "Accounting Standards Update 2018-07 [Member]", "terseLabel": "Accounting Standards Update 2018-07" } } }, "localname": "AccountingStandardsUpdate201807Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms": { "auth_ref": [ "r32", "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.", "label": "Contract Receivable", "terseLabel": "Transaction price" } } }, "localname": "AccountsReceivableBilledForLongTermContractsOrPrograms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r14", "r100", "r101", "r146" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r70" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of discount on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accruals and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r39", "r40" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r37", "r40", "r41", "r187" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Other Accumulated Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "terseLabel": "Other non-cash operating activities" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r154", "r156", "r172", "r173" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r156", "r163", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "positiveLabel": "Total stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r96", "r260", "r271" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r33" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r107" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r108" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r105", "r115" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r103", "r106", "r115" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r157", "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails", "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r191", "r195" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accruals" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r22", "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r64", "r71", "r76" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH \u2014 End of period", "periodStartLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH \u2014 Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r64", "r210" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share (in USD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Shares available for purchase under common stock warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r182", "r183", "r185" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Revenue" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r125", "r266", "r275" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r124", "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollar per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r138" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.001 per share \u2014 95,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 44,108,407 and 36,975,203 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r43", "r45", "r46" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r77", "r186", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetGross": { "auth_ref": [ "r141", "r143", "r146" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "terseLabel": "Contract with customer, asset, before allowance for credit loss" } } }, "localname": "ContractWithCustomerAssetGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "auth_ref": [ "r141", "r143" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Gross, Current", "terseLabel": "Additional one-time payment receivable" } } }, "localname": "ContractWithCustomerAssetGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r141", "r142", "r146" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Non-refundable upfront payment" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r141", "r142", "r146" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r141", "r142", "r146" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with customer, liability, revenue recognized (less than $0.1 million for the three months ended sept. 30, 2019)" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityNoncurrent": { "auth_ref": [ "r148" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent.", "label": "Contract with Customer, Refund Liability, Noncurrent", "terseLabel": "Contract with customer, refund liability, noncurrent" } } }, "localname": "ContractWithCustomerRefundLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditRiskContractMember": { "auth_ref": [ "r150", "r197" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the creditworthiness or the credit spread of an entity.", "label": "Credit Risk Contract [Member]", "terseLabel": "Product Approval Payment Derivative" } } }, "localname": "CreditRiskContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.", "label": "Deferred Rent Credit", "negatedLabel": "Deferred rent liabilities" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r29", "r215" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r69", "r121" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r192", "r193", "r196", "r198" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Derivative liability for the product approval payment" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liability associated with the Medicis settlement" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss (in dollar per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Outstanding common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r205", "r208" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r205", "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Financial Instruments" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r150", "r151", "r153", "r201", "r241" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r200", "r201", "r203", "r204", "r209" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r150", "r151", "r153", "r201", "r242" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r150", "r151", "r153", "r201", "r243" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r150", "r151", "r153", "r201", "r244" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r205", "r208" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Total assets measured at fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value as of September 30, 2019", "periodStartLabel": "Fair value as of December 31, 2018" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r207", "r209" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Fair value of assets acquired" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Gain on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r176", "r177", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r65", "r72" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accruals and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r47", "r95", "r211", "r212", "r268" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r52" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r109", "r259", "r269", "r279" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Cash Equivalents and Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r227", "r229" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total operating lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Operating Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2024 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019 remaining three months" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r228" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest (1)" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Extended term of lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r261", "r273" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r135", "r136" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Settlement agreement, payable" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r132", "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies Disclosure [Text Block]", "terseLabel": "Medicis Settlement" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlement" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputEntityCreditRiskMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using risk of default, credit spread risk and downgrade risk.", "label": "Measurement Input, Entity Credit Risk [Member]", "terseLabel": "Measurement Input, Entity Credit Risk" } } }, "localname": "MeasurementInputEntityCreditRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r67", "r70" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r42", "r44", "r49", "r70", "r85", "r267", "r276" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTerseLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification", "terseLabel": "Cumulative-effect adjustment from adoption of ASU 2018-07" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "terseLabel": "Annual base salary" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r221", "r229" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r218" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease payments", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r218" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r218" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r219", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r217" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r226", "r229" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r225", "r229" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "verboseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "verboseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "verboseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r213", "r216" ], "calculation": { "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "2023 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesAggregateFutureNoncancelableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "The Company and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r36", "r38" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized gain (loss) and adjustment on securities included in net loss", "verboseLabel": "Unrealized gain (loss) and adjustment on securities included in net loss" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r191", "r199" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Short-term investments" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale", "terseLabel": "Other-than-temporary impairments on available-for-sale securities" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r63" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "negatedTerseLabel": "Payment of offering costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Settlement payment" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payments of Stock Issuance Costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r61" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r57" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedTerseLabel": "Payment for acquisition of in-process research and development" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based Common Stock" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r157", "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Convertible preferred stock authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Convertible preferred stock issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Convertible preferred stock outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Convertible preferred stock, par value $0.001 per share \u2014 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2019 and December 31, 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r20", "r21" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r56", "r59" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments", "terseLabel": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sales of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r60", "r165" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r122", "r274" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r231", "r234", "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r152", "r232", "r234", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r62" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.", "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security", "negatedLabel": "Principal payments made on financing obligations" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.", "label": "Repurchase Agreements [Member]", "terseLabel": "Overnight repurchase agreements" } } }, "localname": "RepurchaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r174", "r281" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r5", "r9", "r71", "r76", "r280" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock awards", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r139", "r272" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r48", "r93", "r94", "r97" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r224", "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r156", "r162", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r156", "r162", "r171" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r200", "r201" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value of Financial Instruments" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r78", "r232", "r234", "r235", "r236", "r237" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsRelatedPartyTransactionsDetails", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r157", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r51", "r120" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceAgreementsMember": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.", "label": "Service Agreements [Member]", "terseLabel": "Service Agreements" } } }, "localname": "ServiceAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted under restricted stock awards (shares)", "verboseLabel": "Equity awards other than options granted (shares)Shares granted -based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails", "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares underlying stock options granted (in shares)", "verboseLabel": "Options granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails", "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r155", "r158" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails", "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted, exercise price per share (in USD)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollar per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r10", "r262", "r263", "r265", "r270" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r138" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r31", "r138" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r12", "r13", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock relating to employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period, shares, new issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r138", "r139", "r159" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r12", "r13", "r138", "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock relating to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r31", "r138", "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r102" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/MedicisSettlementAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r150", "r264" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency obligations" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r150", "r153", "r264" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r86", "r87", "r88", "r89", "r90", "r91", "r92" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r222", "r229" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost (1)" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant", "verboseLabel": "Outstanding common stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityStockholdersEquityCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/StockholdersEquityStockholdersEquityStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127163" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/subtopic&trid=2127197" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL116876444-165333" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL116876444-165333" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL116876444-165333" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL116876446-165333" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL116876446-165333" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(5)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=118388040&loc=d3e49354-109356" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r284": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r285": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r286": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r287": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" } }, "version": "2.1" } XML 25 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - Recurring - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value $ 206,762 $ 171,776
Total liabilities measured at fair value 2,892 2,753
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 40,153 38,354
U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 75,353 80,844
U.S. government agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 32,882 52,578
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 43,873  
Overnight repurchase agreements    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 14,501  
Derivative liability associated with the Medicis settlement    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total liabilities measured at fair value 2,892 2,753
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 115,506 119,198
Total liabilities measured at fair value 0 0
Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 40,153 38,354
Level 1 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 75,353 80,844
Level 1 | U.S. government agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 1 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0  
Level 1 | Overnight repurchase agreements    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0  
Level 1 | Derivative liability associated with the Medicis settlement    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total liabilities measured at fair value 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 91,256 52,578
Total liabilities measured at fair value 0 0
Level 2 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 2 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 2 | U.S. government agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 32,882 52,578
Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 43,873  
Level 2 | Overnight repurchase agreements    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 14,501  
Level 2 | Derivative liability associated with the Medicis settlement    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total liabilities measured at fair value 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Total liabilities measured at fair value 2,892 2,753
Level 3 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 3 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 3 | U.S. government agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0 0
Level 3 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0  
Level 3 | Overnight repurchase agreements    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total assets measured at fair value 0  
Level 3 | Derivative liability associated with the Medicis settlement    
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]    
Total liabilities measured at fair value $ 2,892 $ 2,753
XML 26 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Medicis Settlement - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2012
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2014
Dec. 31, 2013
Medicis Pharmaceutical Corporation          
Settlement And Termination [Line Items]          
Settlement consideration payable $ 25,000,000.0        
Upfront payment paid 7,000,000.0        
Medicis Pharmaceutical Corporation | Proceeds Sharing Arrangement          
Settlement And Termination [Line Items]          
Settlement agreement, payable $ 14,000,000.0        
Settlement payment       $ 7,100,000 $ 6,900,000
Medicis Pharmaceutical Corporation | Product Approval Payment Derivative          
Settlement And Termination [Line Items]          
Derivative liability for the product approval payment   $ 2,900,000 $ 2,700,000    
Valeant Pharmaceuticals International, Inc. | Product Approval Payment Derivative          
Settlement And Termination [Line Items]          
Accrued milestone obligations   $ 4,000,000.0      
Measurement Input, Expected Term | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative          
Settlement And Termination [Line Items]          
Fair value, measurement input, duration   1 year 1 month 6 days 1 year 6 months    
Measurement Input, Risk Free Interest Rate | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative          
Settlement And Termination [Line Items]          
Fair value, measurement input   1.70% 2.60%    
Measurement Input, Entity Credit Risk | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative          
Settlement And Termination [Line Items]          
Fair value, measurement input   7.50% 8.00%    
XML 27 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Financial Instruments
The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:
 
September 30, 2019
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
40,153

 
$
40,153

 
$
—

 
$
—

U.S. treasury securities
75,353

 
75,353

 
—

 
—

U.S. government agency obligations
32,882

 
—

 
32,882

 
—

Commercial paper
43,873

 
—

 
43,873

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

Total assets measured at fair value
$
206,762

 
$
115,506

 
$
91,256

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,892

 
$
—

 
$
—

 
$
2,892

Total liabilities measured at fair value
$
2,892

 
$
—

 
$
—

 
$
2,892

 
December 31, 2018
(in thousands)
Fair Value
 
Level 1
 
Level 2
 
Level 3
Assets
 
 
 
 
 
 
 
Money market funds
$
38,354

 
$
38,354

 
$
—

 
$
—

U.S. treasury securities
80,844

 
80,844

 
—

 
—

U.S. government agency obligations
52,578

 
—

 
52,578

 
—

Total assets measured at fair value
$
171,776

 
$
119,198

 
$
52,578

 
$
—

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Derivative liability associated with the Medicis settlement
$
2,753

 
$
—

 
$
—

 
$
2,753

Total liabilities measured at fair value
$
2,753

 
$
—

 
$
—

 
$
2,753
Summary of Changes in Fair Value of Financial Instruments
The following table summarizes the change in the fair value of the Company’s Level 3 financial instrument:
(in thousands)
Derivative Liability Associated with the Medicis Settlement
Fair value as of December 31, 2018
$
2,753

Change in fair value
139

Fair value as of September 30, 2019
$
2,892
XML 28 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 29 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Event (Details) - Subsequent Event - USD ($)
Oct. 13, 2019
Oct. 11, 2019
President, Chief Executive Officer and Principal Executive Officer    
Subsequent Event [Line Items]    
Annual base salary $ 650,000  
Annual target bonus as percent of base salary 75.00%  
Options granted (shares) 740,000  
Options granted, exercise price per share (in USD) $ 12.18  
Former President and Chief Executive Officer    
Subsequent Event [Line Items]    
Severance payment, months of salary   15 months
Restricted Stock | President, Chief Executive Officer and Principal Executive Officer    
Subsequent Event [Line Items]    
Equity awards other than options granted (shares)Shares granted -based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 200,000  
Performance-based Common Stock | President, Chief Executive Officer and Principal Executive Officer    
Subsequent Event [Line Items]    
Equity awards other than options granted (shares)Shares granted -based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 860,000  
XML 30 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2018
Jan. 31, 2019
Dec. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Aug. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Deferred revenue, current portion     $ 8,588,000 $ 5,241,000   $ 5,241,000    
Deferred revenue, net of current portion     42,684,000 50,707,000   50,707,000    
Mylan                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Non-refundable upfront payment $ 25,000,000.0              
Contingent payments 100,000,000.0              
Revenue maximum for receipt of tiered milestone payments 225,000,000.0              
Revenue maximum for waiver of royalties 50,000,000.0              
Additional one-time payment receivable               $ 5,000,000.0
Transaction price 81,000,000.0              
Remaining performance obligation       107,000,000.0   107,000,000.0    
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contingent payments       230,500,000   230,500,000    
Revenue maximum for receipt of tiered milestone payments     1,000,000.0          
Remaining performance obligation       31,000,000.0   31,000,000.0    
Contract with customer, liability, revenue recognized (less than $0.1 million for the three months ended sept. 30, 2019)           0    
Contract with customer, asset, before allowance for credit loss   $ 30,000,000.0            
Foreign withholding tax, amount   $ 3,000,000.0            
Deferred revenue, net of current portion       30,000,000.0   30,000,000.0    
Development Services                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer, liability, revenue recognized (less than $0.1 million for the three months ended sept. 30, 2019)       100,000 $ 2,400,000 300,000 $ 3,200,000  
Deferred revenue, current portion     8,600,000 5,200,000   5,200,000    
Contract with customer, refund liability, noncurrent     $ 12,700,000 $ 20,700,000   $ 20,700,000    
Development Milestones | Mylan                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue maximum for receipt of tiered milestone payments $ 40,000,000.0              
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases (Tables)
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Operating Lease Costs
The operating lease costs are summarized as follows:
 
Three Months Ended
 
Nine Months Ended
(in thousands)
September 30, 2019
 
September 30, 2019
Operating lease cost
$
1,425

 
$
4,193

Variable lease cost (1)
298

 
886

Total operating lease costs
$
1,723

 
$
5,079

(1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
Operating Lease Liability Maturities
As of September 30, 2019, maturities of the Company’s operating lease liabilities are as follows:
Year Ending December 31,
(in thousands)
2019 remaining three months
$
1,633

2020
6,735

2021
6,942

2022
5,464

2023
5,557

2024 and thereafter
17,959

Total operating lease payments
44,290

Less imputed interest (1)
(14,195
)
Present value of operating lease payments
$
30,095

(1) The Company’s lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates.

As of December 31, 2018, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows:
Year Ending December 31,
(in thousands)
2019
$
5,826

2020
6,011

2021
6,196

2022
4,696

2023 and thereafter
20,173

Total payments
$
42,902
Supplemental Cash Flow Information
Supplemental cash flow information related to the operating leases was as follows:
 
Nine Months Ended
(in thousands)
September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
$
4,704

Right-of-use assets obtained in exchange for operating lease liabilities
$
3,890
XML 32 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) - Derivative Liability Associated with the Medicis Settlement
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair value as of December 31, 2018 $ 2,753
Change in fair value 139
Fair value as of September 30, 2019 $ 2,892
EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 34 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Event
 9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
Subsequent Event Subsequent Event
Effective as of October 13, 2019, the Company’s Board of Directors (the “Board”) appointed Mark J. Foley as the Company’s President, Chief Executive Officer and Principal Executive Officer. In connection with his appointment, the Company has entered into an executive employment agreement, pursuant to which Mr. Foley will initially receive an annual base salary of $650,000 and an annual target bonus of 75% of his base salary. The Board also approved the grant of certain equity awards to Mr. Foley under the 2014 EIP. Mr. Foley received (i) a stock option to purchase 740,000 shares of the Company’s common stock at $12.18 per share, (ii) 200,000 shares of restricted common stock awards of the Company and (iii) 860,000 shares of performance-based common stock awards. The performance-based common stock awards will vest based on the Company’s certain market and performance conditions.
Effective as of October 11, 2019, the Company entered into a separation agreement with L. Daniel Browne providing for (i) a release of claims against the Company, (ii) cash severance payments to Mr. Browne in an amount equal to fifteen months of Mr. Browne’s 2019 base salary; and (iii) certain health care continuation benefits. The separation agreement
also provides for an extension of the post-termination exercise period for all vested stock options held by Mr. Browne through the earlier of a Change in Control (as defined in the 2014 EIP) or January 31, 2021.
The Company is currently evaluating the effect on its Consolidated Financial Statements of Mr. Foley’s equity compensation and the modification to Mr. Browne’s vested stock options.
XML 35 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Leases
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Leases Leases
The Company has non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. One of the facility operating leases commenced in February 2019. As of September 30, 2019, the weighted average remaining lease term is 7.2 years. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of 2022. The Company has options to extend the facility operating leases for up to 14 years. The Company’s lease contracts do not contain termination options, residual value guarantees or restrictive covenants.
The operating lease costs are summarized as follows:
 
Three Months Ended
 
Nine Months Ended
(in thousands)
September 30, 2019
 
September 30, 2019
Operating lease cost
$
1,425

 
$
4,193

Variable lease cost (1)
298

 
886

Total operating lease costs
$
1,723

 
$
5,079

(1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
As of September 30, 2019, maturities of the Company’s operating lease liabilities are as follows:
Year Ending December 31,
(in thousands)
2019 remaining three months
$
1,633

2020
6,735

2021
6,942

2022
5,464

2023
5,557

2024 and thereafter
17,959

Total operating lease payments
44,290

Less imputed interest (1)
(14,195
)
Present value of operating lease payments
$
30,095

(1) The Company’s lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates.

As of December 31, 2018, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows:
Year Ending December 31,
(in thousands)
2019
$
5,826

2020
6,011

2021
6,196

2022
4,696

2023 and thereafter
20,173

Total payments
$
42,902


Supplemental cash flow information related to the operating leases was as follows:
 
Nine Months Ended
(in thousands)
September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
$
4,704

Right-of-use assets obtained in exchange for operating lease liabilities
$
3,890
XML 36 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity Stockholders' Equity - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) - shares
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Outstanding common stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares) 4,402,244 3,491,751
Outstanding common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares) 34,113 34,113
Unvested restricted stock awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares) 788,125 679,541
Shares of common stock expected to be purchased on December 31 under the 2014 ESPP    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares) 45,123 16,712
XML 37 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Convertible preferred stock authorized (shares) 5,000,000 5,000,000
Convertible preferred stock issued (shares) 0 0
Convertible preferred stock outstanding (shares) 0 0
Common stock, par value (in dollar per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 95,000,000 95,000,000
Common stock, shares issued (in shares) 44,108,407 36,975,203
Common stock, shares outstanding (in shares) 44,108,407 36,975,203
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases (Details)
Sep. 30, 2019
Leases [Abstract]  
Weighted average remaining lease term 7 years 2 months 12 days
Extended term of lease 14 years
XML 39 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases - Supplemental Cash Flow Information (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Cash paid for amounts included in the measurement of operating lease liabilities $ 4,704
Right-of-use assets obtained in exchange for operating lease liabilities $ 3,890
XML 40 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (114,103) $ (101,952)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,152 1,251
Amortization of discount on investments (2,215) (904)
Stock-based compensation expense 12,882 12,422
Gain on disposal of property and equipment (7) (1,480)
Other non-cash operating activities 418 178
Changes in operating assets and liabilities:    
Accounts receivable 22,000  
Prepaid expenses and other current assets (1,426) (5,141)
Operating lease right of use assets (2,414)  
Other non-current assets 999 (1,919)
Accounts payable (1,050) 793
Accruals and other liabilities 3,532 1,889
Deferred revenue 4,676 21,758
Operating lease liabilities 1,903  
Net cash used in operating activities (72,653) (73,105)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchases of investments (228,568) (212,197)
Purchases of property and equipment (2,950) (5,367)
Proceeds from maturities of investments 183,000 50,000
Proceeds from sales of property and equipment 7 1,537
Payment for acquisition of in-process research and development   (100)
Net cash used in investing activities (48,511) (166,127)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from issuance of common stock in connection with the 2019 follow-on offering, net of commissions and discount 108,100  
Proceeds from the exercise of stock options and employee stock purchase plan 480 4,822
Net settlement of restricted stock awards for employee taxes (1,229) (1,906)
Payment of offering costs (521) (366)
Principal payments made on financing obligations   (932)
Net cash provided by financing activities 106,830 1,618
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH (14,334) (237,614)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period 73,986 283,476
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period 59,652 45,862
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid for income taxes 3,000 0
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:    
Property and equipment purchases included in accounts payable and accruals $ 313 $ 920
ZIP 41 0001479290-19-000109-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001479290-19-000109-xbrl.zip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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Cash Equivalents and Investments - Related Party Transactions (Details) - USD ($)
shares in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Related Party Transaction [Line Items]    
Related party transactions $ 0  
J.P. Morgan Securities LLC    
Related Party Transaction [Line Items]    
Cash, cash equivalents and investments, held by JP Morgan Chase   $ 87,700,000
JPMorgan Chase & Co. and Wholly-owned Subsidiaries    
Related Party Transaction [Line Items]    
Common stock outstanding, held by JP Morgan Chase (in shares)   3.8
Percent of outstanding common stock held by JP Morgan Chase during the period (less than 10$ at Sept. 30, 2019) 10.00% 10.30%

XML 44 R23.htm IDEA: XBRL DOCUMENT v3.19.3
The Company and Summary of Significant Accounting Policies- Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 01, 2019
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]            
Net loss $ 41,409 $ 32,834 $ 114,103 $ 101,952    
Working capital surplus 186,400   186,400      
Accumulated deficit 798,878   798,878     $ 684,775
Contract with customer, liability, net 209,000   $ 209,000      
Cash and cash equivalents, and investments, expected funding term for operating plan (in months)     12 months      
Operating lease right of use assets 27,078   $ 27,078   $ 24,700  
Operating lease liabilities $ 30,095   $ 30,095   28,200  
Deferred rent liabilities         $ (3,500)  
XML 45 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Medicis Settlement
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Medicis Settlement Medicis Settlement
In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a proceeds sharing arrangement payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and $7.1 million in 2014, and (iii) a product approval payment of $4.0 million to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. In December 2012, Medicis was subsequently acquired by Valeant Pharmaceuticals International Inc., now known as Bausch Health Companies Inc.
The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled.
As of September 30, 2019, the fair value of the Company’s liability for the product approval payment was $2.9 million, which was measured using a term of 1.1 years, a risk-free rate of 1.7% and a credit risk adjustment of 7.5%. As of December 31, 2018, the fair value of the Company’s liability for the product approval payment was $2.7 million, which was measured using a term of 1.5 years, a risk-free rate of 2.6% and a credit risk adjustment of 8.0%. The term is based on an expected Biologics License Application (“BLA”) approval in 2020. For the nine months ended September 30, 2019 and 2018, no payment was made for the product approval payment.
XML 46 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2019
Oct. 24, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 001-36297  
Entity Registrant Name Revance Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 77-0551645  
Entity Address, Address Line One 7555 Gateway Boulevard  
Entity Address, City or Town Newark  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94560  
City Area Code 510  
Local Phone Number 742-3400  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol RVNC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   45,108,360
Entity Central Index Key 0001479290  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases - Operating Lease Liability Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
Leases [Abstract]    
2019 remaining three months $ 1,633  
2020 6,735  
2021 6,942  
2022 5,464  
2023 5,557  
2024 and thereafter 17,959  
Total operating lease payments 44,290  
Less imputed interest (1) (14,195)  
Present value of operating lease payments $ 30,095 $ 28,200
Weighted average discount rate (percent) 12.00%  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity Stockholders' Equity - Stock Option Plan Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 01, 2019
Jan. 31, 2019
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Follow On Offering            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock issued during period, shares, new issues (in shares)   6,764,705        
Share price (in dollar per share)   $ 17.00        
Proceeds from issuance of common stock   $ 107,600,000        
Over-Allotment Option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock issued during period, shares, new issues (in shares)   882,352        
At the Market Offering            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock issued during period, shares, new issues (in shares)       0 0  
Stock issuance sales agreement, authorized offering price, maximum       $ 125,000,000.0    
Stock issuance sales agreement, commission rate (percent)       3.00%    
Common Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for purchase under common stock warrants (in shares)     34,113 34,113   34,113,000
Employee Stock Option and Restricted Stock Awards | 2014 Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares) 1,479,008          
Shares underlying stock options granted (in shares)     1,202,650      
Shares granted under restricted stock awards (shares)     513,225      
Shares available for issuance (in shares)     2,018,200 2,018,200    
Employee Stock Option | 2014 Inducement Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares underlying stock options granted (in shares)       0    
Shares available for issuance (in shares)     170,019 170,019    
Employee Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares) 300,000          
Common stock, capital shares reserved for future issuance (in shares)     1,443,774 1,443,774    
Weighted Average | Warrant            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise price per share (in USD per share)     $ 14.95 $ 14.95   $ 14.95
XML 49 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statement - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Other Accumulated Comprehensive Gain (Loss)
Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2017   36,516,075      
Beginning Balance at Dec. 31, 2017   $ 37 $ 810,975 $ 0 $ (542,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative-effect adjustment from adoption of ASU 2018-07 | Accounting Standards Update 2018-07     40   (40)
Issuance of common stock upon exercise of stock options (in shares)   284,094      
Issuance of restricted stock awards, net of cancellation (in shares)   232,284      
Net settlement of restricted stock awards for employee taxes (in shares)   (59,126)      
Issuance of common stock relating to employee stock purchase plan (in shares)   18,795      
Stock-based compensation expense     12,422    
Issuance of common stock upon exercise of stock options     4,382    
Net settlement of restricted stock awards for employee taxes     (1,906)    
Issuance of common stock relating to employee stock purchase plan     439    
Unrealized gain (loss) and adjustment on securities included in net loss $ (133)     (133)  
Net loss $ (101,952)       (101,951)
Ending Balance (in shares) at Sep. 30, 2018 36,992,122 36,992,122      
Ending Balance at Sep. 30, 2018 $ 182,098 $ 37 826,352 (133) (644,158)
Beginning Balance (in shares) at Jun. 30, 2018   36,917,723      
Beginning Balance at Jun. 30, 2018   $ 37 821,326 (223) (611,284)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative-effect adjustment from adoption of ASU 2018-07 | Accounting Standards Update 2018-07     40   (40)
Issuance of common stock upon exercise of stock options (in shares)   51,006      
Issuance of restricted stock awards, net of cancellation (in shares)   26,598      
Net settlement of restricted stock awards for employee taxes (in shares)   (3,205)      
Stock-based compensation expense     4,092    
Issuance of common stock upon exercise of stock options     987    
Net settlement of restricted stock awards for employee taxes     (93)    
Unrealized gain (loss) and adjustment on securities included in net loss 90     90  
Net loss $ (32,834)       (32,834)
Ending Balance (in shares) at Sep. 30, 2018 36,992,122 36,992,122      
Ending Balance at Sep. 30, 2018 $ 182,098 $ 37 826,352 (133) (644,158)
Beginning Balance (in shares) at Dec. 31, 2018 36,975,203 36,975,203      
Beginning Balance at Dec. 31, 2018 $ 145,622 $ 37 830,368 (8) (684,775)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock in connection with the 2019 follow-on offering (in shares)   6,764,705      
Issuance of common stock in connection with the 2019 follow-on offering   $ 7 107,572    
Issuance of common stock upon exercise of stock options (in shares)   8,240      
Issuance of restricted stock awards, net of cancellation (in shares)   400,720      
Net settlement of restricted stock awards for employee taxes (in shares)   (75,627)      
Issuance of common stock relating to employee stock purchase plan (in shares)   35,166      
Stock-based compensation expense     12,882    
Issuance of common stock upon exercise of stock options     93    
Net settlement of restricted stock awards for employee taxes     (1,229)    
Issuance of common stock relating to employee stock purchase plan     387    
Unrealized gain (loss) and adjustment on securities included in net loss 50     50  
Net loss $ (114,103)       $ (114,103)
Ending Balance (in shares) at Sep. 30, 2019 44,108,407 44,108,407     0
Ending Balance at Sep. 30, 2019 $ 151,281 $ 44 950,073 42 $ (798,878)
Beginning Balance (in shares) at Jun. 30, 2019   44,105,474      
Beginning Balance at Jun. 30, 2019   $ 44 945,851 116 (757,469)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of restricted stock awards, net of cancellation (in shares)   9,697      
Net settlement of restricted stock awards for employee taxes (in shares)   (6,764)      
Stock-based compensation expense     4,303    
Net settlement of restricted stock awards for employee taxes     (81)    
Unrealized gain (loss) and adjustment on securities included in net loss (74)     (74)  
Net loss $ (41,409)       $ (41,409)
Ending Balance (in shares) at Sep. 30, 2019 44,108,407 44,108,407     0
Ending Balance at Sep. 30, 2019 $ 151,281 $ 44 $ 950,073 $ 42 $ (798,878)
XML 50 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Cash Equivalents and Investments (Tables)
 9 Months Ended
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Available-for-sale Securities
The following table is a summary of amortized cost, unrealized gains and losses, and fair value:
 
September 30, 2019
 
December 31, 2018
 
 
 
Unrealized
 
 
 
 
 
Unrealized
 
 
(in thousands)
Cost
 
Gains
 
Fair Value
 
Cost
 
Gains
 
Losses
 
Fair Value
Money market funds
$
40,153

 
$
—

 
$
40,153

 
$
38,354

 
$
—

 
$
—

 
$
38,354

U.S. treasury securities
75,326

 
27

 
75,353

 
80,844

 
5

 
(5
)
 
80,844

U.S. government agency obligations
32,867

 
15

 
32,882

 
52,586

 
—

 
(8
)
 
52,578

Commercial paper
43,873

 
—

 
43,873

 
—

 
—

 
—

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

 
—

 
—

 
—

Total cash equivalents and available-for-sale securities
$
206,720

 
$
42

 
$
206,762

 
$
171,784

 
$
5

 
$
(13
)
 
$
171,776

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classified as:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
$
56,652

 
 
 
 
 
 
 
$
69,220

Short-term investments
 
 
 
 
150,110

 
 
 
 
 
 
 
102,556

Total cash equivalents and available-for-sale securities
 
 
 
 
$
206,762

 
 
 
 
 
 
 
$
171,776
XML 51 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock Warrants
As of September 30, 2019 and December 31, 2018, 34,113 common stock warrants were outstanding at an exercise price of $14.95 per share, which expire in 2020.
Stock Option Plan
2014 Equity Incentive Plan (“2014 EIP”)
On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 1,479,008 shares. For the nine months ended September 30, 2019, 1,202,650 stock options and 513,225 restricted stock awards were granted under the 2014 EIP. As of September 30, 2019, 2,018,200 shares were available for issuance under the 2014 EIP.
2014 Inducement Plan (the “2014 IN”)
For the nine months ended September 30, 2019, no stock options or restricted stock awards were granted under the 2014 IN. As of September 30, 2019, 170,019 shares were available for issuance under the 2014 IN.
2014 Employee Stock Purchase Plan (the “2014 ESPP”)
On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 300,000 shares. As of September 30, 2019, 1,443,774 shares were available for issuance under the 2014 ESPP.
Stock-Based Compensation
Stock-based compensation expense was allocated as follows:
(in thousands)
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Research and development
$
2,106

 
$
1,836

 
$
6,438

 
$
5,627

General and administrative
2,197

 
2,256

 
6,444

 
6,795

Total stock-based compensation expense
$
4,303

 
$
4,092

 
$
12,882

 
$
12,422


Net Loss per Share
The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive.
Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:
 
As of September 30,
 
2019
 
2018
Outstanding common stock options
4,402,244

 
3,491,751

Outstanding common stock warrants
34,113

 
34,113

Unvested restricted stock awards
788,125

 
679,541

Shares of common stock expected to be purchased on December 31 under the 2014 ESPP
45,123

 
16,712


Follow-On Public Offering
In January 2019, the Company completed the 2019 follow-on public offering, pursuant to which the Company issued 6,764,705 shares of common stock at $17.00 per share, including the exercise of the underwriters’ over-allotment option to purchase 882,352 additional shares of common stock, for aggregate net proceeds of $107.6 million, after deducting underwriting discounts, commissions and other offering expenses.
At-The-Market Offering
The Company and Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) are parties to a Controlled Equity Offering sales agreement (the “2018 ATM Agreement”), under which the Company may offer and sell common stock having aggregate proceeds of up to $125.0 million through Cantor Fitzgerald as its sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon the Company’s instructions, and the Company will pay a commission to Cantor Fitzgerald of up to 3.0% of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the nine months ended September 30, 2019 and 2018, no common stock was sold under the 2018 ATM Agreement.
XML 52 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Cash Equivalents and Investments
 9 Months Ended
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Cash Equivalents and Investments Cash Equivalents and Investments
The Company’s cash equivalents and investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.
The following table is a summary of amortized cost, unrealized gains and losses, and fair value:
 
September 30, 2019
 
December 31, 2018
 
 
 
Unrealized
 
 
 
 
 
Unrealized
 
 
(in thousands)
Cost
 
Gains
 
Fair Value
 
Cost
 
Gains
 
Losses
 
Fair Value
Money market funds
$
40,153

 
$
—

 
$
40,153

 
$
38,354

 
$
—

 
$
—

 
$
38,354

U.S. treasury securities
75,326

 
27

 
75,353

 
80,844

 
5

 
(5
)
 
80,844

U.S. government agency obligations
32,867

 
15

 
32,882

 
52,586

 
—

 
(8
)
 
52,578

Commercial paper
43,873

 
—

 
43,873

 
—

 
—

 
—

 
—

Overnight repurchase agreements
14,501

 
—

 
14,501

 
—

 
—

 
—

 
—

Total cash equivalents and available-for-sale securities
$
206,720

 
$
42

 
$
206,762

 
$
171,784

 
$
5

 
$
(13
)
 
$
171,776

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classified as:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
$
56,652

 
 
 
 
 
 
 
$
69,220

Short-term investments
 
 
 
 
150,110

 
 
 
 
 
 
 
102,556

Total cash equivalents and available-for-sale securities
 
 
 
 
$
206,762

 
 
 
 
 
 
 
$
171,776


As of September 30, 2019 and December 31, 2018, the Company has no other-than-temporary impairments on its available-for-sale securities.
Related Party Transactions
The Company had no related party transactions for the nine months ended September 30, 2019.
As of December 31, 2018, JPMorgan Chase & Co. and its wholly owned subsidiaries JPMorgan Chase Bank, National Association (NA), J.P. Morgan Investment Management Inc., and JPMorgan Asset Management (UK) Limited held approximately 3.8 million shares or 10.3% of the Company’s outstanding common stock. J.P. Morgan Securities LLC is an affiliate of JPMorgan Chase Bank, NA, and it acts as a custodian and trustee for certain investments of the Company. As of December 31, 2018, cash, cash equivalents, and investments of $87.7 million were held in an investment account with J.P. Morgan Securities LLC. As of September 30, 2019, JPMorgan Chase & Co. and its wholly owned subsidiaries owned less than 10% of the Company’s outstanding common stock.
XML 53 rvncq31910q_htm.xml IDEA: XBRL DOCUMENT 0001479290 2019-01-01 2019-09-30 0001479290 2019-10-24 0001479290 2018-12-31 0001479290 2019-09-30 0001479290 2018-07-01 2018-09-30 0001479290 2019-07-01 2019-09-30 0001479290 2018-01-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001479290 us-gaap:RetainedEarningsMember 2017-12-31 0001479290 us-gaap:RetainedEarningsMember 2018-12-31 0001479290 us-gaap:CommonStockMember 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2019-06-30 0001479290 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001479290 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-12-31 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001479290 us-gaap:CommonStockMember 2018-06-30 0001479290 us-gaap:RetainedEarningsMember 2019-09-30 0001479290 us-gaap:RetainedEarningsMember 2018-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001479290 us-gaap:CommonStockMember 2019-06-30 0001479290 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001479290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001479290 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001479290 us-gaap:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001479290 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-01 2019-09-30 0001479290 2017-12-31 0001479290 2019-01-01 0001479290 rvnc:MylanIrelandLimitedMember 2018-02-28 0001479290 rvnc:DevelopmentServicesMember 2019-09-30 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-09-30 0001479290 rvnc:DevelopmentServicesMember 2018-01-01 2018-09-30 0001479290 rvnc:DevelopmentServicesMember 2019-07-01 2019-09-30 0001479290 rvnc:MylanIrelandLimitedMember 2018-02-28 2018-02-28 0001479290 rvnc:DevelopmentServicesMember 2018-12-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-01 2019-09-30 0001479290 rvnc:DevelopmentServicesMember 2018-07-01 2018-09-30 0001479290 rvnc:DevelopmentServicesMember 2019-01-01 2019-09-30 0001479290 rvnc:MylanIrelandLimitedMember 2019-08-31 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2018-12-01 2018-12-31 0001479290 rvnc:MylanIrelandLimitedMember rvnc:DevelopmentMilestonesMember 2018-02-28 2018-02-28 0001479290 rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member 2019-01-01 2019-01-31 0001479290 rvnc:MylanIrelandLimitedMember 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2019-09-30 0001479290 rvnc:MedicisPharmaceuticalCorporationMember 2012-10-01 2012-10-31 0001479290 us-gaap:CreditRiskContractMember rvnc:ValeantPharmaceuticalsInternationalInc.Member 2019-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputEntityCreditRiskMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2014-01-01 2014-12-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputExpectedTermMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2012-10-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputRiskFreeInterestRateMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputEntityCreditRiskMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:MedicisPharmaceuticalCorporationMember 2018-09-30 0001479290 rvnc:ProceedsSharingArrangementMember rvnc:MedicisPharmaceuticalCorporationMember 2013-01-01 2013-12-31 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputRiskFreeInterestRateMember rvnc:MedicisPharmaceuticalCorporationMember 2018-01-01 2018-09-30 0001479290 us-gaap:CreditRiskContractMember us-gaap:MeasurementInputExpectedTermMember rvnc:MedicisPharmaceuticalCorporationMember 2019-01-01 2019-09-30 0001479290 rvnc:JPMorganChaseCo.andWhollyownedSubsidiariesMember 2018-01-01 2018-12-31 0001479290 rvnc:JPMorganChaseCo.andWhollyownedSubsidiariesMember 2019-01-01 2019-09-30 0001479290 rvnc:J.P.MorganSecuritiesLLCMember 2018-12-31 0001479290 us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:CommercialPaperMember 2018-12-31 0001479290 us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:OtherCurrentAssetsMember 2018-12-31 0001479290 us-gaap:RepurchaseAgreementsMember 2018-12-31 0001479290 us-gaap:CashEquivalentsMember 2018-12-31 0001479290 us-gaap:OtherCurrentAssetsMember 2019-09-30 0001479290 us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:CashEquivalentsMember 2019-09-30 0001479290 2018-01-01 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 rvnc:DerivativeLiabilitySettlementMember 2018-12-31 0001479290 rvnc:DerivativeLiabilitySettlementMember 2019-01-01 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RepurchaseAgreementsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001479290 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember rvnc:DerivativeLiabilitySettlementMember 2019-09-30 0001479290 us-gaap:CreditRiskContractMember rvnc:ListLaboratoriesMember 2019-09-30 0001479290 us-gaap:OtherCurrentLiabilitiesMember 2019-01-01 2019-09-30 0001479290 us-gaap:ServiceAgreementsMember rvnc:AjinomotoAltheaInc.Member 2019-09-30 0001479290 rvnc:BotulinumToxinResearchAssociatesInc.Member 2019-09-30 0001479290 rvnc:BioSentinelInc.Member 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001479290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001479290 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-01 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-07-01 2019-09-30 0001479290 srt:WeightedAverageMember us-gaap:WarrantMember 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2019-09-30 0001479290 rvnc:AttheMarketOfferingMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockMember 2019-01-01 2019-01-01 0001479290 us-gaap:EmployeeStockMember 2019-09-30 0001479290 rvnc:FollowOnOfferingMember 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-01-01 2019-01-01 0001479290 us-gaap:EmployeeStockOptionMember rvnc:TwoThousandAndFourteenInducementPlanMember 2019-01-01 2019-09-30 0001479290 us-gaap:OverAllotmentOptionMember 2019-01-01 2019-01-31 0001479290 rvnc:EmployeeStockOptionandRestrictedStockAwardsMember rvnc:TwoThousandAndFourteenEquityIncentivePlanMember 2019-09-30 0001479290 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001479290 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001479290 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001479290 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001479290 rvnc:ESPPPurchasesMember 2018-01-01 2018-09-30 0001479290 rvnc:ESPPPurchasesMember 2019-01-01 2019-09-30 0001479290 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001479290 srt:WeightedAverageMember us-gaap:WarrantMember 2018-12-31 0001479290 rvnc:AttheMarketOfferingMember 2018-01-01 2018-09-30 0001479290 stpr:CA 2019-01-01 2019-09-30 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 0001479290 rvnc:FormerPresidentandChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-10-11 2019-10-11 0001479290 rvnc:PresidentChiefExecutiveOfficerandPrincipalExecutiveOfficerMember us-gaap:PerformanceSharesMember us-gaap:SubsequentEventMember 2019-10-13 2019-10-13 iso4217:USD shares pure shares iso4217:USD false --12-31 Q3 2019 0001479290 14.95 34113000 0.001 0.001 95000000 95000000 36975203 44108407 36975203 0 521000 0.001 0.001 5000000 5000000 0 0 0 0 0 10-Q true 2019-09-30 false 001-36297 Revance Therapeutics, Inc. DE 77-0551645 7555 Gateway Boulevard Newark CA 94560 510 742-3400 Common Stock, par value $0.001 per share RVNC NASDAQ Yes Yes Large Accelerated Filer false false false 45108360 58922000 73256000 150110000 102556000 5000000 27000000 6536000 5110000 220568000 207922000 14917000 14449000 27078000 730000 730000 2519000 3247000 265812000 226348000 6902000 8434000 18694000 14948000 5241000 8588000 3317000 34154000 31970000 2892000 2753000 50707000 42684000 26778000 3319000 114531000 80726000 0 0 44000 37000 950073000 830368000 42000 -8000 -798878000 -684775000 151281000 145622000 265812000 226348000 46000 2362000 324000 3242000 25847000 21848000 75368000 66968000 16739000 14155000 43245000 40505000 42586000 36003000 118613000 107473000 -42540000 -33641000 -118289000 -104231000 1329000 996000 4495000 3099000 0 0 0 44000 -68000 -45000 -139000 -150000 -130000 -144000 -170000 -626000 -41409000 -32834000 -114103000 -101952000 -74000 90000 50000 -133000 -41483000 -32744000 -114053000 -102085000 -41409000 -32834000 -114103000 -101952000 -0.96 -0.91 -2.67 -2.82 43314831 36272445 42730983 36116745 44105474 44000 36917723 37000 36975203 37000 36516075 37000 6764705 7000 51006 8240 284094 9697 26598 400720 232284 6764 3205 75627 59126 35166 18795 44108407 44000 36992122 37000 44108407 44000 36992122 37000 945851000 821326000 830368000 810975000 40000 40000 107572000 4303000 4092000 12882000 12422000 987000 93000 4382000 81000 93000 1229000 1906000 387000 439000 950073000 826352000 950073000 826352000 116000 -223000 -8000 0 -74000 90000 50000 -133000 42000 -133000 42000 -133000 -757469000 -611284000 -684775000 -542167000 -40000 -40000 -41409000 -32834000 -114103000 -101951000 0 -798878000 -644158000 -798878000 -644158000 44108407 151281000 36992122 182098000 44108407 151281000 36992122 182098000 -114103000 -101952000 2152000 1251000 2215000 904000 12882000 12422000 7000 1480000 418000 178000 -22000000 1426000 5141000 2414000 -999000 1919000 -1050000 793000 3532000 1889000 4676000 21758000 1903000 -72653000 -73105000 228568000 212197000 2950000 5367000 183000000 50000000 7000 1537000 100000 -48511000 -166127000 108100000 480000 4822000 1229000 1906000 521000 366000 932000 106830000 1618000 -14334000 -237614000 73986000 283476000 59652000 45862000 3000000 0 313000 920000 The Company and Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Company</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revance Therapeutics, Inc. (the “Company” or “Revance”) is a biotechnology company developing new innovations in neuromodulators for aesthetic and therapeutic indications. The Company’s lead product candidate, DaxibotulinumtoxinA for Injection (“DAXI”), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. The Company has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, demonstrating efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. The Company is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as three therapeutic indications including cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine. Beyond DAXI, the Company has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DAXI, DaxibotulinumtoxinA Topical, and the biosimilar to BOTOX®. The Company has incurred losses and negative cash flows from operations. The Company has not commenced commercial operations, has not generated product revenue to date, and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$41.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$114.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;"><span>$186.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$798.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has funded its operations primarily through </span><span style="font-family:inherit;font-size:10pt;">the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had capital resources of </span><span style="font-family:inherit;font-size:10pt;"><span>$209.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> consisting of cash, cash equivalents, and investments. The Company believes that its existing capital resources will fund the operating plan through at least the next </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> months following the issuance of this Form 10-Q, and may identify additional capital resources to fund its operations.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Balance Sheet for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 28, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements include the Company’s accounts and those of its wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. The Company operates in one segment.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements include the accounts of the company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842) </span><span style="font-family:inherit;font-size:10pt;">which requires an entity to recognize right-of-use asset and lease liabilities arising from a lease for both financing and operating leases with terms greater than twelve months. In July 2018, the FASB issued ASU 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Codification Improvements</span><span style="font-family:inherit;font-size:10pt;"> and ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, to provide additional guidance for the Topic 842 adoption. ASU 2018-10 clarifies certain provisions and correct unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders’ equity. ASU 2018-11 provides an alternative transition method to allow entities initially applying Topic 842 at the adoption date, rather than at the beginning of the earliest comparative period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. ASU 2018-11 also provides a number of optional practical expedients in transition. In March 2019, the FASB issued </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASU 2019-01, Leases (Topic 842): Codification Improvements</span><span style="font-family:inherit;font-size:10pt;">. The Company evaluated ASU 2019-01 in its entirety and determined that Issue 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transition disclosures related to Topic 250, Accounting Changes and Error Corrections</span><span style="font-family:inherit;font-size:10pt;">, is the only provision that currently applies to the Company. Issue 3 of ASU 2019-01 exempts certain interim disclosures in the fiscal year of adoption. ASU 2018-11, ASU 2018-10, ASU 2016-02, and Issue 3 of ASU 2019-01 (collectively, “the new lease standards”) are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has elected the transition method under ASU 2018-11 at the adoption date of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company has also elected all of the available practical expedients except the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease. For real estate leases, the Company did not elect the practical expedient to combine lease and non-lease components, therefore the Company accounts for lease and non-lease components separately. For equipment leases, lease and non-lease components are accounted for as a single lease component. The Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$24.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as total right-of-use assets and total lease liabilities, respectively, on its Condensed Consolidated Balance Sheet as of January 1, 2019 for its existing operating lease agreements for the office and manufacturing spaces in Newark, California and equipment leases. The existing deferred rent liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the same lease agreements was reversed as of January 1, 2019.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company intends to adopt ASU 2018-15 prospectively when it becomes effective on January 1, 2020. The Company’s Condensed Consolidated Financial Statements and disclosures before adoption are not expected to be impacted as a result of the adoption.</span></div> -41400000 -114100000 186400000 -798900000 209000000.0 P12M <div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Balance Sheet for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 28, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements include the Company’s accounts and those of its wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. The Company operates in one segment.</span></div> <div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements include the accounts of the company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div> <div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></div> <div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842) </span><span style="font-family:inherit;font-size:10pt;">which requires an entity to recognize right-of-use asset and lease liabilities arising from a lease for both financing and operating leases with terms greater than twelve months. In July 2018, the FASB issued ASU 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Codification Improvements</span><span style="font-family:inherit;font-size:10pt;"> and ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, to provide additional guidance for the Topic 842 adoption. ASU 2018-10 clarifies certain provisions and correct unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders’ equity. ASU 2018-11 provides an alternative transition method to allow entities initially applying Topic 842 at the adoption date, rather than at the beginning of the earliest comparative period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. ASU 2018-11 also provides a number of optional practical expedients in transition. In March 2019, the FASB issued </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASU 2019-01, Leases (Topic 842): Codification Improvements</span><span style="font-family:inherit;font-size:10pt;">. The Company evaluated ASU 2019-01 in its entirety and determined that Issue 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transition disclosures related to Topic 250, Accounting Changes and Error Corrections</span><span style="font-family:inherit;font-size:10pt;">, is the only provision that currently applies to the Company. Issue 3 of ASU 2019-01 exempts certain interim disclosures in the fiscal year of adoption. ASU 2018-11, ASU 2018-10, ASU 2016-02, and Issue 3 of ASU 2019-01 (collectively, “the new lease standards”) are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has elected the transition method under ASU 2018-11 at the adoption date of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company has also elected all of the available practical expedients except the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease. For real estate leases, the Company did not elect the practical expedient to combine lease and non-lease components, therefore the Company accounts for lease and non-lease components separately. For equipment leases, lease and non-lease components are accounted for as a single lease component. The Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$24.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as total right-of-use assets and total lease liabilities, respectively, on its Condensed Consolidated Balance Sheet as of January 1, 2019 for its existing operating lease agreements for the office and manufacturing spaces in Newark, California and equipment leases. The existing deferred rent liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the same lease agreements was reversed as of January 1, 2019.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company intends to adopt ASU 2018-15 prospectively when it becomes effective on January 1, 2020. The Company’s Condensed Consolidated Financial Statements and disclosures before adoption are not expected to be impacted as a result of the adoption.</span></div> 24700000 28200000 3500000 Revenue<span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Mylan Collaboration and License Agreement</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) entered into a collaboration agreement in February 2018 (the “Mylan Collaboration”), pursuant to which the companies will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Mylan Collaboration, Mylan paid the Company a non-refundable upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> with additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate, upon the achievement of specified clinical and regulatory (i.e., biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The upfront payment does not represent a financing component for the transfer of goods or services. The contingent payments would be payable following Mylan’s decision (“Continuation Decision”) to continue development services for the Initial Phase and Phase 3 clinical trials and upon meeting certain milestones. In addition, Mylan would pay the Company low to mid double-digit royalties on any sales of the biosimilar in the U.S., mid double-digit royalties on any sales in Europe, and high single-digit royalties on any sales in other areas excluding Japan. However, the Company agreed to waive royalties for U.S. sales, up to a limit of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in annual sales, during the first approximately four years after commercialization to defray launch costs.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, the Company and Mylan entered into an amendment (the “Mylan Amendment”) to the Mylan Collaboration, pursuant to which, among other things, the Company has agreed to extend the period of time for Mylan to make the Continuation Decision under the Mylan Collaboration as to whether to continue the development and commercialization of the biosimilar beyond the initial development plan, for which both parties prepared and conducted the Biosimilar Initial Advisory Meeting (“BIAM”) with the U.S. Food and Drug Administration (“FDA”). In accordance with the Mylan Amendment, Mylan is required to notify the Company of the Continuation Decision on or before the later of (i) </span><span style="font-family:inherit;font-size:10pt;color:#000000;">April 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> or (ii) 30 calendar days from the date that the Company provides Mylan with certain deliverables, and Mylan has agreed to make an incremental payment to the Company in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the Mylan Amendment date, the Company has the following unfulfilled non-distinct performance obligations within the Mylan Collaboration: (1) intellectual property (“IP”) license for technology and know–how related to the biosimilar, (2) the performance of development services after the Initial Phase for the biosimilar through the filing of an Investigational New Drug (“IND”) application by the Company, and (3) manufacturing services to provide drug substance or drug product during the development and commercialization periods. The performance obligation related to the initial development services for the biosimilar up to the BIAM was completed in February 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The initial estimated transaction price was </span><span style="font-family:inherit;font-size:10pt;"><span>$81.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> which included a </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment, </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of development milestones, and the estimated variable consideration for cost-sharing payments from Mylan. The Company re-evaluates the transaction price at each reporting period. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to the unfulfilled performance obligations is </span><span style="font-family:inherit;font-size:10pt;"><span>$107.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which incorporates the impact from the incremental payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and estimated variable consideration for cost-sharing payments resulting from the Mylan Amendment.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue and estimates deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. As a result of the extended period of time for Mylan to make the Continuation Decision provided in the Mylan Amendment, both short-term and long-term deferred revenue have been adjusted accordingly to reflect the impact of the extension. For revenue recognition purposes, the development period is estimated to extend through 2024. However, it is possible that this period will change and is assessed at each reporting date. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three and nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to development services of less than </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the three and nine months ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to development services of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company estimated short-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively; and long-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fosun License Agreement </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”) entered into a license agreement (the “Fosun License Agreement”) in December 2018, whereby the Company has granted Fosun the exclusive rights to develop and commercialize the Company’s proprietary DAXI in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Fosun License Agreement, the Company received a non-refundable upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> net of foreign withholding tax of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from Fosun in January 2019. The Company is also eligible to receive (i) additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$230.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified milestones, and (ii) tiered royalty payments in low double-digit to high-teen percentages on annual net sales.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The Company estimated the transaction price for the Fosun License Agreement using the most likely amount method. The Company evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered, and concluded only a certain milestone of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was included in the transaction price. The Company will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to unfulfilled performance obligation is </span><span style="font-family:inherit;font-size:10pt;"><span>$31.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company will recognize revenue on the single performance obligation as control of the manufactured product is supplied to Fosun.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> revenue has been recognized from the Fosun License Agreement. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, substantially all of the </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> non-refundable upfront payment was included in long-term deferred revenue.</span></div> 25000000.0 100000000.0 225000000.0 50000000.0 5000000.0 81000000.0 25000000.0 40000000.0 107000000.0 5000000.0 100000 300000 2400000 3200000 5200000 8600000 20700000 12700000 30000000.0 3000000.0 230500000 1000000.0 31000000.0 0 30000000.0 Medicis Settlement<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, comprised of (i) an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0</span></span><span style="font-family:inherit;font-size:10pt;"> million due upon specified capital raising achievements by the Company, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9</span></span><span style="font-family:inherit;font-size:10pt;"> million was paid in 2013 and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in 2014, and (iii) a product approval payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0</span></span><span style="font-family:inherit;font-size:10pt;"> million to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. In December 2012, Medicis was subsequently acquired by Valeant Pharmaceuticals International Inc., now known as Bausch Health Companies Inc. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.1 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.7%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>8.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The term is based on an expected Biologics License Application (“BLA”) approval in 2020. For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, no payment was made for the product approval payment.</span></div> 25000000.0 7000000.0 14000000.0 6900000 7100000 4000000.0 2900000 P1Y1M6D 0.017 0.075 2700000 P1Y6M 0.026 0.080 Cash Equivalents and Investments<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s cash equivalents and investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,652</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102,556</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2018, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on its available-for-sale securities.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> related party transactions for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, JPMorgan Chase &amp; Co. and its wholly owned subsidiaries JPMorgan Chase Bank, National Association (NA), J.P. Morgan Investment Management Inc., and JPMorgan Asset Management (UK) Limited held approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares or </span><span style="font-family:inherit;font-size:10pt;"><span>10.3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding common stock. J.P. Morgan Securities LLC is an affiliate of JPMorgan Chase Bank, NA, and it acts as a custodian and trustee for certain investments of the Company. As of December 31, 2018, cash, cash equivalents, and investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$87.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> were held in an investment account with J.P. Morgan Securities LLC. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, JPMorgan Chase &amp; Co. and its wholly owned subsidiaries owned less than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span> of the Company’s outstanding common stock. <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,652</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102,556</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 40153000 0 40153000 38354000 0 0 38354000 75326000 27000 75353000 80844000 5000 5000 80844000 32867000 15000 32882000 52586000 0 8000 52578000 43873000 0 43873000 0 0 0 0 14501000 0 14501000 0 0 0 0 206720000 42000 206762000 171784000 5000 13000 171776000 56652000 69220000 150110000 102556000 206762000 171776000 0 0 3800000 0.103 87700000 0.10 Fair Value Measurements<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines the fair value of certain financial assets and liabilities using three levels of inputs as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability associated with the Medicis settlement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability associated with the Medicis settlement</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies U.S. government agency obligations, commercial paper, and overnight repurchase agreements within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair values.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of the Company’s Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability Associated with the Medicis Settlement</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the derivative liability associated with the Medicis settlement was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (Note 3). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.</span></div> <div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,501</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability associated with the Medicis settlement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability associated with the Medicis settlement</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 40153000 40153000 0 0 75353000 75353000 0 0 32882000 0 32882000 0 43873000 0 43873000 0 14501000 0 14501000 0 206762000 115506000 91256000 0 2892000 0 0 2892000 2892000 0 0 2892000 38354000 38354000 0 0 80844000 80844000 0 0 52578000 0 52578000 0 171776000 119198000 52578000 0 2753000 0 0 2753000 2753000 0 0 2753000 <div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of the Company’s Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability Associated with the Medicis Settlement</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2753000 139000 2892000 Leases<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. One of the facility operating leases commenced in February 2019. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>7.2 years</span></span><span style="font-family:inherit;font-size:10pt;">. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of 2022. The Company has options to extend the facility operating leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> years. The Company’s lease contracts do not contain termination options, residual value guarantees or restrictive covenants. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,193</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></span><span style="font-family:inherit;font-size:9pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 remaining three months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;">The Company’s lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,826</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P7Y2M12D P14Y <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,193</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></span><span style="font-family:inherit;font-size:9pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div> 1425000 4193000 298000 886000 1723000 5079000 <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 remaining three months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,095</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;">The Company’s lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,826</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1633000 6735000 6942000 5464000 5557000 17959000 44290000 14195000 30095000 0.120 5826000 6011000 6196000 4696000 20173000 42902000 <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4704000 3890000 Commitments and Contingencies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Purchase Commitments</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and Ajinomoto Althea, Inc. (“Althea”) are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Althea Services Agreement”), under which Althea provides the Company a contract development and manufacturing organization, which allows the Company to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DAXI. Under the Althea Services Agreement, the initial term is to 2024, unless terminated sooner by either company, and the Company has minimum purchase obligations based on its production forecasts. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, non-refundable advanced payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the Althea Services Agreement have been recorded in prepaid expense on the Company’s Condensed Consolidated Balance Sheets. The remaining services can be canceled at any time, with the Company required to pay costs incurred through the cancellation date.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the milestone has not been achieved. The Company is also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and Botulinum Toxin Research Associates, Inc. (“BTRX”) are parties to an asset purchase agreement (the “BTRX Purchase Agreement”), under which the Company is obligated to pay up to </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to BTRX upon the satisfaction of milestones relating to the Company’s product revenue, intellectual property, and clinical and regulatory events. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a one-time intellectual property development milestone liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been recorded in accruals on the Company’s Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and BioSentinel, Inc. (“BioSentinel”) are parties to an agreement under which the Company in-licenses BioSentinel’s technology and expertise for research, development and manufacturing purposes. The Company is obligated to pay BioSentinel minimum quarterly use fees, and a one-time milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> when regulatory approval is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the milestone has not been achieved.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Indemnification</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments the Company is obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against the Company in the future, but have not been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> amounts associated with the indemnification agreements have been recorded.</span></div> 1300000 2000000.0 16000000.0 1000000.0 300000 0 Stockholders’ Equity<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock Warrants</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span><span style="font-family:inherit;font-size:10pt;"> common stock warrants were outstanding at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.95</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which expire in 2020.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock Option Plan</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Equity Incentive Plan (“2014 EIP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 EIP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>1,479,008</span></span><span style="font-family:inherit;font-size:10pt;"> shares. For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,202,650</span></span><span style="font-family:inherit;font-size:10pt;"> stock options and </span><span style="font-family:inherit;font-size:10pt;"><span>513,225</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards were granted under the 2014 EIP. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2,018,200</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 EIP.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Inducement Plan (the “2014 IN”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> stock options or restricted stock awards were granted under the 2014 IN. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>170,019</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 IN. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Employee Stock Purchase Plan (the “2014 ESPP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>300,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,443,774</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 ESPP.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Loss per Share</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,402,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>788,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>679,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on December 31 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, the Company completed the 2019 follow-on public offering, pursuant to which the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>6,764,705</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share, including the exercise of the underwriters’ over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>882,352</span></span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock, for aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$107.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">At-The-Market Offering</span></div><span style="font-family:inherit;font-size:10pt;">The Company and Cantor Fitzgerald &amp; Co. (“Cantor Fitzgerald”) are parties to a Controlled Equity Offering sales agreement (the “2018 ATM Agreement”), under which the Company may offer and sell common stock having aggregate proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> through Cantor Fitzgerald as its sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by the Company and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon the Company’s instructions, and the Company will pay a commission to Cantor Fitzgerald of up to </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span> common stock was sold under the 2018 ATM Agreement. 34113 14.95 1479008 1202650 513225 2018200 0 170019 300000 1443774 <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2106000 1836000 6438000 5627000 2197000 2256000 6444000 6795000 4303000 4092000 12882000 12422000 <div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,402,244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>788,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>679,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on December 31 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4402244 3491751 34113 34113 788125 679541 45123 16712 6764705 17.00 882352 107600000 125000000.0 0.030 0 Income Taxes<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">California State Apportionment</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, the Company petitioned the California Franchise Tax Board for an alternative apportionment percentage due to the insignificant apportionment percentage derived from the single sales factor methodology for California. In January 2019, the California Franchise Tax Board approved the use of an alternative apportionment method. The Company’s net operating losses (“NOL”) in California is estimated to increase by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$219 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a result of the change in apportionment model. The Company has increased its deferred tax assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding offsetting adjustment to its valuation allowance. There is no impact to the Company’s net loss in the period as a result of the adjustment.</span></div> 219000000 15000000 Subsequent Event<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective as of </span><span style="font-family:inherit;font-size:10pt;">October 13, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s Board of Directors (the “Board”) appointed Mark J. Foley as the Company’s President, Chief Executive Officer and Principal Executive Officer. In connection with his appointment, the Company has entered into an executive employment agreement, pursuant to which Mr. Foley will initially receive an annual base salary of </span><span style="font-family:inherit;font-size:10pt;"><span>$650,000</span></span><span style="font-family:inherit;font-size:10pt;"> and an annual target bonus of </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of his base salary. The Board also approved the grant of certain equity awards to Mr. Foley under the 2014 EIP. Mr. Foley received (i) a stock option to purchase </span><span style="font-family:inherit;font-size:10pt;color:#000000;"><span>740,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock at </span><span style="font-family:inherit;font-size:10pt;color:#000000;"><span>$12.18</span></span><span style="font-family:inherit;font-size:10pt;"> per share, (ii) </span><span style="font-family:inherit;font-size:10pt;color:#000000;"><span>200,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock awards of the Company and (iii) </span><span style="font-family:inherit;font-size:10pt;color:#000000;"><span>860,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of performance-based common stock awards. The performance-based common stock awards will vest based on the Company’s certain market and performance conditions.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective as of </span><span style="font-family:inherit;font-size:10pt;">October 11, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a separation agreement with L. Daniel Browne providing for (i) a release of claims against the Company, (ii) cash severance payments to Mr. Browne in an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen months</span></span><span style="font-family:inherit;font-size:10pt;"> of Mr. Browne’s 2019 base salary; and (iii) certain health care continuation benefits. The separation agreement </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">also provides for an extension of the post-termination exercise period for all vested stock options held by Mr. Browne through the earlier of a Change in Control (as defined in the 2014 EIP) or </span><span style="font-family:inherit;font-size:10pt;">January 31, 2021</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently evaluating the effect on its Consolidated Financial Statements of Mr. Foley’s equity compensation and the modification to Mr. Browne’s vested stock options.</span></div> 650000 0.75 740000 12.18 200000 860000 P15M XML 54 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases - Aggregate Future Noncancelable Lease Payments (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 5,826
2020 6,011
2021 6,196
2022 4,696
2023 and thereafter 20,173
Total payments $ 42,902
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity Stockholders' Equity - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock based compensation expense $ 4,303 $ 4,092 $ 12,882 $ 12,422
Research and Development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock based compensation expense 2,106 1,836 6,438 5,627
General and Administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock based compensation expense $ 2,197 $ 2,256 $ 6,444 $ 6,795
XML 56 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]        
Revenue $ 46 $ 2,362 $ 324 $ 3,242
Operating expenses:        
Research and development 25,847 21,848 75,368 66,968
General and administrative 16,739 14,155 43,245 40,505
Total operating expenses 42,586 36,003 118,613 107,473
Loss from operations (42,540) (33,641) (118,289) (104,231)
Interest income 1,329 996 4,495 3,099
Interest expense 0 0 0 (44)
Change in fair value of derivative liability associated with the Medicis settlement (68) (45) (139) (150)
Other expense, net (130) (144) (170) (626)
Net loss (41,409) (32,834) (114,103) (101,952)
Unrealized gain (loss) and adjustment on securities included in net loss (74) 90 50 (133)
Comprehensive loss (41,483) (32,744) (114,053) (102,085)
Basic and diluted net loss $ (41,409) $ (32,834) $ (114,103) $ (101,952)
Basic and diluted net loss (in dollar per share) $ (0.96) $ (0.91) $ (2.67) $ (2.82)
Basic and diluted weighted-average number of shares used in computing net loss per share (in shares) 43,314,831 36,272,445 42,730,983 36,116,745
XML 57 R8.htm IDEA: XBRL DOCUMENT v3.19.3
The Company and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Summary of Significant Accounting Policies The Company and Summary of Significant Accounting Policies
The Company
Revance Therapeutics, Inc. (the “Company” or “Revance”) is a biotechnology company developing new innovations in neuromodulators for aesthetic and therapeutic indications. The Company’s lead product candidate, DaxibotulinumtoxinA for Injection (“DAXI”), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. The Company has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, demonstrating efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. The Company is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as three therapeutic indications including cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine. Beyond DAXI, the Company has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.
Since inception, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DAXI, DaxibotulinumtoxinA Topical, and the biosimilar to BOTOX®. The Company has incurred losses and negative cash flows from operations. The Company has not commenced commercial operations, has not generated product revenue to date, and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three and nine months ended September 30, 2019, the Company had a net loss of $41.4 million and $114.1 million, respectively. As of September 30, 2019, the Company had a working capital surplus of $186.4 million and an accumulated deficit of $798.9 million. The Company has funded its operations primarily through the issuance and sale of common stock, convertible preferred stock, notes payable, and convertible notes. As of September 30, 2019, the Company had capital resources of $209.0 million consisting of cash, cash equivalents, and investments. The Company believes that its existing capital resources will fund the operating plan through at least the next 12 months following the issuance of this Form 10-Q, and may identify additional capital resources to fund its operations.
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented.
The Condensed Consolidated Balance Sheet for the year ended December 31, 2018 was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2019, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (“SEC”), on February 28, 2019.
The Condensed Consolidated Financial Statements include the Company’s accounts and those of its wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. The Company operates in one segment.
Principles of Consolidation
The Condensed Consolidated Financial Statements include the accounts of the company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.
Use of Estimates
The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which requires an entity to recognize right-of-use asset and lease liabilities arising from a lease for both financing and operating leases with terms greater than twelve months. In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements and ASU 2018-11, Leases (Topic 842), Targeted Improvements, to provide additional guidance for the Topic 842 adoption. ASU 2018-10 clarifies certain provisions and correct unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders’ equity. ASU 2018-11 provides an alternative transition method to allow entities initially applying Topic 842 at the adoption date, rather than at the beginning of the earliest comparative period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. ASU 2018-11 also provides a number of optional practical expedients in transition. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements. The Company evaluated ASU 2019-01 in its entirety and determined that Issue 3, Transition disclosures related to Topic 250, Accounting Changes and Error Corrections, is the only provision that currently applies to the Company. Issue 3 of ASU 2019-01 exempts certain interim disclosures in the fiscal year of adoption. ASU 2018-11, ASU 2018-10, ASU 2016-02, and Issue 3 of ASU 2019-01 (collectively, “the new lease standards”) are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has elected the transition method under ASU 2018-11 at the adoption date of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company has also elected all of the available practical expedients except the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease. For real estate leases, the Company did not elect the practical expedient to combine lease and non-lease components, therefore the Company accounts for lease and non-lease components separately. For equipment leases, lease and non-lease components are accounted for as a single lease component. The Company recognized $24.7 million and $28.2 million as total right-of-use assets and total lease liabilities, respectively, on its Condensed Consolidated Balance Sheet as of January 1, 2019 for its existing operating lease agreements for the office and manufacturing spaces in Newark, California and equipment leases. The existing deferred rent liabilities of $3.5 million associated with the same lease agreements was reversed as of January 1, 2019.
Recent Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company intends to adopt ASU 2018-15 prospectively when it becomes effective on January 1, 2020. The Company’s Condensed Consolidated Financial Statements and disclosures before adoption are not expected to be impacted as a result of the adoption.
XML 59 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Commitments
The Company and Ajinomoto Althea, Inc. (“Althea”) are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Althea Services Agreement”), under which Althea provides the Company a contract development and manufacturing organization, which allows the Company to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DAXI. Under the Althea Services Agreement, the initial term is to 2024, unless terminated sooner by either company, and the Company has minimum purchase obligations based on its production forecasts. As of September 30, 2019, non-refundable advanced payments of $1.3 million under the Althea Services Agreement have been recorded in prepaid expense on the Company’s Condensed Consolidated Balance Sheets. The remaining services can be canceled at any time, with the Company required to pay costs incurred through the cancellation date.
Contingencies
The Company is obligated to pay $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of September 30, 2019, the milestone has not been achieved. The Company is also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.
The Company and Botulinum Toxin Research Associates, Inc. (“BTRX”) are parties to an asset purchase agreement (the “BTRX Purchase Agreement”), under which the Company is obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to the Company’s product revenue, intellectual property, and clinical and regulatory events. As of September 30, 2019, a one-time intellectual property development milestone liability of $1.0 million has been recorded in accruals on the Company’s Condensed Consolidated Balance Sheets.
The Company and BioSentinel, Inc. (“BioSentinel”) are parties to an agreement under which the Company in-licenses BioSentinel’s technology and expertise for research, development and manufacturing purposes. The Company is obligated to pay BioSentinel minimum quarterly use fees, and a one-time milestone payment of $0.3 million when regulatory approval is achieved. As of September 30, 2019, the milestone has not been achieved.
Indemnification
The Company has standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments the Company is obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against the Company in the future, but have not been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
The Company has indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
For the nine months ended September 30, 2019, no amounts associated with the indemnification agreements have been recorded.
XML 60 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue Revenue    
Mylan Collaboration and License Agreement    
The Company and Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) entered into a collaboration agreement in February 2018 (the “Mylan Collaboration”), pursuant to which the companies will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®.
Under the Mylan Collaboration, Mylan paid the Company a non-refundable upfront payment of $25.0 million with additional contingent payments of up to $100.0 million in the aggregate, upon the achievement of specified clinical and regulatory (i.e., biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to $225.0 million. The upfront payment does not represent a financing component for the transfer of goods or services. The contingent payments would be payable following Mylan’s decision (“Continuation Decision”) to continue development services for the Initial Phase and Phase 3 clinical trials and upon meeting certain milestones. In addition, Mylan would pay the Company low to mid double-digit royalties on any sales of the biosimilar in the U.S., mid double-digit royalties on any sales in Europe, and high single-digit royalties on any sales in other areas excluding Japan. However, the Company agreed to waive royalties for U.S. sales, up to a limit of $50.0 million in annual sales, during the first approximately four years after commercialization to defray launch costs.
In August 2019, the Company and Mylan entered into an amendment (the “Mylan Amendment”) to the Mylan Collaboration, pursuant to which, among other things, the Company has agreed to extend the period of time for Mylan to make the Continuation Decision under the Mylan Collaboration as to whether to continue the development and commercialization of the biosimilar beyond the initial development plan, for which both parties prepared and conducted the Biosimilar Initial Advisory Meeting (“BIAM”) with the U.S. Food and Drug Administration (“FDA”). In accordance with the Mylan Amendment, Mylan is required to notify the Company of the Continuation Decision on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that the Company provides Mylan with certain deliverables, and Mylan has agreed to make an incremental payment to the Company in the amount of $5.0 million.
Revenue Recognition
As of the Mylan Amendment date, the Company has the following unfulfilled non-distinct performance obligations within the Mylan Collaboration: (1) intellectual property (“IP”) license for technology and know–how related to the biosimilar, (2) the performance of development services after the Initial Phase for the biosimilar through the filing of an Investigational New Drug (“IND”) application by the Company, and (3) manufacturing services to provide drug substance or drug product during the development and commercialization periods. The performance obligation related to the initial development services for the biosimilar up to the BIAM was completed in February 2019.
In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The initial estimated transaction price was $81.0 million which included a $25.0 million upfront payment, $40.0 million of development milestones, and the estimated variable consideration for cost-sharing payments from Mylan. The Company re-evaluates the transaction price at each reporting period. As of September 30, 2019, the transaction price allocated to the unfulfilled performance obligations is $107.0 million, which incorporates the impact from the incremental payment of $5.0 million and estimated variable consideration for cost-sharing payments resulting from the Mylan Amendment.
The Company recognizes revenue and estimates deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. As a result of the extended period of time for Mylan to make the Continuation Decision provided in the Mylan Amendment, both short-term and long-term deferred revenue have been adjusted accordingly to reflect the impact of the extension. For revenue recognition purposes, the development period is estimated to extend through 2024. However, it is possible that this period will change and is assessed at each reporting date.
For the three and nine months ended September 30, 2019, the Company recognized revenue related to development services of less than $0.1 million and $0.3 million, respectively. For the three and nine months ended September 30, 2018, the Company recognized revenue related to development services of $2.4 million and $3.2 million, respectively. As of September 30, 2019 and December 31, 2018, the Company estimated short-term deferred revenue of $5.2 million and $8.6 million, respectively; and long-term deferred revenue of $20.7 million and $12.7 million, respectively.
Fosun License Agreement
The Company and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”) entered into a license agreement (the “Fosun License Agreement”) in December 2018, whereby the Company has granted Fosun the exclusive rights to develop and commercialize the Company’s proprietary DAXI in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.
Under the Fosun License Agreement, the Company received a non-refundable upfront payment of $30.0 million net of foreign withholding tax of $3.0 million from Fosun in January 2019. The Company is also eligible to receive (i) additional contingent payments of up to $230.5 million upon the achievement of specified milestones, and (ii) tiered royalty payments in low double-digit to high-teen percentages on annual net sales.
Revenue Recognition
In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. The Company estimated the transaction price for the Fosun License Agreement using the most likely amount method. The Company evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered, and concluded only a certain milestone of $1.0 million was included in the transaction price. The Company will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of September 30, 2019, the transaction price allocated to unfulfilled performance obligation is $31.0 million. The Company will recognize revenue on the single performance obligation as control of the manufactured product is supplied to Fosun.
For the nine months ended September 30, 2019, no revenue has been recognized from the Fosun License Agreement. As of September 30, 2019 and December 31, 2018, substantially all of the $30.0 million non-refundable upfront payment was included in long-term deferred revenue.
XML 61 R18.htm IDEA: XBRL DOCUMENT v3.19.3
The Company and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented.
The Condensed Consolidated Balance Sheet for the year ended December 31, 2018 was derived from audited Consolidated Financial Statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2019, or any other future period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (“SEC”), on February 28, 2019.
The Condensed Consolidated Financial Statements include the Company’s accounts and those of its wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. The Company operates in one segment.
Principles of Consolidation
Principles of Consolidation
The Condensed Consolidated Financial Statements include the accounts of the company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.
Use of Estimates
Use of Estimates
The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.
Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which requires an entity to recognize right-of-use asset and lease liabilities arising from a lease for both financing and operating leases with terms greater than twelve months. In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements and ASU 2018-11, Leases (Topic 842), Targeted Improvements, to provide additional guidance for the Topic 842 adoption. ASU 2018-10 clarifies certain provisions and correct unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders’ equity. ASU 2018-11 provides an alternative transition method to allow entities initially applying Topic 842 at the adoption date, rather than at the beginning of the earliest comparative period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. ASU 2018-11 also provides a number of optional practical expedients in transition. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements. The Company evaluated ASU 2019-01 in its entirety and determined that Issue 3, Transition disclosures related to Topic 250, Accounting Changes and Error Corrections, is the only provision that currently applies to the Company. Issue 3 of ASU 2019-01 exempts certain interim disclosures in the fiscal year of adoption. ASU 2018-11, ASU 2018-10, ASU 2016-02, and Issue 3 of ASU 2019-01 (collectively, “the new lease standards”) are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has elected the transition method under ASU 2018-11 at the adoption date of January 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company has also elected all of the available practical expedients except the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease. For real estate leases, the Company did not elect the practical expedient to combine lease and non-lease components, therefore the Company accounts for lease and non-lease components separately. For equipment leases, lease and non-lease components are accounted for as a single lease component. The Company recognized $24.7 million and $28.2 million as total right-of-use assets and total lease liabilities, respectively, on its Condensed Consolidated Balance Sheet as of January 1, 2019 for its existing operating lease agreements for the office and manufacturing spaces in Newark, California and equipment leases. The existing deferred rent liabilities of $3.5 million associated with the same lease agreements was reversed as of January 1, 2019.
Recent Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company intends to adopt ASU 2018-15 prospectively when it becomes effective on January 1, 2020. The Company’s Condensed Consolidated Financial Statements and disclosures before adoption are not expected to be impacted as a result of the adoption.
XML 63 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Cash Equivalents and Investments (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]    
Cost $ 206,720,000 $ 171,784,000
Gains 42,000 5,000
Losses   (13,000)
Fair Value 206,762,000 171,776,000
Other-than-temporary impairments on available-for-sale securities 0 0
Cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 56,652,000 69,220,000
Short-term investments    
Debt Securities, Available-for-sale [Line Items]    
Fair Value 150,110,000 102,556,000
Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Cost 40,153,000 38,354,000
Gains 0 0
Losses   0
Fair Value 40,153,000 38,354,000
U.S. treasury securities    
Debt Securities, Available-for-sale [Line Items]    
Cost 75,326,000 80,844,000
Gains 27,000 5,000
Losses   (5,000)
Fair Value 75,353,000 80,844,000
U.S. government agency obligations    
Debt Securities, Available-for-sale [Line Items]    
Cost 32,867,000 52,586,000
Gains 15,000 0
Losses   (8,000)
Fair Value 32,882,000 52,578,000
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Cost 43,873,000 0
Gains 0 0
Losses   0
Fair Value 43,873,000 0
Overnight repurchase agreements    
Debt Securities, Available-for-sale [Line Items]    
Cost 14,501,000 0
Gains 0 0
Losses   0
Fair Value $ 14,501,000 $ 0
XML 64 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of Stock-based Compensation Expense
Stock-based compensation expense was allocated as follows:
(in thousands)
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Research and development
$
2,106

 
$
1,836

 
$
6,438

 
$
5,627

General and administrative
2,197

 
2,256

 
6,444

 
6,795

Total stock-based compensation expense
$
4,303

 
$
4,092

 
$
12,882

 
$
12,422
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share
Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:
 
As of September 30,
 
2019
 
2018
Outstanding common stock options
4,402,244

 
3,491,751

Outstanding common stock warrants
34,113

 
34,113

Unvested restricted stock awards
788,125

 
679,541

Shares of common stock expected to be purchased on December 31 under the 2014 ESPP
45,123

 
16,712